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Infection with human immunodeficiency virus (HIV) is associated with a slow
deterioration of the immune system culminating in acquired immunodeficiency
syndrome (AIDS). Approximately 42 million people worldwide are currently living with
HIV/AIDS and new infections are occurring at a rate of around 5 million per year. A
common consequence of HIV type 1 (HIV-1) infection is the development of
neurological symptoms, which often manifest as a syndrome of cognitive and motor
dysfunction termed HIV-associated dementia (HAD). HIV-1 is frequently detected
within the brain of infected individuals, where the major reservoir of replicating virus is
monocyte-derived macrophages and microglial cells. The resultant HIV encephalitis
(HIVE) is often characterised by the presence of syncytia, which are a product of HIV-1
envelope (Env) protein-directed fusion of infected cells. Further HIV-induced damage to
neuronal cell types can occur by a number of different mechanisms, and may directly
contribute to the neurological symptoms experienced by infected individuals. Nucleotide
sequence analysis of HIV-1 variants in the brain of individuals with HIVE, usually
based upon partial env gene sequences, often demonstrates the presence of a viral
subpopulation that is genetically distinct from viral variants present in the lymphoid
system. Several different factors could lead to such sequence segregations, including
viral adaptation, physical isolation of the different subpopulations, and variation in virus
turnover rates in different anatomical compartments. Determining what underlies these
frequently observed genetic divisions is important for a more complete understanding of
HIV-1 neuropathogenesis. Thus the aim of this project was to further characterise the
X
evolutionary relationships between HIV-1 variants in the brain and lymphoid system,
and in particular to search for evidence of recombination between variants in the two
compartments by analysing sequence segments both within and outside the major
genetic determinants ofHIV-1 cellular tropism.
The evolutionary relationships manifest in the pl7gag and V3 genomic regions were
assessed between HIV-1 variants derived from the brain and lymphoid system of four
infected individuals with evidence of HIVE. pl7gag genetic distances between brain and
lymph node variants were calculated, allowing approximate divergence times to be
inferred. In two cases this indicated that pl7gag sequences present in the brain and
lymphoid compartments had diverged prior to the individual progressed to AIDS,
possibly indicating an autonomous pre-AIDS infection of the brain in these two study
subjects. A correlation was also noted between the severity of HIVE and both the V3
sequence divergence within brain, and the extent to which variants in brain differed from
those in the lymphoid system. In addition, pl7gag and V3 phylogenetic tree topologies
generated with sequences obtained from the same tissues exhibited discordant
phylogenetic relationships in each study subject. The most obvious explanation for these
complex evolutionary relationships is the occurrence of recombination among HIV-1
variants present within the brain, and also between brain and lymphoid derived HIV-1
variants.
In order to characterise this in vivo recombination more comprehensively it was
necessary to obtain longer sequences that may contain identifiable recombination
breakpoints between viral variants from different tissues. The entire HIV-1 env gene was
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chosen for this application. To ensure rigorous sequence analysis it was first essential to
quantify and eliminate a range of potentially confounding in vitro artefacts associated
with the polymerase chain reaction (PCR) amplification and subsequent molecular
cloning of HIV-1 env sequences. Artefacts included in this assessment were the
incorporation of single nucleotide errors during PCR, recombination during PCR and
resampling of clones. The results demonstrated that each of these artefacts could
significantly affect the final sequences obtained. In particular, recombination during
PCR was found to occur at a very high level even when small numbers of template
molecules were present at the start of the reaction. Resampling of clones was also
evident despite addition of a large number of amplifiable template molecules to the
PCR. Limiting dilution PCR was therefore used to obtain entire HIV-1 env sequences
for genetic analysis. Inter-tissue recombination was apparent in several env sequences,
providing further evidence for the occurrence of this mutational mechanism in the
context of a single HIV-1 infection. Close relationships between particular brain and
lymphoid tissue derived HIV-1 variants were also noted in certain genomic regions,
despite apparent tissue specificity in others.
If artefactually altered sequences are subsequently used in phenotypic assays, this may
lead to alterations in the observed functional properties of encoded proteins. These
considerations are especially important in the case of HIV-1 Env, where receptor
interactions can be both conformationally complex and strain dependent, and the
potential determinants of properties such as neurotropism and neurovirulence are poorly
defined. Therefore two approaches were designed with the aim of maintaining the exact
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characteristics of the env sequences present in vivo. The first involved consensus
cloning, whereby env sequences amplified from single proviral templates were cloned
and ten clones mixed before use in an Env-pseudotype virus assay. This approach
resulted in the production of infectious virus, which in principal would be expected to
contain no errors due to in vitro processes. However, issues with clone stability during
plasmid expansion in E. coli restricted its general utility and also raised the possibility
that defective envelopes may be preferentially isolated during the cloning process.
Therefore in the second approach a novel technique was developed for the addition of
promoter and polyadenylation sequences directly to PCR products, allowing expression
of open reading frames in mammalian cells without the need for prior molecular cloning.
The efficiency of this technique was verified by using two reporter genes and HIV-1 env
and nef sequences derived from autopsy tissue. As envelope genes were amplified at
limiting dilution, use of this method ensured that sequence characteristics and genetic
linkages present in vivo were maintained, and not affected by the various in vitro
artefacts that may significantly alter retrieved sequences.
Together these results indicate that recombination between HIV-1 variants that have
diverged during a single infection is an extremely common event. The identification of
recombination between brain and lymphoid derived virus also suggests that physical
separation or differences in viral turnover rates are not the source of the commonly
observed genetic differences between viral variants within these two compartments.
Therefore it may be speculated that those regions of the viral genome that do show tissue
specificity are the result of an adaptive process.
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Chapter 1: General Introduction
i
1.1 Historical perspective
The acquired immunodeficiency syndrome (AIDS) first came to public notice in
1981, when five unusual cases of young, previously healthy homosexual men with
Pneumocystis carinii pneumonia were registered in the USA (CDC, 1981). It soon
became evident that members of other groups including intravenous drug users,
hemophiliacs, blood transfusion recipients, and recent Haitian immigrants to the
USA were also being affected by what appeared to be a new immunodeficiency
disease. This unusual syndrome was characterised by the presence of opportunistic
infections (Pneumocystis carinii pneumonia, Toxoplasma gondii encephalitis,
cytomegalovirus-associated retinitis, and cryptococcal meningitis), generalised
lymphadenopathy, and a range of unusual cancers (non-Hodgkin's lymphoma and
Kaposi's sarcoma). Significantly, the sexual partners and children of members of the
various risk groups often presented with similar symptoms. Together these
epidemiological observations suggested that the disease was caused by a novel
pathogen, which was being transmitted within contaminated blood or via sexual
intercourse with an affected individual (Marmor et al., 1982; Jaffe et al., 1983;
Cowan et al., 1984).
In 1983 Barre-Sinoussi and colleagues provided the first evidence that a retrovirus
was the etiological agent of AIDS. These researchers recovered a virus containing
reverse transcriptase (RT) from the lymph node of an individual with
lymphadenopathy, and termed it lymphadenopathy-associated virus (LAV) (Barre
Sinoussi et al., 1983). Subsequently, a group led by Gallo also isolated retroviruses
from AIDS patients. Believing them to be closely related to the human T-
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lymphotropic viruses (HTLV), and to distinguish them from the noncytopathic
HTLV-I, and HTLV-II, these researchers named the new agent HTLV-III (Gallo et
al., 1984). At the same time Levy and colleagues isolated a similar retrovirus from
both AIDS patients and healthy individuals from the various risk groups, and named
the virus AIDS-associated retrovirus (ARV) (Levy et al., 1984). It became apparent
that LAV, HTLV-III, and ARV shared many common properties and in 1986 the
International Committee for the Taxonomy of Viruses ultimately named the
causative agent of AIDS the human immunodeficiency virus (HIV), and later HIV
type 1 (HIV-1) (Coffin et al., 1986). In 1986 a related but genetically quite distinct
and less pathogenic retrovirus was isolated from individuals in western Africa (Barin
et al., 1985; Clavel et al., 1986a; Clavel et al., 1986b). This virus was termed HIV
type 2 (HIV-2).
The World Health Organisation estimated that at the end of 2002 approximately 42
million people worldwide were living with HIV/AIDS. Around five million new HIV
infections and 3.1 million AIDS deaths occurred in that year alone. The best current
projections suggest that unless a drastically expanded prevention effort is mounted,
then a further 45 million people will become infected between the years 2002 and
2010. HIV prevalence is currently highest in Sub-Saharan Africa, with an estimated
29.4 million people infected. Rapidly expanding epidemics are also evident in areas
of Asia and the Pacific. Approximately 980 thousand HIV infected individuals are
currently living in North America and the corresponding figure for Western Europe
is estimated at 570 thousand.
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1.1.1 Classification and morphology of retroviruses
HIV is classified as a member of the Lentivirus genus in the family Retroviridae.
Two features of the retroviral life cycle (when together) distinguish retroviruses from
members of all other virus families: Reverse transcription of viral genomic RNA into
DNA, and integration of the viral DNA genome into the host cell chromosome.
Based upon features such as genome structure and phylogenetic relationships,
retroviruses have been classified into 7 different genera. These are the
alpharetroviruses (e.g. Rous sarcoma virus), betaretroviruses (e.g. mouse mammary
tumor virus), gammaretroviruses (e.g. murine leukemia virus), deltaretroviruses (e.g.
human T-lymphotropic virus 1), epsilonretroviruses (e.g. walleye dermal sarcoma
virus), lentiviruses (e.g. human immunodeficiency virus type 1), and spumaviruses
(e.g. human foamy virus). Alpha- beta- and gamma-retroviruses are considered
"simple" and encode only group specific antigens (Gag), protease (PR), polymerase
(Pol), and envelope (Env) gene products. Members of the remaining retroviral genera
are considered "complex", and also encode a number of regulatory proteins with
diverse functions (Goff, 2001).
The name Lentivirus is derived from lentus, Latin for slow. Lentiviral infections are
characterised by persistent viral replication, long and variable incubation periods,
neurological manifestations, and the destruction of immunologic or hematologic cells
(Desrosiers and Letvin, 1987). Common features of lentiviruses include the presence
of regulatory genes not found in other retroviruses, similar virion morphology,
extensive genetic and antigenic diversity, and a tropism for macrophages. The
Lentivirus genus may be split into 6 groups by virtue of primary host species and
other features: primates (e.g. HIV, simian immunodeficiency virus), horses (e.g.
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equine infectious anaemia virus; EIAV), cats (e.g. feline immunodeficiency virus),
sheep (e.g. Visna virus), goats (e.g. caprine arthritis-encephalitis virus), and cattle
(e.g. bovine immunodeficiency virus) (Coffin, 1996). The first account of what later
transpired to be a lentiviral disease was equine infectious anemia in 1904 (Vallee
and Carre, 1904). Subsequently the description of Visna (a neurological disease in
sheep caused by a lentivirus), gave rise to the concept of slow disease onset that is
characteristic ofmany lentiviral infections (Sigurdsson, 1954).
In 1971 the human foamy virus was described, representing the first reported
retroviral infection in humans (Achong et al., 1971). More recently, interest in
retroviruses has greatly expanded. This primarily reflects their role as human and
animal pathogens, but other retroviral properties have proved valuable in diverse
areas of biological research. For example retroviruses have been of great use in gene
therapy applications, as evolutionary markers, in the identification of proto-
oncogenes, and as a source of enzymatic tools for molecular biology.
Mature retrovirus virions are slightly pleomorphic spheres of approximately 100 nm
diameter. The virions are enveloped in a lipid bilayer containing envelope
glycoprotein spikes. Within the envelope is a roughly spherical shell consisting of
matrix proteins. Retroviral cores may be spherical, conical, or rod shaped, and are
largely composed of capsid proteins. Two copies of highly condensed genomic RNA
are associated with nucleocapsid protein and carried within the core. Viral enzymes
and other components required for replication, which can include accessory gene
products, are also present in the virion. The genome is a dimer of linear, positive
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sense, single stranded RNA of between approximately 7 Kb and 12.3 Kb in length
(Vogt, 1997).
1.1.2 Origins and Global Diversity of HIV
HIV-l and HIV-2 each originate from the zoonotic transmission of simian
immunodeficiency virus (SIV) into humans from different primate sources.
HIV-l is closely related to SIVcpz, a virus endemic to Pan troglodytes troglodytes
(chimpanzees) in Central Africa (Gao et al., 1999). Phylogenetic analysis of diverse
HIV-l strains has revealed the presence of three clearly distinct clades of viruses,
termed groups M (main), N (new, or non-M, non-O), and O (outlier). These lineages
are interspersed with SIVcpz lineages, and therefore must have arisen from separate
cross-species transmission events (Hahn et al., 2000; Gao et al, 1999; Corbet et al.,
2000). Group O strains are generally localised in West Central Africa (Deleys et al.,
1990; Peeters et al., 1997; Zekeng et al., 1994), and group N strains are only
represented by a few isolates from Cameroon (Simon et al., 1998). HIV-l group M
strains have spread throughout the world and are responsible for the great majority of
global HIV infections. Group M viruses fall into phylogenetically distinct clades, and
there are currently 9 recognised group M subtypes designated A, B, C, D, F, G, H, J,
and K (Robertson et al., 2000). In Env proteins approximately 25% to 35% amino
acid sequence differences are exhibited between subtypes, and up to 20% differences
within subtypes (Sharp et al., 1999). Group M subtypes vary in prevalence in
different geographical areas. Representatives of all subtypes are present in Africa,
and subtype C has the greatest overall worldwide prevalence. Subtype B strains are
responsible for the majority of infections in North America and Western Europe
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(Thomson et al., 2002). A large number of inter-subtype recombinants have also
arisen, and in some geographical areas are responsible for the majority of HIV
infections. For example an A/G recombinant is very common in parts of West and
Central Africa (McCutchan et al., 1999), and an A/E recombinant has a high
prevalence in many parts ofAsia (Gao et al., 1996b).
HIV-2 was originally identified in West Africa (Barin et al, 1985; Clavel et al,
1986a; Clavel et al, 1986b) and is closely related to SIVsmm in Cercocebus atys
(sooty mangabeys). Therefore this primate species is believed to be the source of
HIV-2 in humans (Gao et al., 1992; Hirsch et al., 1989). HIV-2 is less pathogenic
than HIV-1, and infection with HIV-2 is associated with an increased time between
initial infection and the diagnosis of AIDS (Marlink et al., 1994). HIV-2 is also less
readily transmitted than HIV-1 (Kanki et al., 1994), perhaps explaining why it has
not spread significantly from West Africa where HIV-2 prevalence rates are stable or
even decreasing (Schim van der LoeffMF and Aaby, 1999).
With regard to the timing of HIV entry into human populations, the earliest direct
evidence for HIV infection in humans comes from the retrospective analysis of an
African blood sample stored from 1959 (Zhu et al., 1998). The recovered sequence
was phylogenetically positioned near the ancestral nodes ofHIV-1 group M subtypes
B and D, and close to the centre of the group M radiation. This indicated that HIV-1
group M originated from a single cross-species transmission event, which occurred
not long before 1959 (Zhu et al, 1998). More recently this approximation has been
refined by the use of sequence data from a large number of viral isolates to estimate
the coalescence time of group M (Korber et al., 2000). The results of this analysis
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suggest that the cross-species transmission event occurred between the years 1915
and 1941, most likely around 1931 (Korber et al, 2000). Currently, the most accepted
theory for the method of HIV introduction into humans is through acquisition of
SIVcpz by contact with contaminated chimpanzee meat or blood during the
acquirement, processing, or consumption of bushmeat.
1.2 The HIV-1 Virion
Mature HIV-1 virions are approximately 100 nm in diameter, with a cone shaped
core composed of p24 capsid (CA) protein (Fig. 1.1). Within this core are two copies
of the positive sense RNA genome, closely associated with the p7 nucleocapsid
protein (NC). Also within the core are the reverse transcriptase (RT), protease (PR),
integrase (IN), Vpr, and p6 proteins. Small amounts of the Nef and Vif viral proteins
are incorporated into virions, but this incorporation may be non-specific and its
significance is unclear. Host-cell derived cyclophilin A is incorporated through a
specific association with p24. The virion is enveloped by a lipid bilayer derived from
the host cell membrane, and contains host cell cytoplasmic membrane-associated
proteins in addition to the virally encoded gp41 transmembrane (TM) and gpl20
surface (SU) envelope glycoproteins. gp41 and gpl20 are non-covalently associated
as heterodimers, and arranged as trimers on the surface of the virion. The pi 7 matrix

















Figure 1.1. The HIV-1 virion. Schematic representation of a cross section
through the mature HIV-1 virion. The host cell-derived lipid bilayer contains
trimeric Env glycoproteins composed of SU (gpl20) and TM (gp41)
heterodimers. Host cell membrane proteins such as HLA molecules are also
incorporated during virion budding. The MA protein is closely associated with
the inner surface of the lipid membrane. CA forms the viral core, and
specifically incorporates the host protein cyclophilin into the virion. Two
copies of single stranded genomic RNA coated in NC protein are located
within the core. The three viral enzymes PR, RT, and IN are also present within
the virion, as are the Vpr and p6 viral proteins. Figure copied from (Vogt,
1997).
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1.2.1 Genomic organisation of HIV-1
HIV-l is a complex retrovirus and therefore includes a number of accessory genes in
addition to the gag, pol, and env open reading frames (ORFs) that are common to all
retroviruses. The 9.2 kilobase (Kb) HIV-1 RNA genome contains nine ORFs and is
flanked by regulatory sequences that form components of the proviral long terminal
repeats (LTRs). HIV-1 genomic RNA also contains a number of cA-acting elements,
which are necessary for efficient and coordinated viral replication. A diagram of the
HIV-1 genome and encoded proteins is shown (Fig. 1.2). The gag, pol, and env genes
encode structural proteins and are translated as polyprotein precursors (Pr55Gag,
Prl60Ga8"Po1, and gpl60 respectively), which are subsequently cleaved into their
component proteins by viral or cellular proteases, gag encodes the matrix (MA, pi7),
capsid (CA, p24), nucleocapsid (NC, p7), and p6 proteins, pol encodes the three viral
enzymes, protease (PR, plO), the heterodimeric reverse transcriptase (RT), and
integrase (IN, p32). env encodes for surface (SU, gpl20) and transmembrane (TM,
gp41) envelope glycoproteins. The remaining six ORFs encode the regulatory and
accessory proteins Vif, Vpr, Vpu, Tat, Rev, and Nef (Freed and Martin, 2001).
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fat
Figure 1.2. HIV-1 Genome and Encoded Proteins. A genome map showing
the location and reading frames of the nine HIV-1 genes. Sizes of the primary
translation products (in some cases polyproteins), and the processed mature viral




The 55 kilodalton (KDa) Gag precursor protein (Pr55ga8) is translated from an
unspliced 9.2 Kb mRNA transcript. After translation Pr55Cae oligomerises and is
targeted to the cellular membrane, where it is cleaved by the viral protease
concomitantly with budding to release the MA, CA, NC, and p6 proteins (Gottlinger
et al., 1989).
The N-terminus of Pr55Gag comprises the 132 amino acid pi7 (MA) protein. MA
attaches to the inner surface of the viral membrane and forms a matrix between the
envelope and capsid. A host cell N-myristyl transferase post-translationally modifies
MA by adding a myristic acid moiety to the N-terminal glycine. This myristate
anchors the Pr55Cag polyprotein to the cellular membrane during virion assembly
(Ono and Freed, 1999). Additional regions of MA are required for targeting of
Pr55Gag to the plasma membrane during this process (Ono et al., 2000; Ono et al.,
1997). MA also interacts with gp41 and has a role in the incorporation of Env
glycoproteins into the nascent virion during budding (Freed and Martin, 1996;
Murakami and Freed, 2000). It has been reported that mutations in MA can lead to
impairment of viral DNA synthesis upon infection of a new cell, possibly by causing
defects in uncoating (Casella et al., 1997; Kiernan et al., 1998). Other reports suggest
that the basic domain ofMA has a role in translocation of the preintegration complex
into the nucleus (Bukrinsky et al., 1993a; Vonschwedler et al., 1994), and that C-
terminal phosphorylation of MA may be important for productive infection of
terminally differentiated cells (Gallay et al., 1995).
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Positioned next to MA in the Pr55Gag polyprotein is p24 (CA), which forms the viral
core. CA is composed of two domains, an N-terminal core domain and a C-terminal
dimerisation domain. The core domain is important for correct viral core
condensation/maturation, and contains a cyclophilin A-binding loop (Gamble et al.,
1996). Incorporation of cyclophilin A into virions enhances infectivity, perhaps by
aiding correct CA refolding upon maturation or facilitating the uncoating process in
the new host cell, although its specific role in these processes role is unclear (Gamble
et al., 1997; Grattinger et al., 1999; Wiegers et al., 1999). The C-terminal
dimerisation domain is involved in virion assembly, CA dimerisation, and Gag
multimerisation (Gamble et al, 1997). Within the dimerisation domain is a 20 amino
acid region known as the major homology region (MHR), which is highly conserved
between retroviral genera. The MHR has been implicated in the incorporation of
Prl60Ga8"Po1 into virions and is required for particle formation (Srinivasakumar et al.,
1995).
The p7 (NC) protein is associated with genomic RNA within the virion core. NC has
two zinc finger motifs, which are essential for its function (Mizuno et al., 1996; Poon
et al., 1996). The NC protein binds specifically to an approximately 120 nucleotide
sequence of genomic RNA situated at the 5' end of the viral genome around the
major splice donor site, known as the packaging signal (i|/) (DeGuzman et al., 1998;
Laughrea et al., 1997). Full-length genomic RNA is then delivered by NC to the
assembling virion (Clever and Parslow, 1997). NC also performs a variety of other
functions in the virus life cycle. These include Gag multimerisation, annealing of
tRNAL>" to the primer binding site, stabilisation of genomic RNA dimers,
facilitating initiation and obligatory strand transfers during reverse transcription, and
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melting RNA secondary structures (Bennett et al., 1993; Rist and Marino, 2002;
Bernacchi et al., 2002; Li et al., 1996; Muriaux et al., 1996).
The 51 amino acid p6 protein is liberated from the C-terminus of Pr55Gag. One
function of p6 is to facilitate a step late in virus assembly. More specifically a highly
conserved four amino acid motif towards the N-terminus of p6 has been identified as
necessary for efficient virion budding (Huang et al., 1995). A further role of p6 is
incorporation of Vpr into virions. This function is dependent upon the presence of
several conserved residues near the C-terminus, which interact directly with an alpha
helical structure at the N-terminus of Vpr (Selig et al., 1999; Kondo and Gottlinger,
1996; Paxton et al., 1993; Bachand et al., 1999).
Poi
The pol gene is translated as part of a 160 KDa Gag-Pol fusion protein (Prl60Gag"Po1).
This fusion protein is generated by a -1 ribosomal frameshift during translation of
gag, mediated by a heptanucleotide "slippy sequence" and a short stem loop. The
requirement for a frameshift ensures that po/-derived proteins are expressed at
between 5% and 10% of Gag protein levels. Prl60Oag"Po1 is myristylated at the N-
terminus and targeted to the plasma membrane. The virally encoded PR cleaves
Prl60Gag"Po1 at a number of sites, thereby liberating Gag and the three Pol proteins
plO (PR), p66/p51 (RT), and p32 (IN).
During or soon after viral budding, PR first liberates itself from the Gag-Pol
precursor protein. A number of sites in both Gag and Gag-Pol are then cleaved by
PR, which releases their component proteins and gives rise to the conformational
changes associated with virus maturation. PR is an aspartic protease, with two 10
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KDa monomers of 99 amino acids forming the functional homodimeric enzyme
(Copeland and Oroszlan, 1988; Debouck et al., 1987). The substrate binding site is
located at the interface between the two monomers, and each contributes an aspartic
acid residue to this active site. Upon substrate binding flexible flaps within the dimer
close upon the substrate, creating hydrophobic pockets. The two opposed aspartic
acid residues then coordinate a water molecule to catalyse the hydrolysis of a peptide
bond in the target protein. Protease activity is also dependent on the presence of the
NC and p6 domains, which facilitate dimerisation of the Prl60Gag"Po1 precursor
protein (Zybarth and Carter, 1995)
The mature RT enzyme is a heterodimeric protein composed of p51 and p66
subunits. p51 is obtained by proteolytic cleavage of the C-terminal 15 KDa RNase H
domain from p66, in a reaction performed by the viral PR. Despite being derived
from polyproteins with the same amino acid sequence, the p51 and p66 subunits have
substantially different folding patterns (Huang et al., 1998). As is the case with many
other nucleic acid polymerases, each subunit is composed of four subdomains named
fingers, palm, thumb, and connection. An RNase H domain is also present in the p66
subunit. The active site is situated in the palm of p66, and contains three aspartic acid
residues that are critical for polymerisation activity. Reverse transcriptase catalyses
three distinct enzymatic reactions, RNA-dependent DNA polymerisation, DNA-
dependent DNA polymerisation, and degradation of RNA in DNA-RNA
heteroduplexes (Jacobomolina et al., 1993; Baltimore, 1970; Temin and Mizutani,
1970). HIV-1 reverse transcription is initiated at the 3' end of a tRNALysj primer,
which is annealed to the primer binding site (pbs) situated upstream of the gag
initiation codon. During polymerisation the finger domains close upon the template
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and dNTP. This facilitates a nucleophilic attack by the 3'-OH of the primer upon the
incoming dNTP. The finger domains may then adopt a more open conformation,
allowing release of the pyrophosphate and introduction of the next dNTP into the
active site (Huang et al, 1998).
The IN enzyme is a 32 KDa protein whose role is to integrate the double stranded
DNA viral genome into the host cell chromosome. IN functions as a multimer, and
has 3'-end processing and strand transfer activities (Sayasith et al., 2000). Each
monomer is composed of three domains, an N-terminal domain, a core domain, and a
C-terminal domain. The N-terminal domain has a zinc finger motif and contributes to
multimerisation (Zheng et al., 1996). The core domain plays an essential role in
catalysis (Bushman et al., 1993). The C-terminal domain is required for both 3' end
processing and integration reactions. Regions of the C-terminus may also facilitate
the association of IN with the viral genome during reverse transcription, and nuclear
import of the pre integration complex (Gallay et al., 1997; Engelman et al., 1994).
Env
HIV Env proteins are responsible for the binding of virions to CD4 and a coreceptor
present on target cells, and the subsequent fusion of viral and host cell membranes.
The env gene is translated from singly spliced 4.3 Kb Vpu/Env bicistronic mRNA,
by ribosomes associated with the rough endoplasmic reticulum. A linear
representation of the Env glycoprotein with structural and functional domains
labelled is shown (Fig. 1.3).
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Figure 1.3. Linear representation of HIV-1 Env glycoprotein. The upper
arrow indicates the site of gpl 60 cleavage into gpl 20 and gp41. In gpl 20
crossed-hatched areas represent variable domains (V1-V5) and open boxes
depict conserved sequences (C1-C5). In the gp41 ectodomain the N-terminal
fusion peptide and both N- and C- helices are indicted. The membrane-spanning
domain, endocytosis motif (YXXL), and two predicted cytoplasmic helical
domains (helix-1 and -2) are also shown. Amino acid numbers are indicated.
Figure copied from (Goff, 2001).
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Env is synthesised as a 160 KDa polyprotein precursor (gpl60) of approximately
845-870 amino acids, which is cotranslationally glycosylated by the addition of
asparagine-linked, high mannose sugar chains (Earl et al., 1991; Earl et ah, 1990;
Chan et ah, 1997).
The glycosylation of Env and subsequent post-translational addition of complex
sugars is substantial, and it is estimated that half the molecular mass of virion-
associated gpl20 is composed of oligosaccharide side chains. After translation gpl60
oligomerises and is transported to the Golgi apparatus, where it is cleaved into the
SU (gpl20) and TM (gp41) subunits by a host furin or furin-like protease (Willey et
ah, 1988; Veronese et ah, 1985; Hallenberger et ah, 1992). Newly liberated gp41 and
gpl20 subunits then form a noncovalent association and are transported to the cell
surface. This gp41-gpl20 interaction is fairly weak, leading to substantial shedding
of gpl20 from the surface of Env expressing cells. The Env glycoprotein complex is
then incorporated into budding virion particles, possibly aided by interactions
between the long gp41 cytoplasmic tail and MA (Murakami and Freed, 2000).
Complete, virion-associated gp41/gpl20 heterodimers are arranged as trimers
protruding from the viral envelope (Weiss et ah, 1990; Earl et al, 1990).
The surface protein gpl20 is composed of five variable regions (V1-V5) interspersed
with five more conserved regions (C1-C5) (Starcich et ah, 1986). Formation of
intramolecular disulphide bonds in gpl20 results in the first four variable regions
being arranged into looplike structures (Leonard et ah, 1990) that are well exposed
on the surface of gpl20 (Wyatt et ah, 1993; Moore et ah, 1994). A schematic
representation of the gpl20 folding pattern is shown (Fig. 1.4).
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Figure 1.4. Folded representation of HIV-1 gpl20. Disulphide bonds
and variable regions are shown in colour, N-linked oligosaccharide side
chains are shown as branched structures. Grey regions depict domains
involved in CD4 binding. Figure copied from (Hunter, 1997).
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The conserved regions fold into the gpl20 core, which is composed of an inner
domain, an outer domain, and a 3 sheet also referred to as the "bridging sheet"
(Wyatt et al., 1998). The inner domain faces the trimer axis and gp41, and the outer
domain is exposed on the surface of the trimer. Areas of both domains and the
bridging sheet mediate CD4 binding. Following CD4 binding a conformational
change occurs in gpl20 that forms or exposes the coreceptor binding site (Sattentau
et al., 1993; Trkola et al., 1996). Binding of CD4 and the subsequent engagement of
a coreceptor molecule are likely to promote other conformational changes in the
envelope glycoproteins, which result in activation of gp41 and membrane fusion. The
gpl20 glycoprotein also contains the principal determinants of HIV-1 cellular
tropism. Mutations in gpl20 that lead to altered viral phenotypic properties such as
second receptor usage and cellular tropism will be discussed further (section 1.7.4).
The transmembrane protein gp41 is responsible for fusion of the viral and host cell
membranes. gp41 is similar in many respects to other proteins involved in membrane
fusion such as the HA2 hemagglutinin protein of orthomyxoviruses, the F protein of
paramyxoviruses, and the SNAREs and other eukaryotic proteins involved in fusion
of intracellular vesicles (Chan et al, 1997; Tan et al., 1997; Dutch et al., 2000; Tamm
and Han, 2000; Martin et al., 1999; Jahn and Sudhof, 1999). The N-terminus of
gp41, referred to as the fusion peptide, is highly hydrophobic and essential for
membrane fusion. Two helical structures are C-terminal to the fusion domain, the bl¬
and C-helices. Prior to membrane fusion these two helices may be kept apart, and
held in position by regions of gpl20 (Doms and Moore, 2000). In the fusion-
activated conformation the two helices of each gp41 molecule in the trimer are
arranged in an antiparallel fashion to form six helical bundles (Chan et al, 1997). The
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N-helices, each containing a leucine zipper domain, are situated in the centre to form
a coiled-coil structure. Conformational changes in gpl20 and gp41 that immediately
precede membrane fusion have not been fully elucidated. One proposed mechanism
is the formation of an extended coiled-coil structure, which facilitates insertion of the
fusion peptide into the host cell membrane. Complexing of the N- and C-helices
would then bring the two membranes into close proximity. This "spring-loaded"
model for membrane fusion is similar to that proposed for influenza virus (Bullough
et al., 1994).
1.2.3 Regulatory proteins
Tat (transactivator of transcription)
Tat is a 101 amino acid protein encoded by two exons. The first exon is located just
upstream of env, and the second overlaps with both the env and rev ORFs (Arya et
al., 1985). A further 72 amino acid "one exon" Tat protein is also produced by
translation of only the first exon, and appears to retain all the transactivating
properties of the full length protein. When Tat is absent the RNA polymerase II
transcriptional complex recruited by promoter and regulatory elements within the
LTR is inefficient, and typically results in the transcription of only a few hundred
nucleotides (Feinberg et al., 1991). This basal level of transcription is sufficient to
allow the expression of small amounts of Tat protein. Tat is a nuclear protein, and its
function is to direct the formation of a more processive transcription complex,
thereby increasing the levels of viral mRNA by several hundred fold (Alonso and
Peterlin, 1999). The activity of Tat is dependent upon binding to the Tat-responsive
element (TAR), a 59 nucleotide long stem loop present at the 5' end of all nascent
viral RNAs (Feng and Holland, 1988). Tat-defective HIV-1 mutants do not produce
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progeny virus, hence this protein is essential for viral replication (Sodroski et al.,
1986). The N-terminal 47 amino acids comprise the activation domain, which
contains a cysteine-rich region and a hydrophobic core segment. The C-terminal
(basic) domain is involved in TAR binding, and serves as a nuclear localisation
signal (Siomi et al., 1990; Dingwall et al., 1989). In addition to transactivation, Tat
has a number of other effects including induction of apoptosis in uninfected
bystander cells (Li et al., 1995).
Rev
Rev (regulator of expression of viral proteins) is a 116 amino acid 19 KDa protein
encoded by two exons. Rev is expressed during the early phase of infection, and is
localised primarily in the nucleus but shuttles rapidly between the nucleus and
cytoplasm (Zhang et al., 1996). Its function is to bind to partially spliced and
unspliced viral RNA transcripts that accumulate in the nucleus, and export them
through the nuclear pore complex into the cytoplasm (Fritz et al., 1995; Alonso and
Peterlin, 1999). Binding of Rev to viral RNAs is dependent upon the presence of a
250 nucleotide RNA secondary structure named the Rev response element (RRE),
which is located within env and is present in all partially spliced and unspliced viral
RNA transcripts (Malim et al., 1989). Rev contains two functional domains, an
arginine-rich domain, and an activation domain. The N-terminal arginine-rich
domain mediates nuclear localisation and RNA binding, and is flanked by sequences
that facilitate multimerisation (Hammerschmid et al., 1994). The activation domain is




Nef (negative factor) is a 206 amino acid, 27 KDa membrane-associated
phosphoprotein. The nefgene is unique to primate lentiviruses, and overlaps with the
3' LTR. Nef serves a number of functions in infected cells, although the best
characterised is the downregulation of CD4 and major histocompatibility complex
(MHC) class I molecules from the cell surface (Rhee and Marsh, 1994; Mangasarian
and Trono, 1997; Garcia and Miller, 1991). After translation, Nef is myristoylated
near the N-terminus and directed to the inner surface of the plasma membrane. Nef
then attaches to the cytoplasmic tail of CD4, and associates CD4 with adapter protein
complexes in clathrin-coated pits, leading to CD4 internalisation (Aiken et al., 1994;
Greenberg et al., 1997). Following endocytosis Nef interacts with (3-COP in the
endosome, thereby targeting CD4 for lysosomal degradation (Benichou et al., 1994;
Piguet et al., 1999). This downregulation of CD4 reduces the formation of
intracellular complexes between CD4 and gpl20. Downregulation of MHC class I
molecules provides some protection for virally infected cells against recognition by
cytotoxic T lymphocytes (Collins et al., 1998). Other functions of Nef include the
enhancement of virion infectivity (Chowers et al., 1995; Chowers et al., 1994), and
modulation of cellular activation pathways (Swingler et al., 1999). Small amounts of
Nef are also incorporated into virions (Pandori et al., 1996). Viral isolates from a few
individuals who have been infected with HIV-1 for many years without progressing
to AIDS have inactivating mutations in nef (Rhodes et al., 2000; Deacon et al.,
1995). Thus in some cases Nefmay be important for disease progression.
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Vif
The vif (viral infectivity factor) gene overlaps with both the pol and vpr genes in the
centre of the viral genome. All lentiviruses with the exception of EIAV encode a Vif
accessory protein (Kawakami et al., 1987). Vif is a 192 amino acid, 23 KDa
cytoplasmic protein, present within infected cells in both membrane associated and
cytosolic forms. The primary function of Vif is to enhance the infectivity of viral
particles. This augmentation is highly dependent upon producer cell type, and
independent of target cell type (Gabuzda et al., 1992; Sodroski et al, 1986). When
Vif is not expressed then virions produced by "non-permissive" cells such as primary
lymphocytes and macrophages have altered core structures, and fail to reverse
transcribe correctly in new host cells (Vonschwedler et al., 1993; Borman et al.,
1995). Vif overcomes the antiviral action ofCEM15 (also known as apolipoprotein B
mRNA editing enzyme, catalytic polypeptide-like 3G: APOBEC3G), a cytidine
deaminase only present in non-permissive cell types (Sheehy et al., 2002; Zhang et
al., 2003). CEM15 is incorporated into virions and induces hypermutation during
reverse transcription of the viral genome in the newly infected host cell (Sheehy et al,
2002; Harris et al., 2003; Lecossier et al., 2003). Therefore CEM15 may represent
part of an innate antiretroviral immune effector mechanism that is inactivated by Vif.
Vif may also play a role in virion assembly and maturation, possibly by affecting
Gag processing (Simm et al., 1995; Borman et al, 1995), and it is incorporated into
virions.
Vpr
The vpr (viral protein R) gene encodes a 96 amino acid, 14 KDa protein that is
incorporated at high levels into virions (Cohen et al., 1990). Virion incorporation of
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Vpr is mediated by an interaction with the C-terminus of p6 within Pr55gag. A
number of different functions have been proposed for Vpr. These include aiding
transport of the pre integration complex into the nucleus (Popov et al., 1998a; Popov
et al., 1998b), arresting infected cells in G2 of the cell cycle (Poon et al., 1998), and
stimulation of gene expression driven by the HIV LTR (Cohen et al, 1990). Vpr has
two helical domains that have been implicated in dimerisation, one near the N-
terminus and the other near the centre of the protein (Schuler et al., 1999; Zhao et al.,
1994). The C-terminus of Vpr contains an arginine-rich domain. Vpr forms part of
the preintegration complex, and is particularly important in facilitating replication
within terminally differentiated cells such as monocyte-derived macrophages (Balliet
et al., 1994; Heinzinger et al., 1994). The significance of Vpr arresting cells in G2 is
not clear, but this may represent a mechanism for prolonging the enhanced LTR-
driven transcription that is associated with this stage of the cell cycle (Felzien et al.,
1998). Vpr has also been shown to have a wide range of other properties such as the
formation of ion channels (Piller et al., 1998), instigation or suppression of apoptosis
(Ayyavoo et al., 1997; Stewart et al., 1997), and reduction of mutation rates during
reverse transcription (Mansky et al., 2000; Mansky, 1996).
HIV-2 carries a vpx gene that is homologous to vpr, which may have been obtained
by acquisition of the SIVagm (African green monkey) vpr gene by recombination
(Sharp et al., 1996; Tristem et al., 1998).
Vpu
vpu (viral protein U) is unique to HIV-l/SIVcpz, and no similar gene is present in
HIV-2 or other SIVs (Cohen et al., 1988; Huet et al., 1990; Strebel et al., 1989). Vpu
is a multimeric, 81 amino acid, 16 KDa integral membrane phosphoprotein that is
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translated from vpu-env bicistronic RNA (Schwartz et al., 1990). The N-terminus
comprises a hydrophobic membrane-spanning domain, and the C-terminus consists
of an approximately 50 amino acid hydrophilic cytoplasmic domain (Maldarelli et
al., 1993; Strebel et al, 1989). Serine residues at amino acid positions 52 and 56 are
phosphorylated by casein kinase II (Schubert et al., 1994). Vpu has been associated
with two major functions, degradation of CD4 (Chen et al., 1993; Lenburg and
Landau, 1993; Vincent et al., 1993), and enhancement of virion release from the
plasma membrane (Geraghty and Panganiban, 1993). Vpu mediated degradation of
CD4 is dependent upon binding to the cytoplasmic tail of CD4. gpl60 is thereby
disassociated from CD4 and can be transported to the cell surface for incorporation
into virions (Chen et al, 1993). The mechanism by which Vpu enhances virion
release is less well characterised. However, it appears to be independent of both Env
and CD4 (Geraghty and Panganiban, 1993), and may involve the ability of Vpu to
form cation-selective ion channels (Ewart et al., 1996; Schubert et al., 1996).
1.3 The HIV-1 life cycle
The first step in the HIV-1 replicative cycle is virion adsorption to a target cell
expressing CD4 and a coreceptor molecule (Fig. 1.5). This is followed by fusion of
the viral and host cell membranes, leading to internalisation and uncoating of
subviral particles, and exposure of the viral nucleoprotein complex.
Reverse transcription of the viral genome occurs within this complex soon after entry
into the cell, and results in the production of linear, double stranded viral DNA. The
preintegration complex is then transported from the cytoplasm into the nucleus and
the viral genome is integrated into the host cell chromosome. Transcription of the
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integrated provirus and subsequent modifications by host cell enzymes results in the
production of both full-length and spliced viral transcripts, which are transported into
the cytoplasm for translation into proteins. At the host cell membrane genomic RNA
is packaged into the newly forming virion. The virion then buds from the cell and is
released into the extracellular matrix.
Protease mediated cleavage of Gag and Gag-Pol precursor proteins during or soon
after budding results in core condensation, and the new virion is then prepared for
infection of a new cell.
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Figure 1.5. The HIV-1 Life Cycle.
Early stage: (1) HIV-1 adsorbs to cell and interacts with both CD4 and a
coreceptor molecule via gpl20. (2) Membrane fusion mediated by gp41
allows entry of the subviral particle into host cell. (3) Partial uncoating
takes place during or soon after entry. (4) Reverse transcription occurs in
the cell cytoplasm. (5) The linear, double stranded DNA product is
transported into the nucleus within a preintegration complex. (6) The
integrase enzyme (open circles) mediates integration of viral DNA into the
host cell chromosome.
Late stage: (7) Integrated viral DNA serves as a template for transcription
of viral mRNAs, which are transported into the cytoplasm and translated
into proteins. (8) and (9) Envelope and Pr55Gag/Prl60Gag"Po1 are
transported to the plasma membrane via independent pathways. (10) Full-
length viral genomic RNA and other virion components are also assembled
at the cellular membrane. The progeny virus then buds from the cell as an
immature particle. (11) Proteolysis of virion polyproteins by virally
encoded protease leads to the production of mature infectious particles.
Figure modified from (Goff, 2001).
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1.3.1 Adsorption and fusion
In contrast to enveloped viruses such as influenza that are internalised prior to
membrane fusion, HIV-1 fusion can occur at the cell surface and is not dependent
upon pH changes associated with endocytosis. A large number of factors can lead to
adsorption ofHIV-1 virions to host cells, but the first requisite interaction for cellular
entry of naturally occurring HIV-1 isolates is between gpl20 and CD4 (Maddon et
al., 1986; Dalgleish et ah, 1984). CD4 has four extracellular immunoglobulin-like
domains named D1 to D4 (D4 being proximal to the cellular membrane). Residues in
Dl, corresponding to the complemantarity-determining region 2 of an
immunoglobulin light chain variable domain, form a charged ridge and are
responsible for binding gpl20 (Kwong et ah, 1998). In particular, a phenyalanine
side chain at position 43 in CD4 inserts into a cavity in gpl20, making multiple
contacts with discontinuous residues in gpl20 (Kwong et al, 1998). The determinants
in Env for CD4 binding map mostly to regions of C3 and C4, but also to a
discontinuous and conformation dependent domain of gpl20. Binding of CD4
induces conformational changes in the core of gpl20 (Myszka et ah, 2000), and
exposes/forms the coreceptor binding site. Each gpl20 monomer in the trimeric
envelope glycoprotein spike contains a binding site for CD4, and engagement of a
single monomer by one CD4 molecule is sufficient to induce conformational changes
in all three gpl20 monomers in the spike (Salzwedel and Berger, 2000). Other
changes in Env at this point may include rearrangements of the N- and C- helices of
gp41 (exposure) necessary for membrane fusion (Furuta et ah, 1998; Sattentau and
Moore, 1991). CD4 has flexible regions between D2 and D3, and also between D4
and the cellular membrane, which are important for its function as a lentiviral
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receptor (Yachou and Sekaly, 1999; Healey et al., 1990; Moir et al., 1996). It is
possible that bending of CD4 at these points allows gpl20 to "approach" CD4
laterally for binding, and also facilitates the subsequent contacts between gpl20 and
the coreceptor molecule (Clapham and McKnight, 2002).
Engagement of a second receptor or "coreceptor" molecule is also necessary for
entry ofHIV into cells. HIV coreceptors are all members of the 7-transmembrane G
protein coupled receptor superfamily, and the two most frequently used by HIV-1
isolates are CCR5 and CXCR4 (Feng et al., 1996; Alkhatib et al., 1996b; Choe et al.,
1996; Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996). Different HIV-1
isolates vary greatly in the specifics of their interactions with coreceptor molecules,
but generally the N-terminus of CCR5 and the second extracellular loop of CXCR4
contain the most important determinants for binding of gpl20 (Hill et al., 1998; Lu et
al., 1997). Differential coreceptor usage is an important determinant of HIV-1
cellular tropism. Therefore the structure and cellular distribution of different
coreceptors, as well as their role in HIV entry and tropism will be discussed later in
more detail (section 1.7.2)
The conformational changes in both gpl20 and gp41 associated with CD4 and
coreceptor binding result in exposure of the fusion peptide at the N-terminus of gp41.
This fusion peptide inserts into the cellular membrane, making gp41 an integral
protein in the two membranes. Further interactions within the gp41 trimer result in
the formation of a thermodynamically stable six helical bundle (Chan et al, 1997).
Energy released during this transition is thought to drive fusion of the viral and host
cell lipid bilayers. Several trimeric envelope spikes are involved in the induction of a
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fusion pore, but the exact number required is not known (Clapham and McKnight,
2002). In influenza virus three to six HA trimers are necessary for this process
(Danieli et al., 1996). HIV-1 envelope proteins present on the surface of infected
cells can also mediate fusion directly with adjacent cells if they express the
appropriate receptors, resulting in the formation of syncytia.
1.3.2 Reverse transcription
Subsequent to membrane fusion the viral core enters the cell cytoplasm. Events
immediately after membrane fusion and prior to reverse transcription (collectively
referred to as uncoating) are poorly defined but involve partial disruption of the viral
core to form a preintegration complex (PIC). The PIC is composed ofMA, NC, Vpr,
RT, IN, and viral RNA. This nucleoprotein complex is involved in reverse
transcription, nuclear import, and possibly integration of the double stranded DNA
viral genome (Bowerman et al., 1989; Bukrinsky et al., 1993b; Heinzinger et al,
1994; Freed and Martin, 1994).
Retroviral reverse transcription is performed by the RT enzyme, and occurs in a
number of discrete steps (Gilboa et al., 1979). The primer used by HIV-1 is
tRNALys3, which is carried within the virion (Jiang et al., 1993). Primer annealing to
the primer binding site (pbs) located near the 5' end of the viral genome is facilitated
by NC (Rodriguezrodriguez et al., 1995; Huang et al., 1997). The primer is elongated
towards the 5' end of the genomic RNA to synthesise U5 and R sequences, and
thereby generate minus strand strong-stop DNA. RNase H activity of RT then
degrades RNA outwith the pbs in the resultant DNA/RNA heteroduplex. This is
followed by a strand transfer or "jump" of the minus strand strong-stop DNA from
32
the 5' to the 3' end of the viral genome, guided by complementary R sequences.
Elongation of minus strand strong-stop DNA then continues to the 5' end of the
genome, and as polymerisation proceeds RNase H activity degrades the entire RNA
genome, with the exception of short purine-rich sequences that serve as primers for
plus strand DNA synthesis. In HIV there are two such regions, the standard
polypurine tract (PPT), which is located just 5' to U3 in the 3' LTR and is common
to all retroviruses, and an additional central PPT (cPPT) located near the middle of
the genome. The cPPT is required for optimal HIV reverse transcription (Charneau
et al., 1992). Plus strand synthesis is initiated at the PPTs using minus strand DNA as
template. The original tRNALys3 primer and RNA PPTs are degraded, and transfer of
plus strand strong-stop DNA occurs, facilitated by the complementary pbs sequences
at each end of the genome. Elongation of both plus and minus strands then proceeds
to completion. Plus strand synthesis initiated at the cPPT terminates at the end of the
minus strand. However, the transferred plus strand strong-stop DNA terminates at a
sequence known as the central termination signal (Charneau et al., 1994), which is
situated downstream of the cPPT. This causes the displacement of approximately 99
nucleotides, and the resultant DNA "flap" has been implicated as a determinant of
nuclear import in terminally differentiated cells (Zennou et al., 2001; Zennou et al.,
2000). Any discontinuities in the final double stranded viral DNA are likely resolved
post integration (Miller et al., 1995).
1.3.3 Integration
After reverse transcription the double stranded DNA is transported into the nucleus
within the preintegration complex. Unlike simple retroviruses, lentiviruses do not
require the breakdown of the nuclear membrane associated with mitosis to gain
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access to cellular DNA. Therefore lentiviruses can productively infect nondividing
and terminally differentiated cells such as macrophages and microglia. The specific
process by which the HIV-1 pre integration complex is transported across the intact
nuclear membrane is not known, but c/s-acting components of the double stranded
viral DNA and nuclear localisation signals present in several proteins within the PIC
have been implicated in this process (Zennou et al, 2001; Zennou et al, 2000; Gallay
et al, 1997; Popov et al, 1998a; Popov et al, 1998b).
The steps required for integration of HIV into the host cell DNA are performed by
IN. Firstly 3' end processing takes place, whereby IN removes the two terminal
nucleotides at the 3' ends of the blunt ended LTRs (Roth et al., 1989). This
endonucleolytic cleavage occurs at the 3' end of a highly conserved CA dinucleotide,
and produces 3' hydroxyl groups. The resultant 3' OH ends are used in a strand
transfer reaction to attack the phosphodiester bonds of host cell target DNA
(Fujiwara and Mizuuchi, 1988). This forms new phosphodiester bonds between the
viral and host DNA, and leaves two staggered nicks in the double stranded host
DNA. The result is a gapped intermediate, where several nucleotides immediately
flanking the 5' ends of the viral DNA are missing. Host enzymes repair these gaps
and the provirus is then both fully integrated, and flanked by 5 bp of duplicated
target site sequence.
Retroviral proviruses appear to be inserted into the host genome in a nearly random
fashion with little or no sequence specificity. However, slight deviations from a
completely random distribution of integration sites have sometimes been noted
(King et al., 1985). Investigations using in vitro systems have identified some
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potential "hot spots" for integration (Kitamura et al., 1992; Shih et al., 1988). Other
in vivo observations have identified a slight preference for integration into
transcriptionally active genes (Scherdin et al., 1990; Mooslehner et al., 1990), and
open or accessible chromatin structures (Craigie, 1992; Pryciak et al., 1992).
Because some sites in the host genome are transcriptionally silent whereas others are
expressed at high levels, the specific site of proviral integration can greatly affect
subsequent expression of the viral genome (Feinstein et al., 1982; Akroyd et al.,
1987).
1.3.4 Transcription of viral DNA
Events following integration mark the beginning of the "late" stage of retroviral
replication. The integrated provirus is expressed in a similar manner to cellular
genes, and is dependent upon host cell proteins for transcription. Promoter and
enhancer sequences within the 5' LTR recruit RNA polymerase II and other cellular
proteins to the transcriptional start site situated at the U3-R border. This results in the
production of full-length viral transcripts. Cellular machinery adds a 5' cap then
cleaves and polyadenylates the RNA at the R-U5 border of the 3' LTR. Resultant
full-length transcripts are either packaged into new virions, used as templates for the
translation of Gag and Gag-Pol precursor proteins, or spliced to produce mRNA for
translation of Env and auxiliary proteins. Splicing of HIV-1 RNA is complex, and
over 30 different HIV-1 transcripts have been identified in productively infected cells
(Schwartz et al, 1990; Purcell and Martin, 1993). The promoter clearance and
processivity of RNA polymerase II instigated by transcription factors such as NF-tcB
and Spl is inefficient, and results in only basal levels of transcription. This early
transcription leads to expression of Tat, which localises within the nucleus. Tat then
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promotes phosphorylation of the C-terminal domain of RNA polymerase II by
interacting with both the cyclin T/CDK9 complex, and the TAR stem loop in nascent
viral RNAs. The result is a several hundred-fold increase in production of full-length
viral transcripts (Alonso and Peterlin, 1999).
HIV-1 gene expression results in the translation of "early" and "late" gene products.
Initially, multiply spliced viral transcripts are exported from the nucleus by normal
cellular pathways, allowing translation of the early proteins Tat, Rev, and Nef. After
translation Rev is imported into the nucleus and facilitates export of full-length and
partially spliced viral RNAs into the cytoplasm by interaction with both the RRE and
the nuclear export machinery. This allows the translation of the late gene products
Pr55Gag, Prl60Gag"Po1, Env, Vpu, Vpr, and Vif. The transition from early to late gene
expression is associated with the accumulation of a critical level of Rev (Pomerantz
et al., 1990; Kim et al., 1989).
1.3.5 Assembly and Budding
HIV-l virions are assembled at the plasma membrane. Virion assembly is driven
primarily by the Pr55sag precursor protein, and expression of this polyprotein in
isolation of the rest of the HIV-1 genome is sufficient to produce non-infectious
virus-like particles (Freed and Martin, 2001). It is estimated that approximately 2000
interacting Gag polyproteins are involved in the formation of a single retroviral
virion (Stromberg et al., 1974). Pr55gag and Prl60gag"po1 assemble and are anchored to
the inner side of the plasma membrane by a myristic acid attached to the N-terminus
of MA. NC incorporates dimers of genomic RNA into the newly forming virion
through an association with the packaging signal. Vpr is included via an interaction
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with p6 (Paxton et al, 1993). Incorporation of envelope glycoproteins may be aided
by a specific interaction between MA and the cytoplasmic domain of gp41 (Freed
and Martin, 1996; Murakami and Freed, 2000). Cellular components such as
cyclophilin A and tRNAs, as well as integral host cell membrane proteins, also form
part of the budding virion. Cleavage of Pr55gag and PrlbO®38*^1 by PR then causes the
dramatic structural rearrangements associated with virus maturation.
1.4 Pathogenesis of HIV-1
1.4.1 Transmission of HIV-1
Early epidemiological observations suggested that homosexual sex between men was
a significant transmission route for HIV. It was subsequently noted that HIV could
also be transmitted through heterosexual sex (Harris et al., 1983). In developed
countries heterosexual HIV transmission has gradually become more prevalent, and
the great majority of newly acquired HIV infections worldwide are via this route.
HIV transmission can also occur from mother to child. Vertical transmission may
occur by intrauterine infection of the foetus, through exposure to maternal blood and
genital secretions at birth, or postnatally via breast-feeding. In the absence of
appropriate treatment and medical advice the transmission rate from mother to child
can be as high as 60% in some geographical areas, although rates of around 30% are
more common (Duong et al., 1999; Peckham and Gibb, 1995). Where available, the
use of antiretroviral therapy for both mothers and neonates, along with caesarean
section delivery and advice against breast-feeding has resulted is a drastic decrease in
vertical transmission (Duong et al, 1999).
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A further mode ofHIV transmission is parenteral. This may occur during transfusion
with infected blood products, by exposure to contaminated blood through re-use of
needles or syringes among intravenous drug users, or in health care facilities where
instrument sterilisation is inadequate (Quinn, 1996). A significant number of
haemophiliacs and blood transfusion recipients have been infected by receiving
either blood or blood products (such as factor VIII and factor XI) contaminated with
HIV. The introduction of compulsory screening of donated blood and heating of
blood products has resulted in a dramatic decrease in this route of HIV transmission
(Lackritz et al., 1995). Moreover provision of sterile injecting equipment has reduced
the rates of HIV transmission among intravenous drug users in developed countries
(Coates et al., 1996)
The probability of HIV transmission is related to the amount of infectious virus
present in the transmitting body fluid. Therefore the transmission risk is greatest
when viral loads are high, such as at the peak of viraemia in the acute stage of
infection, or later during the symptomatic AIDS phase.
1.4.2 Disease Progression
The natural history of HIV infection can be classified into three phases. The first
phase is acute primary infection, characterised by a transiently high viral load. In
over 50% of newly infected individuals this is accompanied by a seroconversion
illness often described as influenza- or infectious mononucleosis-like symptoms
(Schacker et al., 1996). These may include headaches, muscle pains, fever, sore
throat, and swollen lymph nodes. Initial symptoms normally last for several weeks
but lymphadenopathy, lethargy, and malaise may persist for many months.
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Seroconversion can occur any time from several days to several months after primary
infection, but antibodies against the viral core or envelope can usually be detected
within six to eight weeks (Feinberg, 1996).
Following the acute phase a sharp reduction in viral load ensues, marking the
beginning of the "asymptomatic" period of infection. At this point there are few
clinical manifestations associated with HIV infection, although some individuals
may experience a persistent generalised lymphadenopathy (Feinberg, 1996). The
asymptomatic period can last from several months to over ten years in the absence of
antiretroviral therapy.
The third stage of infection is the symptomatic phase, or acquired immunodeficiency
syndrome (AIDS). This phase is characterised by the presence of immune
abnormalities, opportunistic infections, neurological disorders, and
immunodeficiency-associated cancers, which ultimately culminate in death of the
infected individual.
1.4.3 Viral Dynamics and Immune Responses
Each stage of HIV infection is associated with alterations in viral dynamics
accompanied by changes in the anti-HIV immune response (Fig. 1.6). After initial
infection there is a burst of viral replication leading to a rapid increase in plasma





Figure 1.6. Typical Course of HIV Infection. Patterns of CD4 T
lymphocyte decline and duration of infection can vary greatly between
patients, as do the actual values of viral RNA load. Figure copied from (Fauci
and Desrosiers, 1997).
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This initial rse in viraemia in the first few weeks of infection is concomitant with a
significant decline in CD4+ T lymphocytes (Gaines et al., 1990). Specific anti-HIV
immune responses can be detected approximately 3-6 weeks after infection (Ho et
al., 1985; Gaines et al., 1987).
A reduction in virus titre is associated with the appearance of HIV specific CD8+
cytotoxic T lymphocytes (Koup et al., 1994), although factors such as the presence of
virus suppressing cytokines and possible exhaustion of suitable CD4" host cells may
also contribute to this decline (Phillips, 1996). CD4" T lymphocyte levels then
rebound as the asymptomatic stage of infection is entered, but seldom return to
preinfection levels.
The asymptomatic period is usually associated with a steady decline in numbers of
CD4" T lymphocytes, whereas levels of CD8~ lymphocytes remain stable or slightly
increase. Viral loads are generally constant throughout this period, but are
maintained at these steady state levels by a remarkably dynamic process of viral
replication in conjunction with immune-mediated destruction of virions and infected
cells (Coffin, 1995; Perelson et al., 1996; Ho et al., 1995; Wei et al., 1995).
Progression to AIDS is associated with a rapid decline in both CD4^ and CD8+ T
lymphocytes, and an increase in viral load. When CD4 counts have dropped from
normal levels of approximately 600-1200 cells'pi to around 500 cells/pl the first
symptoms can appear in infected individuals. At CD4 counts of below 200 cells/pl
the individual is also susceptible to opportunistic infections and neoplasms
associated with AIDS (Fauci and Desrosiers, 1997). AIDS is the result of both the
progressive depletion of CD4' T lymphocytes which is not matched by a
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corresponding increase in the production of new cells, and a number of other factors
such as the irreversible destruction of lymphoid tissue (Fauci, 1988; Klatzmann et al.,
1984a; Hellerstein, 2002; McCune, 2001; Cohen and Fauci, 2001).
1.4.4 Antiviral Therapy
While the development of a prophylactic vaccine for eliciting protective immune
responses against HIV has proven extremely challenging (Nabel, 2001), significant
advances have been made in the field of antiretroviral therapy (Richman, 2001). All
currently licensed antiretroviral drugs target the RT or PR viral enzymes, and fall
into four different categories: nucleoside reverse transcriptase inhibitors (NRTIs),
nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase
inhibitors (NNRTIs), and protease inhibitors (Pis). Treatment regimens usually
consist of a combination of three drugs, typically comprising 2 NRTIs and a PI or a
NNRTI (BHIVA, 2001). These regimens, termed highly active antiretroviral therapy
(HAART), usually result in a significant decline in viral load, an increase in CD4
count, and a decrease in mortality (Vella and Palmisano, 2000). However, issues
such as expense, bioavailability, toxic side effects, pill burden, and the outgrowth of
resistant viral variants make currently available therapies far from ideal. In addition,
the majority of HIV infected individuals worldwide have no access to such
treatments. A wide range of alternative therapies, designed to target almost every
section of the HIV life cycle are currently under development.
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1.5 Genetic diversity of HIV-1
One of the most striking features of HIV biology is the remarkable genetic diversity
observed between different viral isolates. This high degree of genetic variability was
originally observed soon after the discovery of HIV (Hahn et al., 1984; Muesing et
ah, 1985; Sanchez Pescador et ah, 1985; Ratner et ah, 1985; Shaw et ah, 1984) and it
rapidly became clear that intrapatient HIV sequences exhibit evolution over time
(Saag et ah, 1988; Fisher et ah, 1988; Hahn et ah, 1986). HIV sequences from a
single study subject can be as much as 10% divergent at the nucleotide level. The
resulting group of closely related but genetically distinct viral variants has come to
be referred to as a "viral quasispecies" (Goodenow et ah, 1989). This term is derived
from the "molecular quasispecies" (Eigen and Schuster, 1977) originally used to
describe a well-defined concept in molecular evolution (Eigen, 1971) whereby
selection pressures act upon on a distribution ofmolecules at equilibrium comprising
a master copy surrounded by related sequences. Thus, a viral quasispecies does not
conform to this original mathematical definition of a molecular quasispecies (Eigen,
1996; Domingo and Holland, 1997; Jenkins et ah, 2001) and other designations such
as "viral swarm" have been suggested (Temin, 1989). Despite these inconsistencies a
number of parallels can be drawn between the two situations. Therefore "viral
quasispecies" or simply "quasispecies" has been loosely adopted in virology to refer
to either the related viral variants that have diverged within a single infected
individual, or genetically distinct subpopulations of these variants (although it is also
used in many other contexts: Smith et ah, 1997). This variation may have important
implications for evasion of host immune responses, development of resistance to
antiviral therapies, and in vivo viral adaptation to new cell and tissue types.
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1.5.1 Sources of mutation during HIV replication
Genetic variability is determined by the mutation rate per replication cycle, the
number of replication cycles within a defined time, and the fixation rate ofmutations
within a population. HIV-1 replication is complex and involves three enzymes that
provide opportunities for mutation to occur. During retroviral replication RT uses
viral RNA as a template to produce double stranded DNA, which is then integrated
into the host cell genome. RT does not include a 3'—>5' exonuclease function that
would permit proofreading of misincorporated bases, although several rudimentary
proofreading mechanisms have been identified that may partially compensate for this
deficiency (Arion et al., 1998; Meyer et al., 1998). The fidelity of HIV RT is
therefore low, with estimates ranging from approximately 10"4 to 3.4 x 10"5
mutations per base incorporated, corresponding to between approximately 0.34 and 6
errors per genome per round of replication (Roberts et al., 1988; Preston et al., 1988;
Ji and Loeb, 1992; Mansky and Temin, 1995). The wide range of these estimates
largely reflects differences in experimental designs, with isolated HIV RT having
lower fidelity than in vivo RT reactions (Mansky and Temin, 1995). The mutation
rate of HIV-1 RT is therefore slightly higher but of a similar order to those of RTs
isolated from other retroviruses (reviewed in Mansky, 1998). Interestingly, given
retroviral genome sizes of approximately 8-12 Kb it appears that these mutation rates
are close to the maximum possible while still maintaining genomic and structural
integrity within the viral populations.
Investigations into the regularity that different types of error occur during reverse
transcription have produced varying estimates depending upon the model system
used (reviewed in Preston and Dougherty, 1996). It appears that the overall mutation
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rate is similar regardless of whether the template is DNA or RNA, although the
specific distribution of mutations is partially dependent upon template molecule type
(Preston and Dougherty, 1996). Template position can also have dramatic effects on
the fidelity of reverse transcription (Bebenek et al., 1989). Point mutations
predominate, with transitions more common than transversions. Several additional
types of error are also frequently observed including insertions, deletions,
frameshifts, and recombination events (Bebenek et al, 1989; Temin, 1993) (reviewed
in Katz and Skalka, 1990; Coffin, 1992; Preston and Dougherty, 1996). Frameshifts
are most often represented by the addition or deletion of a single base in a
homopolymeric run, and occur with a frequency several fold lower than point
mutations (Pathak and Temin, 1990b; Pathak and Temin, 1990a). Genetic
rearrangements such as insertions and deletions are less common than frameshifts,
and deletions appear to be potentiated by the presence of internal repeats (Delviks
and Pathak, 1999). Another well-documented event that can occur during reverse
transcription is hypermutation (Vartanian et al., 1991). This is a fairly common
phenomenon probably resulting from fluctuations in intracellular
deoxyribonucleotide triphosphate ratios where (most commonly) a large percentage
of Guanines in the genome are replaced by Adenines (Vartanian et al, 1991; Kim et
al., 1996; Martinez et al., 1994). Hypermutation has also been identified in other
lentiviruses (Wainhobson et al., 1995) and in hepatitis B virus (Gunther et al., 1997).
Finally, recombination can occur between the two copackaged genomic RNA
molecules present in the virion, sometimes leading to extremely dramatic sequence
changes (see section 1.6). The overall fidelity of reverse transcription can be affected
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by a number of additional factors, for example by the presence of some antiretroviral
drugs (Julias et al., 1997; Mansky et al., 2002; Mansky and Bernard, 2000).
If the host cell undergoes mitosis after proviral DNA integration then the provirus is
replicated in the same manner as other cellular genes. This process is guided by
cellular DNA polymerases a and 8 (Waga and Stillman, 1998), which include
proofreading functions and have a misincorporation rate of less than 1 for every
billion bases copied. Therefore mutations incorporated during cell division do not
significantly contribute to the high level of in vivo HIV genetic variation. However, it
is possible that very occasionally mutations incorporated during mitosis (especially
in rapidly dividing cells) may produce new viral variants or cause reversion of a
defective provirus.
New HIV genomes and mRNAs are produced within the cell by RNA polymerase II,
which lacks 3'—>5' exonucleolytic proofreading activity and further contributes to
mutations incorporated during HIV replication. The specific mutation rate for this
enzyme is currently unknown but is likely to be of a similar order to that of
prokaryotic RNA polymerases i.e. one error in every 104-105 nucleotides
polymerised (Erie et al., 1993; Blank et al., 1986; Libby and Gallant, 1991). Hence
misincorporations by cellular RNA polymerase II may be as important for generation
ofHIV diversity as RT induced errors.
In addition to the polymerase errors outlined above, mutation of retroviral DNA or
RNA may also result from other factors. These include spontaneous chemical
"decay" of RNA or DNA (Lindahl, 1993) leading to nucleotide misincorporations
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during double stranded viral DNA synthesis, and aberrant RNA editing (Dougherty
and Temin, 1986).
It has been suggested that certain areas of the HIV genome have especially high
mutation rates and that the presence of these mutational "hotspots" may explain why
specific regions, such as within env, are hypervariable as compared with the rest of
the HIV genome (Bebenek et al, 1989). Other studies have failed to find these
inherent differences in mutation rate (Ji and Loeb, 1994), and instead highlighted the
importance of factors such as selection pressures in the fixation of mutations and
development of variation in different subgenomic regions.
1.5.2 Viral turnover in HIV infected individuals
A high rate of replication also contributes to rapid evolutionary changes. HIV
establishes a persistent infection in humans, which often lasts for over 10 years
before culminating in AIDS. It has long been known that HIV-1 actively replicates to
some extent throughout the course of infection (Embretson et al., 1993; Pantaleo et
al., 1993). However the magnitude of this replication was not fully appreciated until
the development of potent antiretroviral therapies and new techniques for the
measurement of viral RNA, such as branch chain DNA and RT-polymerase chain
reaction assays (RT-PCR). Use of a protease inhibitor or a non-nucleoside reverse
transcriptase inhibitor almost completely suppressed viral replication in treated
patients. Careful measurement of viral loads in these patients after drug
administration therefore allowed the rates of clearance for free virions in the
peripheral blood and productively infected cells to be calculated. Results indicated
that the half-life of HIV virions in plasma is approximately 6 hours or less, and that
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of productively infected CD4+ cells contributing to this virus is approximately 1.5
days (Ho et al, 1995; Wei et al, 1995; Perelson et al, 1996; Perelson et al., 1997). As
there is little natural short-term variability in plasma HIV RNA levels over time
(Hughes et al., 1997c) these figures for the clearance rate of virions and infected cells
must be equivalent to the numbers produced. Therefore approximately 108-109 free
virions and 106-107 productively infected cells must be produced and cleared each
day solely to generate the virus observed in plasma. In the body as a whole the
corresponding figures are likely to be several times higher. Thus the clinically latent
period of HIV-1 infection is not one of virological latency but rather a dynamic
equilibrium characterised by very high levels of viral replication offset by an equally
prodigious immune response.
These interpretations are consistent with data from patients undergoing treatment
with antiviral drugs that require only a small number of mutations for the
development of high level resistance. For example even single codon changes at
specific positions (such as position 181) in the reverse transcriptase gene can
decrease the susceptibility of HIV to the non-nucleoside reverse transcriptase
inhibitor nevirapine by over 100-fold (Richman et al., 1994). Use of nevirapine was
found to cause a rapid drop in HIV RNA levels within the first 1-2 weeks of therapy,
but after this period viral RNA levels rebounded close to pretherapy values (Wei et
al, 1995). The new viral variant that emerged during this period was highly resistant
to nevirapine and by 4 weeks after the initiation of therapy the plasma HIV RNA
consisted of an estimated 100% mutant virus (Wei et al, 1995). Virus that appeared
during this time must either have been pre-existing in the HIV population within the
patient before therapy, or have rapidly evolved after initiation of drug treatment.
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Investigations such as this represent independent confirmation of the extremely rapid
plasma virus turnover, and demonstrate the rate at which previously minor viral
variants can emerge and predominate within the plasma of infected individuals.
Further data from this study came from the investigation of proviral DNA in PBMCs.
In contrast to plasma HIV RNA the accumulation of drug resistant mutant virus in
PBMC proviral DNA was a prolonged process, leading to half-life estimates for
these PBMCs of 50-100 days (Wei et al, 1995). This is compatible with estimates
based on quantification of total HIV proviral levels in patients starting potent
antiretroviral therapy (Stellbrink et al., 1996; Perelson et al, 1997). It therefore
appears that the majority ofHIV virions in plasma are produced by a relatively small
number of HIV DNA-positive cells. One explanation for this finding is that most
HIV DNA in PBMCs is defective, and does not significantly affect the lifespan of the
cell or contribute to plasma virus.
An obvious implication of this consistently high rate of viral turnover is that, when
combined with the error prone nature of viral replication, new genetic variants are
frequently generated. Therefore it is estimated that every possible single base
mutation and a large proportion of possible double mutations are produced every day
in untreated infected individuals (Coffin, 1995).
1.5.3 Fixation rate of mutations in HIV
In addition to the frequency that new genetic variants are generated, the rate at which
specific mutations are fixed within a population is also a major factor in determining
the overall rate of evolutionary change. Clearly, genetic mutations can be deleterious,
neutral, or advantageous to an organism. In coding sequences non-synonymous
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mutations (those that alter the primary amino acid sequence) can compromise
structural or functional constraints manifest in the encoded proteins. Synonymous
changes can also be detrimental in certain circumstances. For example they may alter
RNA secondary structures that are essential for normal functions or involved in
replicative processes. These types of mutation can lead to organisms that are non-
replication competent, or have a selective disadvantage as compared to the parental
phenotype. Such debilitated variants contribute relatively few or no progeny to future
generations and are therefore numerically reduced or removed from the gene pool.
This process is termed negative (or purifying) selection. Mutations may also be
neutral, and have no effect on the organisms chances of survival and persistence
within the population. Selectively neutral mutations can still become fixed by the
random process of neutral genetic drift, or by genetic linkage with advantageous
mutations. Other genetic alterations may endow some form of selective advantage
and lead to fitness gains. Variants with these beneficial characteristics tend to
contribute more progeny to future generations and are therefore subject to positive
selection.
Different genes vary widely in their tolerance to genetic changes (Page and Holmes,
1998b). The extensive diversity within global HIV-1 isolates is testimony to the
ability of HIV to endure mutations at numerous nucleotide positions without a
significant loss of fitness. The largest differences in major open reading frames are
found within the env gene, followed by gag and then pol. These differences are the
product of varying selection pressures acting upon different genes, and are also
reflected in viral isolates within single infected individuals (Rodrigo et al., 2001).
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There has been some debate over the relative contributions of random processes
(genetic drift) and selection pressures in driving the fixation of mutations during HIV
infection (Rouzine and Coffin, 1999; Brown, 1997; Brown and Richman, 1997).
These are often referred to as stochastic and deterministic models respectively. The
fraction of a viral population within an individual that contributes to the gene pool of
the next generation of virus is referred to as the effective population size (Ne), as
opposed to the total population size (N). Behaviour of a quasispecies (or indeed any
genetically diverse population) is highly dependent on the value of Ne (reviewed in
Domingo and Holland, 1997; Rouzine et al., 2001). In small effective populations the
fate of viral variants, regardless of their relative fitness, can be heavily influenced by
random events (stochastic behaviour). By contrast, in large effective populations
undergoing many rounds of replication, random events have less impact and the
ultimate fate of the population is instead governed primarily by the relative fitness of
its component variants (deterministic behaviour).
Genetic bottlenecks can occur at various points of HIV infection, such as during
transmission or drug therapy. These contractions in total population size may
increase the importance of stochastic events. Reduction in Ne during the steady state
of infection can also take place and lead to similar stochastic behaviour. This may be
the result of relatively few productively infected cells contributing to the next
generation of virus, despite the usually large total population sizes at this point.
Alternatively, frequent genetic bottleneck events in viable virus, or
compartmentalisation leading to subdivision of the total viral population into
independent lineages may also lead to reductions in Ne. Evidence from env
sequences has lent weight to the possibility that effective population sizes of HIV in
infected individuals may be several orders of magnitude lower than the total number
of infected cells (Brown and Richman, 1997; Brown, 1997). The extent of a
particular viral variants selective advantage also has an effect on its prevalence in
future generations. Neutral or nearly neutral mutations tend to be governed by
stochastic effects, whereas those conferring large selective advantages or
disadvantages behave more deterministically (Rouzine and Coffm, 1999). It may
therefore be expected that under an extreme selection pressure such as HAART,
stochastic events would be greatly outweighed by the large selective advantage
conferred by mutations associated with antiviral resistance.
The large number of new viral variants produced throughout HIV infection supply
extensive raw material for the subsequent actions of natural selection. Perhaps the
clearest example of selective forces influencing the prevalence of HIV variants in
vivo is provided by the introduction of powerful inhibitors of viral replication from
external sources, in the form of antiviral drugs. There are numerous cases where
treatment with antiretroviral agents has led to the rapid outgrowth of resistant virus,
which is by definition more fit than the drug susceptible variants that generally
predominate up to this point (Wei et al, 1995; Schuurman et al., 1995; Loveday et al.,
1995; Ives et al., 1997). Immune responses also drive viral evolution by selecting for
variants with reduced sensitivity to neutralising antibodies and cytotoxic T cells
(CTLs). Antibody neutralisation escape mutants have been identified during HIV-1
infection (Arendrup et al., 1992; Lathey et al., 1997). Likewise CTL escape mutants
have been described (Phillips et al., 1991; Borrow et al., 1997; Goulder et al., 2001;
Price et al., 1997), and in some cases emerge quickly after primary infection (Borrow
et al, 1997; Price et al, 1997).
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Comparing viral heterogeneity in study subjects with qualitatively different anti-HIV
immune responses has also provided indirect evidence for the impact that immune
pressures can have on viral diversity. Individuals infected with HIV typically
progress to AIDS within ten years. However, some individuals progress much more
quickly (rapid progressors), while others remain asymptomatic for more than ten
years (slow progressors, or long term non-progressors). While many viral and host
factors can influence the rate of disease progression, some studies have identified
stronger CTL responses to HIV-1, and higher neutralising antibody titres in slow
progressors than in individuals with a typical rate of progression (Pantaleo et al.,
1995; Cao et al., 1995; Betts et al., 1999; Montefiori et al., 1996). Rapid progressors
often lack these effective immune responses and have weak or no neutralising
antibodies to HIV-1 (Liu et al., 1997). Differences in the rate of disease progression
also correlate with viral diversity. Slower progressors harbour virus with greater
genetic diversity than that found in rapid or typical progressors (Wolinsky et al.,
1996; Delwart et al., 1997; Liu et al, 1997). Higher ratios of non-synonymous to
synonymous site mutations have also been identified in these individuals (Lukashov
et al., 1995), indicating that the prevailing selection pressures differ between the
groups of study subjects.
Taken together these results suggest that immune responses are an important factor
in the fixation rate of new mutations. When effective immune responses are sparse or
absent, viral diversity is much lower than is the case when vigorous immune
responses cause frequent selective sweeps leading to the outgrowth of previously rare
genetic mutants.
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Adaptation to infect new cell or tissue types is another potentially important way that
selection may act upon specific subsets of HIV-1 variants. Isolation ofminor HIV-1
variants during in vitro culture in PBMCs has been documented (Vartanian et al,
1991; Meyerhans et al., 1989). Substantial natural variation in viral replicative
abilities in T cell lines or macrophages (Schwartz et al., 1989; Fenyo et al., 1988),
and in the use of particular chemokine receptors to enter cells in conjunction with
CD4 (see section 1.7) is also common between different HIV-1 strains. Therefore the
great diversity of HIV-1 variants in vivo may allow the virus to adapt to new niches
in the form of previously uninfected cell or tissue types.
1.6 Recombination in HIV-1
Recombination involves the generation of a nucleic acid molecule that contains
components of sequence from different sources. Some level of genetic exchange
between individuals in a population appears to be advantageous to the long-term
evolution of most organisms (Maynard Smith, 1978). Many eukaryotes have
therefore evolved specialized systems (such as sexual reproduction and
recombination) for reshuffling of genetic information. These can include the
obligatory contribution of half the progenies required chromosome complement by
each parent, and specific mechanisms for the generation of recombinant molecules
during meiosis (chiasmata or crossing over). Horizontal gene transfer is also
common in prokaryotes, and allows the acquisition of genetic material from
contemporaneous members of a population, rather than exclusively from ancestral
organisms. Recombination can increase genetic diversity by bringing together new
genomic sequence combinations from different origins. Conversely, it can also act as
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a repair mechanism, allowing the rescue of defective or debilitated parental genomes
by "patch repair", whereby a defective segment of one parental sequence is provided
by its homologous counterpart in the second parental genome.
Retroviral recombination was originally identified in avian retroviruses (Kawai and
Hanafusa, 1972; Vogt, 1971), and is now known to be a common feature of retroviral
replication in general (Clavel et al., 1989; Wong and McCarter, 1973). The
development of cell culture based systems in which replication of vector virus is
restricted to a single cycle has provided many insights into the process of retroviral
recombination (Anderson et al., 1998; Hu et al., 1997; Hu and Temin, 1990b;
Zhuang et al., 2002; Jetzt et al., 2000). A major factor in this high rate of
recombination is that retroviral particles contain two molecules of single stranded
genomic RNA. Therefore in contrast to members of all other virus families,
retroviruses are diploid. The first step in the production of a new retroviral
recombinant is co-infection of a cell by two genetically distinct viral variants. One
genomic RNA molecule derived from each of the two resulting proviruses must then
be copackaged into a single viral particle, followed by infection of a new cell by this
heterodimeric virion (Hu and Temin, 1990a). During reverse transcription in the new
host cell RT can switch between the two co-packaged RNA templates, resulting in a
new provirus with segments of sequence derived from both original variants.
1.6.1 Molecular mechanisms of retroviral recombination
Reverse transcription takes place in the nucleocapsid core particle released into the
host cell during virus entry. An integral part of retroviral reverse transcription is two
consecutive strand transfer reactions (or "jumps"), which occur during minus- and
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plus strand synthesis respectively (Gilboa et al, 1979). Therefore perhaps the most
conceptually simple model of retroviral recombination is for the strong-stop DNA to
switch template molecules during one or both of these strand transfers. A single
molecule of viral RNA can be used as a template for the synthesis of complete
proviral DNA via intramolecular strand jumps (Jones et al., 1994). However, minus
strand strong-stop DNA can also transfer intermolecularly (between the two
copackaged RNA molecules) leading to a provirus with recombinant LTRs (Hu and
Temin, 1990b; Panganiban and Fiore, 1988; Vanwamel and Berkhout, 1998). In
contrast, plus strand strong-stop DNA appears to transfer only intramolecularly (Yu
et al., 1998; Hu and Temin, 1990b). Yet these obligatory strand transfers do not
explain recombination within internal regions of the viral genome. Hence two basic
models for the mechanism of retroviral recombination have been proposed: The
"strand displacement assimilation model" (plus strand recombination) (Junghans et
al., 1982), and the "copy-choice model" (minus strand recombination) (Coffin,
1979).
In the strand displacement assimilation model two minus strand DNA molecules are
synthesised from one virion, each using a different genomic RNA strand as template.
During plus strand DNA synthesis one of the internally initiated strands is displaced
by another plus strand transcript. The displaced strand then anneals to the
complementary region of the minus strand DNA derived from the second genomic
RNA. The intermediate is then resolved, possibly by mismatch repair. This model
was originally proposed after the observation of "H"-shaped reverse transcription
intermediates by electron microscopy (Junghans et al, 1982) although subsequent
evidence for its occurrence has been limited. Thus, while plus strand recombination
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may be important in some cases the current consensus is that retroviral
recombination is primarily the result of nascent minus strand DNA transfer between
RNA templates.
The original "forced copy choice" model for retroviral recombination during minus
strand synthesis proposed that breakage of the viral RNA template necessitates
switching of nascent DNA to the second undamaged RNA template molecule.
Damaging genomic RNA by y-irradiation of virus particles led to an increased rate of
template switching during minus strand DNA synthesis, providing direct
experimental evidence for this model (Hu and Temin, 1992). However a number of
other ds-acting factors also appear to influence strand transfer during minus strand
DNA synthesis. The original forced copy choice model has therefore been modified
to include these alternative factors. Hence the modified "copy choice" model of
retroviral recombination now encompasses any recombination during minus strand
DNA synthesis.
A high level of sequence similarity between the nascent DNA molecule and acceptor
RNA template facilitates strand transfers, as demonstrated by the close sequence
identity required in the terminal R regions for efficient transfer of strong-stop minus
strand DNA (Luo and Taylor, 1990), and the much higher rates of homologous
rather than non-homologous retroviral recombination (Hu and Temin, 1990a;
Stuhlmann et al., 1990; Zhang and Temin, 1993). Pausing of RT, perhaps
accompanied by enhanced RNase H-dependent RNA degradation at the pause site
may also enhance strand switching (Buiser et al., 1993; Destefano et al., 1992a;
Klarmann et al., 1993; Wu et al., 1995; Luo and Taylor, 1990). This pausing may be
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influenced by sequence content (especially homopolymeric nucleotide runs)
(Klarmann et al, 1993), and RNA secondary or tertiary structures (Klarmann et al,
1993; Destefano et al., 1992b; Klarmann et al, 1993; Klasens et al., 1999). An
"interactive hairpin" model has also been proposed to explain the results of an
investigation into strand transfers around the TAR stem loop, where most
recombination events occurred in the loop or stem regions, rather than the putative
RT pause site (Kim et al., 1997). In this model the stem loop melts as reverse
transcription progresses through it, allowing a new interaction between the donor and
acceptor RNA templates to form. Nascent DNA then hybridises to the acceptor RNA
during copying of the descending part of the hairpin, and synthesis continues using
acceptor RNA as template.
Many studies into the sites and frequencies of strand transfers during reverse
transcription have been based upon in vitro systems with purified RT and relatively
short virus-derived RNA template molecules. The in vivo situation is clearly more
complex. For example during retroviral replication reverse transcription takes place
on a ribonucleoprotein complex, and the nucleocapsid protein is known to both
enhance strand transfer (Negroni and Buc, 1999), and destabilise RNA secondary
structures (Guo et al., 1997) thereby reducing structure induced pausing of RT
(Klasens et al, 1999). Results obtained from in vitro reverse transcription
experiments using short, naked RNA templates can therefore differ from the much
more complex in vivo situation of full-length dimeric RNA genomes in the highly
ordered environment of the nucleocapsid core. One example of discordant results
based upon reverse transcription of synthetic RNA templates compared with those
utilising complete virions or infected cells concerns the mutation rate of
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recombination. In isolated model systems misincorporations during cDNA synthesis
have been shown to induce RT pausing and promote template switching (Diaz and
Destefano, 1996; Palaniappan et al., 1996). Moreover, in similar experiments also
using purified RT, non-template-directed mutations (misincorporations, insertions or
deletions) occurred at the point of strand transfer with a frequency of 30-50% (Patel
and Preston, 1994; Wu et al, 1995). In contrast template switching during reverse
transcription in partially disrupted virions (Zhang and Temin, 1994) and infected
cells (Zhuang et al, 2002) is highly precise. It therefore appears that template
switching during minus strand DNA synthesis is not particularly error prone, and
homologous recombination in retroviruses increases diversity mainly by shuffling
genetic information from the parental genomes rather than facilitating the generation
of new mutations.
An interesting finding of investigations based on single-round infection assays is that
homologous recombination appears to occur in distinct viral subpopulations
exhibiting "high negative interference" (Hu et al, 1997; Hu and Temin, 1990b;
Anderson et al, 1998), whereby multiple recombination events are observed with a
much higher frequency than would be expected if each event occurs independently. It
was originally though that such interdependence of recombination events might be
evidence for a forced copy choice model, as this model predicts that recombination
breakpoints should occur in pairs, corresponding to the two ends of the assimilated
DNA segment (Hu and Temin, 1990b). However, subsequent experiments where
plus strand recombination was prevented by deletion of the primer binding site in one
of the copackaged sequences also demonstrated a higher than expected frequency of
multiple recombination events (Anderson et al, 1998). Possible explanations for
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these observations include the presence of subpopulations of virus that are especially
predisposed to recombination, or that once a recombination event has occurred it
increases the likelihood of further strand switching (Anderson et al, 1998; Hu et al,
1997).
In the context of HIV-1, single round infection assays have demonstrated that this
virus undergoes approximately two to three recombination events per replication
cycle, and these events can occur throughout the genome (Zhuang et al, 2002; Jetzt et
al, 2000; Yu et al, 1998). Given the small genome size involved this means that HIV
replication is the most recombinogenic process observed in any mammalian related
system described to date (Zhuang et al, 2002).
1.6.2 Recombination between global HIV-1 isolates
Retroviral recombination requires the super- or co-infection of a single cell by two or
more virions. Early laboratory studies appeared to indicate that this was a rare event,
because interference based superinfection inhibition takes place during HIV infection
in cell culture systems (mediated mainly by direct receptor blocking or Vpu- and
Nef-induced downregulation of viral receptors) (Hart and Cloyd, 1990; Little et al.,
1994; Taddeo et al., 1993; Benson et al., 1993; Chen et al, 1993). It was therefore
expected that in vivo opportunities for recombination between distinct viral strains
would be similarly limited. However, a number of potentially recombinant strains of
HIV-1 had been identified, most notably the MAL isolate (Alizon et al., 1986),
whose recombinant origin was suggested even before establishment of the subtype
classification system (Li et al., 1988). After the recognition of phylogenetally distinct
HIV-1 genetic subtypes (Louwagie et al., 1993; Louwagie et al., 1995; Myers et al.,
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1992), and as more complete genome sequences became available, a surprisingly
large number of HIV-1 group M strains also appeared to be intersubtype
recombinants (Robertson et al., 1995). Some of these strains had established large
local epidemics (Gao et al, 1996b; Carr et al., 1996; Carr et al., 1998; Bobkov et al.,
1998; Liitsola et al., 1998; Gao et al., 1998; Liitsola et al., 2000; Montavon et al.,
1999), and in certain geographical areas recombinants were more prevalent than
"pure" subtypes. For example a recombinant strain derived from subtypes A and E
(previously designated subtype E) is prevalent in south-east Asia (Gao et al, 1996b;
Carr et al, 1996), and an A/G intersubtype recombinant strain is responsible for the
majority of HIV infections in some areas of western Africa (Carr et al, 1998).
Therefore superinfection of both individual human hosts and single cells within these
individuals by diverse viral strains must be common enough to allow the numerous,
and in many cases complex, intersubtype recombination events that have been
identified in global HIV-1 isolates.
Intersubtype recombinants appear to be present wherever different HIV-1 subtypes
circulate in the same populations (reviewed in Peeters and Sharp, 2000; Thomson et
al, 2002). Some of these are unique and only represented by single isolates, while
others have reached a high prevalence and wide geographic distribution. A number
of recombinant genomes have also undergone subsequent recombination events,
leading to complex mosaic patterns and genomes composed of four or more different
subtypes (Montavon et al., 2002; Montavon et al, 1999; Gao et al, 1998). Clearly,
intersubtype recombinants that are responsible for a large number of infections are as
epidemiologically important as pure subtypes. To reflect this fact, and the increasing
number of identified HIV-1 group M subtypes, a new system of nomenclature for
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subtypes and recombinants has been established (Robertson et al, 2000). In this
system intersubtype recombinants that are responsible for an adequate number of
infections to be considered of significant epidemiological importance (and conform
to several other criteria) are termed "circulating recombinant forms" (CRF), and
given names that reflect the origin of their component subtypes. For example the A/E
recombinant virus, which is prevalent in south east Asia (Gao et al, 1996b) is now
termed CRF01AE (Robertson et al, 2000). HIV-1 genomes containing sequences
originating from more than three different subtypes are denoted complex (cpx).
Hence the isolate from Cyprus originally designated subtype I (Kostrikis et al., 1995)
(in actuality a recombinant composed of subtypes A, G, H, K, and unclassified
regions: Gao et al, 1998) is now termed CRF04-cpx (Robertson et al, 2000). It is
estimated that approximately 10% of current global HIV-1 group M isolates are
intersubtype recombinants.
In addition to being abundantly evident between group M subtypes, recombination
has been identified between members ofHIV-1 groups M and O (Peeters et al., 1999;
Takehisa et al., 1999). This is significant because groups M and O are the result of
separate cross-species transmission events into humans from chimpanzees (Pan
troglodytes troglodytes) (Gao et al, 1999), and the identification of recombination
between the two demonstrates that viable recombinants can be formed between
highly divergent strains of HIV-1. It also raises the possibility that future cross-
species transmissions of SIV into humans may be followed by recombination with
current HIV strains leading to the emergence of novel chimeric HIV/SIV genomes.
However, recombination between HIV-1 and HIV-2 viral strains has not been found,
even though individuals infected by both of these viruses have been reported
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(Rayfield et al., 1988; Grez et al., 1994). Perhaps HIV-1 and HIV-2 are too divergent
to efficiently recombine; alternatively recombination between the two may result in
severely debilitated or unviable progeny.
The biological significance of these numerous recombinant genomes is unclear.
Likewise the evolutionary pressures that allow or select for the emergence of
particular circulating recombinant forms in different human populations are
unknown. This is partly because, while some biological differences between group M
subtypes have been documented (SotoRamirez et al., 1996; Tscherning et al., 1998;
Abebe et al., 1999; Gao et al, 1996b; Korber et al., 1994b), they are either equivocal
or do not readily explain the prevalence of particular subtypes in different human
populations. It may therefore be that the current distribution of subtypes around the
world is largely the result of founder events rather than inherent biological
differences in the viral strains. If this is the case then intersubtype recombinants and
circulating recombinant forms may also be broadly equivalent in terms of important
biological characteristics such as transmissibility in different human populations.
1.6.3 Intrasubtype recombination
Generally, in order to directly identify a recombinant the sequence of each parental
genome must be explicitly known, or belong to different and well-defined sequence
groups. HIV-1 group M subtypes have been comprehensively characterised and are
quite distinct, exhibiting 25-35% amino acid sequence differences in their Env
proteins (Sharp et al., 1994). It is therefore relatively simple to identify an
intersubtype recombinant because different genomic regions will have phylogenetic
affinities that switch between representatives (or consensus sequences) of different
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subtypes. The discrete breakpoints where these affinities cross over represent the
specific genome positions that recombination took place. Identifying recombination
events between members of the same HIV-1 group M subtype is more problematic,
because the parental sequences are not members of such separate and clearly defined
phylogenetic groups. Most intrasubtype recombination events that have been
documented to date have therefore involved single infected individuals in small,
well-characterised transmission networks. For example intrasubtype recombination
has been identified in both a transfusion recipient (Diaz et al., 1995) and an
intravenous drug user (Wang et al., 2000) dually infected with different strains of
HIV-1 group M subtype B. Longitudinal analysis of another individual who was
infected with two genetically distinct subtype B HIV-1 strains (approximately 15%
divergent over the env C2-V5 coding region: Liu et al, 1997), identified a range of
chimeric genome structures between the two original genotypes, which oscillated in
frequency during the 56 month study period (Liu et al., 2002). Recombination
between two distinct HIV-1 subtype B viral strains in vivo has also been
demonstrated experimentally in a dually infected chimpanzee (Wei and Fultz, 1998).
1.6.4 Recombination between closely related HIV-1 strains
It is to be expected that recombination between individual HIV-1 variants that
diverged during the course of a single infection would occur more frequently than
between distinct members of the same subtype, or members of different subtypes.
Closer sequence similarities are likely to facilitate the original generation of
recombinants (Mikkelsen and Pedersen, 2000), and reduce potential incompatibilities
between the newly juxtaposed sequences, leading to a corresponding increased
likelihood that the recombinant genomes will produce viable virus. The probability
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of any two variants present in an infected individual coinfecting a cell and becoming
copackaged is also higher than the likelihood of this event occurring with two
variants belonging to distinct populations. Yet the issues outlined above for detection
of intrasubtype recombinants are compounded in the case of sequences that
diversified within a single infected individual because of the very close sequence
similarities and lack of pre-defined groups involved. Consequently detection of
recombination between these variants has generally been inferred by very indirect
means. For example a drastic reduction in pol sequence diversity identified in several
patients undergoing antiretroviral therapy was not accompanied by a similar
sequence bottleneck in env, suggesting a lack of genetic linkage between the two
subgenomic regions (Dykes et al., 2000; Brown and Cleland, 1996). Similarly, soon
after transmission the V3 region of gpl20 appears to be subject to purifying selection
(Pang et al., 1992; Zhu et al., 1993b; Wolinsky et al., 1992), and is less variable than
other genomic regions such as V4/V5 (Wolinsky et al, 1992) and pl7gag (Zhang et
al., 1993). One explanation for these findings is that strong early selection on V3 is
accompanied by recombination among members of an initially diverse viral
population (Zhang et al, 1993).
A study by Jung and colleagues has elegantly circumvented the problems associated
with detection of recombination between closely related variants by obtaining
proviral sequences from single infected cells (Jung et al., 2002). Using fluorescent in
situ hybridisation, the number of proviruses per cell in single HIV-1 infected
splenocytes from two patients was quantified. Remarkably, the proviral copy number
ranged from one to eight per cell, with a mean of approximately 3.2. Amplification
and sequencing of the VI/V2 region of env from single, laser-dissected interphase
65
nuclei revealed that those nuclei containing three or four proviruses harboured up to
34% amino acid differences in this genomic region. Moreover several of these
proviral sequences appeared to be recombinants (Jung et al, 2002).
It is to be expected that recombination such as this (between HIV-1 variants that
have diversified during a single infection) would provide a powerful mechanism for
viral adaptation to the shifting selection pressures that characterise the natural course
ofHIV-1 infection.
1.7 Molecular determinants of tropism
Identification of the receptors that allow entry of HIV into host cells has provided
many insights into the tropism and pathogenesis of this virus. The original
discoveries and subsequent characterisation of HIV entry receptor usage have been
extensively reviewed (Berger, 1997; Doms and Peipert, 1997; Rucker and Doms,
1998; Dimitrov et al., 1998; Clapham and McKnight, 2002; DSouza and Harden,
1996).
1.7.1 CD4
Binding of gpl20 to CD4 is the first step required for HIV infection and this
interaction is conserved among all primate lentiviaises. The initial evidence
implicating CD4 as a receptor for HIV was the ability of anti-CD4 monoclonal
antibodies to inhibit viral infection (Dalgleish et al, 1984; Klatzmann et al., 1984b).
Subsequently it was demonstrated that a complex of CD4 and the viral envelope
could be immunoprecipitated from infected cells (McDougal et al.. 1986), and that
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expression of CD4 rendered previously resistant cells sensitive to HIV infection
(Maddon et al, 1986).
CD4 is expressed predominantly on T-helper cells where its major role is to act as an
accessory receptor enhancing inter-cellular connections during antigen presentation.
CD4 interacts with components of the T-cell receptor (TCR) and binds the P2
subunit of MHC class II molecules on antigen presenting cells, thus improving the
avidity of associations between T-helper cells and MHC class II+ cells. It also serves
more general roles as an adhesion molecule, a chemotactic receptor (responding to
binding of IL-16: Cruikshank et al., 1998), and in the induction of cellular activation
(Clapham and McKnight, 2002). In addition to T-helper cells dendritic cells,
monocytes, macrophages, and microglia also express CD4 and can be infected by
HIV (Gartner et al., 1986; Klatzmann et al, 1984a; Macatonia et al., 1990; Watkins et
al., 1990). These cells do not express a TCR but their expression of CD4 is likely
explained by additional functions of this molecule. A variety of other lymphoid cell
types including CD8* T lymphocytes, gamma-delta T lymphocytes, and natural killer
cells have been shown to both express CD4 and contain HIV proviral DNA in some
circumstances (Valentin et al., 2002; McBreen et al., 2001; Imlach et al., 2001;
Imlach et al., 2003). However, the contribution to viral pathogenesis that infection of
these alternative cell types represents is not clear. In summary the observed cellular
distribution ofHIV in the immune system closely correlates with expression patterns
of the CD4 molecule.
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1.7.2 Coreceptors
The discovery ofCD4 as the primary receptor for HIV-1 explained several aspects of
observed viral tropism. Yet it was also evident that an additional factor or receptor
was also required for infection. Expression of CD4 alone was not sufficient to confer
sensitivity to HIV-1 infection in some human cells (Chesebro et al., 1990) and most
non-human cells (Maddon et al, 1986), despite apparently normal processing and
expression of this molecule (Clapham et al., 1991). However, if non-human cells
expressing human CD4 were fused with CD4-negative human cells then the resulting
heterokaryon was permissive for HIV infection (Broder et al., 1993; Dragic et al.,
1992), indicating that non-human cells lacked a requisite cofactor or coreceptor for
infection to occur. Isolates of HIV-1 also exhibit two discrete cellular tropisms.
Distinction between these viral phenotypes has variously been described as
macrophage tropic (M-tropic) or T-cell tropic (T-tropic), depending upon the strains
ability to infect macrophages or CD4+ T-cell lines in culture (Gartner et al, 1986);
slow-low or rapid-high, as determined by replication rates in PBMCs (Asjo et al.,
1986); and nonsyncytium-inducing (NSI) or syncytium-inducing (SI), defined by
ability to mediate the formation of multinucleated giant cells in culture (Tersmette et
al., 1988). With a small number of exceptions it became clear that these various
definitions all described the same two biologically different viral types. One obvious
explanation for this dichotomy was that the viral phenotypes represented strains that
used different coreceptor molecules to enter cells (Alkhatib et al., 1996a), a
hypothesis which was strengthened by the observation that determinants of
differential tropism were mainly within the V3 loop of gpl20 (Hwang et al., 1991).
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The first identified HIV coreceptor, CXCR4 (previously called fusin, LESTR, or
HUMSTR), was cloned in 1996 and facilitated entry of T-tropic/SI strains (Feng et
al, 1996). Shortly afterwards CCR5, the coreceptor for M-tropic/NSI strains was
identified simultaneously by several groups (Alkhatib et al, 1996b; Choe et al, 1996;
Deng et al, 1996; Doranz et al, 1996; Dragic et al, 1996). These receptors are G
protein-coupled seven-transmembrane domain receptors whose natural ligands are
chemotactic cytokines (chemokines). The major role of chemokine receptors upon
binding of their ligand is to mediate cellular responses involved in chemotaxis, cell
migration, trafficking, and activation of leukocytes, although they also have a
number of other functions, for example in growth regulation (reviewed in Baggiolini,
1998; Rollins, 1997). Correlation between the two previously identified viral
phenotypes and use of either CXCR4 or CCR5 is far from absolute but does still hold
true in many cases. To ease the previously tangled nomenclature HIV strains that use
CXCR4 to enter CD44 cells have been designated X4, those that use CCR5
designated R5, and dual tropic isolates that can use either coreceptor, R5X4 (Berger
et al., 1998). CCR5 is expressed predominantly on activated memory T CD45RCF
cells, monocyte/macrophages, dendritic cells, and granulocyte precursors. Expression
of CXCR4 is more widespread and includes naive CD45RA T cells, CD8+ T cells,
monocyte/macrophages, and a number of other immune cell types (reviewed in
Luster, 1998). A large number of additional coreceptor molecules have also been
shown to facilitate infection of cell lines in vitro by specific strains of HIV and SIV
(Table 1.1). These molecules are all chemokine receptors or closely related
molecules with the same basic seven-transmembrane structure.
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The importance of CCR5 as a coreceptor for HIV strains transmitted between
individuals was demonstrated by the identification of a naturally occurring 32 bp
deletion (A32) in the CCR5 gene, which leads to a premature stop codon and a
truncated CCR5 protein that fails to reach the cell surface (Benkirane et al., 1997).
Approximately 1% of Caucasians are homozygous for this allele (Dean et al., 1996)
and these individuals are highly resistant although not immune to HIV infection via
sexual (Dean et al, 1996), parenteral (Wilkinson et al., 1998), and vertical (Philpott et
al., 1999) transmission routes. A number of other naturally occurring polymorphisms
in chemokines or their receptors have also been identified, with varying
consequences for susceptibility to HIV infection and disease progression (reviewed
in O'Brien and Moore, 2000).
In addition to being preferentially transmitted R5 variants also predominate during
the early asymptomatic phase and persist throughout infection. In approximately
50% of individuals infected with HIV-1 group M subtype B a "phenotypic switch"
occurs late in the duration of infection, characterised by the appearance of SI variants
able to use CXCR4 and often a more general broadening of viral coreceptor usage
(Scarlatti et al., 1997). This conversion is associated with rapid disease progression,
rapid CD4" T-cell decline, and reduced survival time after AIDS diagnosis (Koot et
al., 1993).
Despite these associations a causative relationship between the change in viral
tropism and disease progression has been difficult to establish, and the underlying
factors leading to the phenotypic switch are presently unknown.
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Coreceptor Ligand HIV-1 HIV-2 SIV Reference for coreceptor
use
CCR1 MlP-la, MPIF-1, MCP-3,
RANTES
_* + + (Bron et al., 1997;
McKnight et at, 1998)
CCR2b MCP-l,MCP-2, MCP-3 + ++ + (Doranz et at, 1996)
CCR3 Eotaxin, eotaxin-2, MCP-3,
MCP-4, RANTES
++ ++ + (Choe et at, 1996; Doranz
et al, 1996)
CCR4 MDC, TARC, RANTES, MIP-1a - + - (McKnight et al, 1998)
CCR5 MlP-la, MIP-ip, RANTES,
MCP-2
++++ ++++ ++++ (Alkhatib et at, 1996;
Deng et al., 1996; Dragic
et at, 1996)
CCR8 1-309 ++ ++ ++ (Rucker et at, 1997)
CCR9 TECK + - - (Choe et at, 1998)
CXCR2 IL-8, NAP-2, ELR+, CXCs - + NT (Bron et al, 1997)
CXCR4 SDF-1 +++ +++ + (Feng et at, 1996)
CX3CR1/V28 Fractalkine + + + (Reeves et at, 1997)
STRL-
33/Bonzo/TYMSTR
CXCL16 + +-H- +++ (Alkhatib et at, 1997;
Deng et at, 1997)
GPR1 ? + ++ +++ (Farzan et at, 1997)
GPRI5/Bob ? + ++ +++ (Farzan et al, 1997)
APJ Apelin + + + (Choe et al, 1998; Edinger
et at, 1998)
Chem R23 ? + - + (Samson et at, 1998)
RDC1 ? + + + (Shimizu et at, 2000)
Table 1.1. Coreceptors that support primate lentivirus infection of CD4+ cell
lines in vitro. *Rarely or never used as a coreceptor (-); occasional use by a few
isolates (+); used by 5-20% of isolates (+ +); frequent use by many isolates or by
major subgroup (for example, CXCR4 use by R5X4 and X4 isolates, indicated in
bold) (+ + +); major coreceptor used by predominant virus in vivo (for example,
CCR5 use by HIV and SIV, indicated in bold) (+ + + +). NT, not tested. Copied from
(Clapham and McKnight, 2002).
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Initial production of X4 variants is unlikely to be a limiting factor in the process as
the small number of mutations required to acquire this phenotype coupled with the
rapid rate ofHIV evolution would be expected to result in the frequent production of
new variants capable of exploiting receptors other than CCR5. It therefore appears
that some in vivo selective constraint prevents the emergence of X4 variants until the
latter stages of disease. The nature of this constraint is not clear although immune
pressures such as neutralising antibodies, downregulation of CXCR4, or high levels
of stromal derived factor-1 (SDF-1, the natural ligand for CXCR4) within the
lymphoid tissue have all been suggested as potentially important factors (reviewed in
Michael and Moore, 1999). Alterations in the predominant cytokine or chemokine
profiles may therefore be an important feature in the change in receptor usage
(reviewed in Kinter et al., 2000). For example interleukin-4 has been shown to
decrease expression of CCR5 while simultaneously upregulating CXCR4 expression
in CD4^ T-cells, thereby providing a selective advantage for X4 over R5 variants
(Valentin et al., 1998).
All HIV-1 isolates identified to date can use either CCR5 or CXCR4 to enter cells,
and strains that utilise additional receptors usually do so with much less efficiency
than via these major coreceptors. Methods for characterising the entry requirements
of a particular viral isolate often involve expression of plasmids encoding CD4 and a
coreceptor "out of context" in cell lines that do not naturally express these molecules.
Several factors must be taken into account when interpreting tropism data obtained in
this manner and applying the results to in vivo situations. Firstly, this approach may
lead to the expression of receptor combinations that are not present in vivo, for
example APJ is not naturally expressed at detectable levels on CD4' cells (Puffer et
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al., 2000; Choe et al., 2000) therefore its significance as an HIV coreceptor is
questionable. Secondly, cell line expression systems appear to produce cell surface
receptor molecules at a higher density and in a conformation more amenable for
HIV-1 entry than primary cell types (Doms, 2000; Clapham and McKnight, 2002).
The biological importance of coreceptors other than CCR5 and CXCR4 is therefore
unclear. There is some evidence for infection of thymocytes via CCR8 (Lee et al.,
2000), and that STRL-33 is expressed at sufficiently high levels to support viral
infection of a subset of CD4" T-cells (Sharron et al., 2000). CCR3 has also been
shown to facilitate infection of microglial cells in some primary human foetal brain
cultures (He et al., 1997), although this does not appear to be a general mechanism
for microglial infection (Albright et al., 1999; Ghorpade et al., 1998b). Despite these
possible exceptions there is an overall lack of evidence for frequent in vivo use of
coreceptor molecules other than CCR5 and CXCR4 by HIV-1.
Considerable interest does still exists in identifying receptors that are expressed at
sufficient levels in vivo to potentially allow their use as coreceptors for HIV. This
attention is driven in part by the fact that chemokine receptors are attractive targets
for therapeutic interventions to prevent entry of HIV into cells, with the apparent
health of CCR5 A32 homozygous individuals suggesting that this receptor may be
aggressively targeted with minimal side effects. Exerting such strong selective
pressure may result in altered patterns of HIV coreceptor usage with unpredictable
consequences for viral cellular tropism. Therapies targeted at specifically inhibiting
the use of CCR5 as a coreceptor may drive the virus to use CXCR4 and possibly
instigate the clinical decline associated with this phenotypic switch (reviewed in
Michael and Moore, 1999), or promote the evolution of variants that can utilise other
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coreceptor molecules which are rarely or never used at present. An example of the
unusual coreceptor use that may result from selective pressure at the level of viral
entry is provided by SIV strains isolated from red-capped mangabeys in Gabon. In
contrast to most SIV strains, these isolates use CCR2b as their major coreceptor. The
likely explanation for this altered phenotype is that the majority of red-capped
mangabeys are homozygous for a defective CCR5 gene (Chen et al., 1998).
1.7.3 Further factors involved in viral entry
A number of biological differences between HIV-1 isolates are manifest at the level
of viral entry yet cannot be simply explained by the presence or absence of particular
receptors on target cells. For example it is not clear why R5 variants are almost
exclusively transmitted and R5X4 variants infrequently infect new individuals by the
same route. Macrophages express sufficient levels of CD4, CCR5, and CXCR4 to
allow HIV-1 entry (Lee et al., 1999b) but only a subset of variants able to use
CXCR4 can infect these cells (generally primary virus isolates as opposed to T-cell
line adapted virus) (Simmons et al., 1998; Yi et al., 1998). There are also several
other examples where a virus strain has proven unable to enter cell lines or primary
cells that appear to express the required receptors (Bazan et al., 1998; Dittmar et al.,
1997), and where an increase in ability to direct membrane fusion is associated with
small changes in env without concomitant changes in the receptors used (Doms,
2000). Biological differences such as these are likely to be determined by more
subtle interactions between Env and the cellular receptors used for HIV entry than
simple specificity for a certain coreceptor molecule.
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Numerous factors may affect the ability of a particular viral strain to enter cells even
if the appropriate receptors are present. The density of CD4 and coreceptors varies
on different cell types (Lee et al, 1999b), and it is clear that HIV-1 isolates can differ
greatly in their affinity for both of these molecules (Kozak et al., 1997; Kabat et al.,
1994). CD4 and coreceptor density requirements also appear to be interrelated. For
example one study demonstrated that when CD4 is expressed at high levels then
relatively low levels of CCR5 are necessary to allow maximum viral infection and if
the expression of CD4 is reduced then a high level of CCR5 is required (Piatt et al.,
1998). Thus cells that express levels of receptor molecules below the threshold
required by a particular viral strain will be refractory to infection. Coreceptor
molecules also exist in multiple antigenic conformations, and this can vary in a cell
type specific fashion (Baribaud et al., 2001; Lee et al., 1999a). Such differences may
be due to interactions with CD4 on the cell surface as has been described for CCR5
(Wu et al., 1996) or dimerisation of chemokine receptors (Lapham et al., 1999). The
full consequences of these multiple conformational states in ability to facilitate
infection by different viral strains have yet to be determined.
The specific regions of coreceptor molecules used by different viral strains also vary
(reviewed in Clapham and McKnight, 2002). Chemokine receptors form pores in the
cellular membrane with four domains exposed on the cell surface, the N terminus
and three extracellular loops (ECL1, ECL2, and ECL3) (Palczewski et al., 2000).
The N terminus of CCR5 is important for the entry of R5 variants (Hill et al, 1998),
although generation of chimeric human/mouse CCR5 receptors has demonstrated
that specific HIV-1 isolates differ in their interactions with CCR5 (Picard et al.,
1997). In the case of X4 variants the ECL2 domain of CXCR4 is critical for
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coreceptor function (Lu et al, 1997). X4 strains also vary in their usage of CXCR4,
with different isolates dependent upon distinct ECL2 residues for coreceptor activity
(Brelot et al., 1999). This capacity for different Envs to utilise distinct residues on
coreceptor molecules presents adaptive possibilities, for example in allowing the
evolution of variants with a reduced sensitivity to inhibition by neutralising
antibodies or chemokine receptor ligands.
Interaction of gpl20 with both CCR5 and CXCR4 can lead to the activation of
intracellular signalling pathways (Davis et al., 1997; Weissman et al., 1997). It is
possible that this signalling helps to prepare the cellular environment for optimal
viral replication and generation of progeny virions. Signalling is not a prerequisite
for productive viral infection to occur (Aramori et al., 1997; Gosling et al., 1997),
although it has been reported that the ability of viruses to pass through early post-
fusion events in macrophages correlates with their capacity to signal via CCR5
(Arthos et al., 2000). gpl20 shed from infected cells could also induce chemotaxis in
nearby uninfected lymphocytes leading to their recruitment and subsequent infection.
A further consequence of cell signalling by soluble gpl20 is that its attachment to
receptors on uninfected bystander cells can lead to toxic effects, even if the cells
express only CCR5 or CXCR4 and are thus largely refractory to direct infection by
HIV. This effect is thought to be important for HIV pathogenesis in the brain where
chemokine receptors are expressed on numerous cell types whose normal function is
strongly affected by the presence of HIV but are only infrequently or never infected
(reviewed in Gabuzda and Wang, 2000).
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1.7.4 Envelope determinants of HIV-1 cellular tropism and
coreceptor use
Envelope sequences obtained from primary HIV-1 isolates within single infected
individuals are often extremely heterogeneous and can be up to 10% divergent at the
nucleotide level. This high level of genetic variability demonstrates a remarkable
plasticity and tolerance to mutations within the env gene and has important
implications for viral pathogenesis. Viral replication in specific cell types can be
restricted at a number of entry and postentry steps, but early studies indicated that the
restriction to HIV replication in non-permissive CD4f cells was primarily at the level
of viral entry (Cheng Mayer et al., 1990; Kim et al., 1990; O'Brien et al., 1990). The
envelope protein (Env) mediates binding to a target cell followed by fusion of the
viral and host cell membranes. It was therefore unsurprising that the principal
determinants of both coreceptor usage and macrophage or T-cell tropism in culture
were found to be within Env. Further alterations in env may lead to more subtle in
vivo adaptations allowing the expansion of virus into new cell or tissue types, for
example by affecting receptor affinity, immune evasion, or resistance to chemokine
inhibition of infection.
Generation of chimeric envelopes from M- and T-tropic isolates led to the
identification of the V3 loop as one of the primary determinants of viral tropism
(Chesebro et al., 1991; Hwang et al, 1991; Shioda et al., 1991). In the context of
certain env sequences even a single amino acid change in V3 is sufficient to alter
cellular tropism (Takeuchi et al., 1991). The most comprehensively characterised of
these mutations is the presence of positively charged amino acids at positions 11 or
25 situated on either side of the crest region of the V3 loop which closely correlates
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to a SI viral phenotype (Fouchier et al., 1992). However, many mutations in the V3
loop that alter tropism have strain-specific effects and no single residue or amino
acid motif is crucial for the phenomenon. In general a low overall positive charge in
the V3 loop and few mutations as compared with the subtype B consensus sequence
is indicative of M-tropic virus (Donaldson et al., 1994a). This is consistent with
longitudinal studies ofHIV infected individuals where an increase in the net positive
charge in the V3 loop is associated to conversion to T-tropism (de Jong et al., 1992a;
de Jong et al., 1992b; Shioda et al., 1992; Fouchier et al, 1992). The V3 loop is also
important in determining coreceptor usage, with the same positively charged amino
acids that confer a SI phenotype also correlating with use of CXCR4 (Speck et al.,
1997).
The V1/V2 region has similarly been shown to effect cellular tropism in many virus
strains. During receptor binding the VI/V2 loops appear to act co-operatively with
V3 and sequence alterations in VI/V2 can modulate both cellular tropism and
coreceptor usage in a V3 specific manner (Carrillo and Ratner, 1996; Shioda et al,
1991; Koito et al., 1994; Cho et al., 1998; Ross and Cullen, 1998). A link between
positively charged residues in V1/V2 and T-tropism has been noted (Groenink et al.,
1993) and in some cases a transient increase in the length of V2 is associated with an
in vivo switch from NSI to an SI viral phenotype (Fouchier et al., 1995a). Several
mutations that can affect cellular tropism in this region are also N-linked
glycosylation sites (Koito et al., 1995; Carrillo and Ratner, 1996). However,
correlation of these mutations with viral tropism is far from absolute, and VI/V2
does not appear to have as critical a role in envelope function as V3. For example
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while deletion of V3 results in the production of non-infectious virus (Wyatt et al,
1993) deletion of V1/V2 does not abrogate viral infectivity (Cao et al., 1997).
A crystal structure of gpl20 in a complex with CD4 and the neutralising CD4
induced antibody 17b has been described (Kwong et al, 1998). This gpl20 had most
of the V1/V2 and V3 loops deleted and lacked 90% of the carbohydrate present in
the natural protein, but these alterations did not appear to affect the global
architecture of the molecule. Information gained from this structure allowed the sites
on gpl20 that interact with coreceptors after CD4 binding to be inferred. They
include the V1/V2 and V3 loops as well as a conserved region composed of |3-
strands situated between these loops and residues in C4, known as the bridging sheet.
Thus the regions of Env previously determined to influence tropism do so (at least in
part) by direct interaction with coreceptor molecules.
Further insights into the specific mechanisms by which Env sequences can affect
chemokine receptor usage have been gained by characterising the regions of
coreceptor molecules that are important for binding different gpl20 molecules
(Clapham and McKnight, 2002). The N terminus of CCR5 (and several other
coreceptors) is negatively charged due to four (potentially) sulphated tyrosine
residues and three acidic amino acids (Farzan et al., 1998). These residues are
important for coreceptor function and may aid electrostatic interactions with basic
amino acids in the bridging sheet of R5 gpl20 molecules (Kwong et al, 1998).
Electrostatic interactions may also help explain the observed association of CXCR4
usage with a more highly positively charged V3 loop. The E2 loop of CXCR4 is
critical for X4 virus entry (Lu et al, 1997; Brelot et al, 1999) and contains five
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negatively charged residues that may interact more readily with a positively charged
V3 loop. However, replacement of all five of these acidic amino acids with alanines
does not eliminate coreceptor function (Wang et al., 1998), therefore the specificity
of the gpl20-coreceptor interaction may be aided but is not completely governed by
electrostatic interactions of this type.
1.7.5 CD4 and coreceptor independent interactions
It is now well established that most HIV-1 primary virus isolates require CD4 and a
member of the seven-transmembrane chemokine receptor family as entry receptors
for fusion with host cells. However a number of additional cell surface molecules
also bind to gpl20 with high affinity (reviewed in Clapham and McKnight, 2002).
These molecules may therefore function as attachment receptors, facilitating viral
adsorption to the cell surface without a direct role in membrane fusion. Interactions
auxiliary to direct gpl20-CD4 binding may be necessary for infection of cell types
such as dendritic cells, macrophages, and microglia, where in vivo CD4 expression is
much lower than found in CD4~ T-cells (Sonza et al., 1995; Dick et al., 1997).
Infection of CD4-negative cell types in vivo has also been poorly characterised at the
molecular level, and adsorption of virus to these cells may well require a stronger
affinity than is achieved between gpl20 and coreceptor molecules alone.
The glycolypid galactocerebroside (galactosylceramide, Gal-C) and its sulphated
derivative (sulphatide) both bind gpl20 with high affinity (Fantini et al., 1993;
Harouse et al., 1991). These receptors are expressed on macrophages (Seddiki et al.,
1996; Seddiki et al., 1994), neural and glial cell lines (Harouse et al, 1991), and
colonic epithelial cell lines (Fantini et al, 1993). When a coreceptor is present then
80
Gal-C can facilitate low-level infection by particular HIV-1 strains in a CD4-
independent manner (Delezay et al., 1997) leading to the suggestion that these
molecules are important factors in HIV infection of CD4-negative cells in the brain
and colon (Harouse et al., 1995). The molecular mechanism of this infection is
unclear, as CD4 binding is usually required to produce the conformational changes in
Env necessary for coreceptor binding and membrane fusion. Yet a number of CD4-
negative cell types do appear to support some level ofHIV-1 infection in vivo and in
vitro, thus alternative interactions allowing CD4-independent adsorption of virus to
host cells may be an important first step in the infection process.
gpl20 is heavily glycosylated and CD4-independent attachment of virions may
therefore also be mediated through carbohydrate groups present on this molecule
associating with lectin-like domains on cellular receptors (Larkin et al., 1989). The
glycosaminoglycan heparan sulphate was found to be important in HIV-1 binding to
both CD4+ T-cell lines (Roderiquez et al., 1995; Patel et al., 1993), and HeLa cells
with or without CD4 expression (Mondor et al., 1998). This interaction appears to be
mainly between positively charged residues in the V3 loop of gpl20 with negative
sulphate groups on glycosaminoglycans, thus the interaction is stronger with X4 and
R5X4 viruses than R5 viruses because the latter generally have a lower overall
positive charge in the V3 loop (Moulard et al., 2000). Dendritic cell-specific inter
cellular adhesion molecule-grabbing nonintegrin (DC-SIGN) is a C-type lectin cell
surface protein with a potentially important biological role in HIV binding (reviewed
in Pohlmann et al., 2001a). This molecule is expressed on some dendritic cell
populations (Geijtenbeek et al., 2000a; Geijtenbeek et al., 2000b) and had previously
been shown to bind gpl20 with high affinity (Curtis et al., 1992). The presence of
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DC-SIGN on dendritic cells provides a model not only for HIV-1 infection of this
cell type despite low levels of CD4 expression, but also for transport of HIV from
mucosal membranes to lymph nodes upon original exposure to virus. Following
mucosal transmission the first cells likely to be encountered by HIV are immature
dendritic cells such as Langerhans cells. During this first contact the virus may either
directly infect dendritic cells or become trapped on the cell surface by DC-SIGN and
carried to a lymph node where it could be transferred to T-cells during antigen
presentation, thus allowing a rapid amplification of virus and enhanced subsequent
systemic dissemination. A homologue of DC-SIGN (DC-SIGNR) binds HIV in a
similar manner but is expressed on endothelial cells (Pohlmann et al., 2001b).
Further interactions between HIV virions and the host cell may be mediated not
directly through gpl20 but rather via association of target cell surface components
with adhesion molecules incorporated into the viral envelope during budding from
the cytoplasmic membrane (Ugolini et al., 1999). The observation that CD4 alone,
but not CD4 associated with its natural intracellular ligand (tyrosine kinase p561ck) is
incorporated into virions (Henriksson and Bosch, 1998) has led to the suggestion that
such incorporations may be not completely random, and that there may be a some
level of selectivity in the process (reviewed in Tremblay et al., 1998). Leukocyte
function-associated antigen 1 (LFA-l) specific monoclonal antibodies (mAbs) were
found to interfere with HIV induced syncytium formation in vitro (Hildreth and
Orentas, 1989), and anti-intercellular adhesion molecule 3 (ICAM-3) mAbs reduced
infectivity of cell-free virus (Sommerfelt and Asjo, 1995). Producing HIV in cells
transfected with genes coding for specific adhesion molecules provides an indication
of their potential importance in viral attachment. For example the presence of HLA-
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DR in producer cells increased HIV infectivity for CD4+ cells by approximately
twofold (Cantin et al., 1997). While up to a tenfold increase in infectivity was
observed when intercellular adhesion molecule 1 (ICAM-1) was present in producer
cells and progeny virus was used to infect LFA-H cells (Paquette et al., 1998; Fortin
et al., 1999). Thus recognition of adhesion molecules present in the viral envelope by
their cognate receptors anchored on the target cell surface may enhance viral
infectivity in both a producer and target cell type specific manner.
Therefore the initial adsorption ofHIV to host cells is governed by many interrelated
factors that could affect the in vivo cellular tropism ofHIV-1 viral variants.
1.8 Compartmentalisation of HIV-1
Soon after transmission HIV-1 disseminates widely throughout the body. At this
point viral sequences in peripheral blood and tissues are closely related (Zhang et al.,
2002), and the virus population as a whole is much more genetically homogeneous
than is found at later timepoints (Zhu et al., 1993a; Shankarappa et al., 1998;
McNearney et al., 1992). As infection progresses distinct viral subpopulations are
frequently identified in different anatomical sites, most evidently when the infected
individual has progressed to AIDS before death. Compartmentalisation may be
detected by sequence differences, differential quantities of viral nucleic acids, or the
presence of phenotypically distinct viral variants (for example differing in cellular
tropism or susceptibility to antiviral agents) in different sites. There are several
possible explanations for the emergence of divergent viral sub-populations. These
include physical barriers between compartments, selective trafficking of infected
cells, localised selection pressures (such as the magnitude and specific manifestation
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of immune responses), and both the type and availability of susceptible cells.
Anatomical sites found in some cases to harbour viral variants that are
phylogenetically distinct from those in peripheral blood include the brain (Donaldson
et al, 1994a; Wong et al., 1997; Korber et al., 1994a), cerebrospinal fluid (Steuler et
al., 1992; Tang et al., 2000), genitourinary tract (Delwart et al., 1998; Zhu et al.,
1996; Ping et al., 2000; Poss et al., 1998), colon (Wang et al., 2001), bone marrow
(Voulgaropoulou et al., 1999), lung (Wang et al, 2001; Nakata et al., 1995;
Vantwout et al., 1998; Itescu et al., 1994), and kidney (Marras et al., 2002). Proviral
sequences in the peripheral blood, spleen, and lymph node are usually closely related
(Ball et al., 1994; Donaldson et al, 1994a), and are therefore considered to represent
a single "lymphoid" compartment. However sequence comparisons between plasma
viral RNA and the proviral DNA present in PBMCs often reveal genetic differences,
with variants detected in viral RNA generally not observed in proviral DNA until
later timepoints (Simmonds et al., 1991; Ball et al, 1994; Wei et al, 1995).
Elucidating the viral and host factors that facilitate or drive the evolution of these
distinct viral sub-populations is likely to enhance our understanding of various
aspects of HIV biology, including sexual transmission and neuropathogenesis. It will
also help define and characterise sanctuary sites in patients undergoing antiretroviral
therapy, thereby providing specific bioavailability objectives for the development of
antiviral agents.
1.9 HIV-1 and the brain
Several cell types in the central nervous system (CNS) are susceptible to infection by
HIV-1, and in late stage AIDS the CNS often constitutes the largest reservoir of
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replicating virus outwith the immune system. The presence of HIV within the CNS
frequently leads to neurological symptoms and a characteristic pathological
appearance.
1.9.1 Neurological symptoms and pathology associated with
HIV-1 infection
Approximately 30-60% of HIV-1 infected individuals experience neurological or
psychiatric symptoms, which may show gradual onset and become more severe with
disease progression. These can include mental slowness, confusion, headaches,
memory loss, behavioural changes, and motor signs (such as unsteady gait and
tremor), that eventually culminate in dementia in approximately 10% of patients with
AIDS (Bell, 1998; Gray et al., 1996; Epstein and Gendelman, 1993). These
symptoms together with a progressive cognitive decline have variously been termed
AIDS related dementia (ARD), the AIDS dementia complex (ADC), or HIV
associated dementia (HAD). HAD represents a significant independent risk factor for
death due to AIDS (Lipton and Gendelman, 1995), and has been classified as an
AIDS defining illness. In developed countries the use of HAART has resulted in a
decrease in the prevalence of HAD in patients with advanced HIV disease and low
CD4 counts from approximately 20-30% in the early 1990s to the current prevalence
of around 10% (Mcarthur et al., 1993; Ferrando et al., 1998; Sacktor et al., 2001).
However, the proportion of new cases of HAD in individuals with a CD4 count
greater than 200/jlxI may be increasing (Sacktor et al, 2001). There is also evidence
that HAART does not completely protect against or cause reversal of HAD (Dore et
al., 1999; Major et al., 2000). Moreover the CNS may constitute a sanctuary site for
HIV and allow continued viral replication despite effective suppression by HAART
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elsewhere in the body. Consequently as the lifespan of HIV-1 infected individuals is
prolonged by the use of anitviral therapies and treatment of opportunistic infections it
is possible that the incidence ofHAD may actually increase. HAD therefore remains
a significant cause ofmorbidity and mortality in HIV-1 infected individuals.
Neuropathological studies have demonstrated abnormalities in the CNS of 80-100%
of AIDS patients (reviewed in Gray et al, 1996; Bell, 1998). In pre-AIDS cases
pathological changes are fairly limited but may sometimes include an inflammatory
T cell reaction, an increased number of microglial cells, upregulation of major
histocompatibility complex class II antigens, localised production of cytokines, and
other changes also consistent with an immunological process (reviewed in Gray et al,
1996). Similar assessments of AIDS autopsies have revealed more profound
neuropathological changes, which can include the presence of opportunistic
infections (such as cytomegalovirus, Toxoplasma gondii, and JC virus) and
lymphomas. HIV encephalitis (HIVE) is a direct effect ofHIV-1 within the CNS and
is observed in 10-50% of AIDS autopsy series. HIVE is characterised by the
presence of multinucleated giant cells and/or the detection of HIV-1 proteins or
nucleic acids in brain parenchymal cells. A definitive diagnosis of HIVE requires the
direct identification of viral antigens or nucleic acids, and can be made in the absence
of multinucleated giant cells. HIVE is often associated with inflammatory (immune
cell mediated) and degenerative (myelin loss and axonal damage) white matter
damage. Other neuropathology in AIDS cases can include neuronal loss, astrocytosis,
inflammatory infiltrates, and apoptosis in a number of different cell types (reviewed
in Bell, 1998; Epstein and Gendelman, 1993). However, there is no exact correlation
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between the clinical expression ofHAD and any neuropathological changes observed
at autopsy (reviewed in Bell, 1998).
1.9.2 Timing of HIV-1 infection of the brain
The blood-brain-barrier (BBB) is composed of brain microvascular endothelial cells
connected to astrocyte foot processes by tight junctions. Under normal circumstances
the BBB restricts the movement of cells, proteins, and ions between the circulation
and the CNS. HIV-1 probably enters the CNS via infected monocytes or possibly
lymphocytes trafficking across the BBB from the peripheral blood (Price, 1996).
This event can occur soon after transmission, perhaps before seroconversion (Davis
et al., 1992; Palmer et al., 1994). However, while infectious HIV-1 can usually be
recovered from the cerebrospinal fluid at all timepoints of infection (Chiodi et al.,
1988; Chiodi et al., 1992), only very low or undetectable levels of HIV-1 antigens
and proviral DNA are usually observed in the brains of asymptomatic individuals
(Donaldson et al, 1994a; Donaldson et al., 1994b; Gray et al., 1992). One possible
interpretation of these observations is that early invasion of the brain by HIV-1 seeds
a latent, low-level infection, which subsequently reactivates with progression to
AIDS. Alternatively, maintenance of HIV-1 in the brain at such low levels may not
be plausible, considering that many years often separate acute infection from the
development of HIVE (Gartner and Liu, 2002; Gartner, 2000). This scenario would
suggest that infection of the brain would need to be re-established at a later
timepoint, possibly with the onset of AIDS, and that infected cells trafficking from
elsewhere in the body are the proximate source of virus in HIVE (as opposed to
reactivation of virus already present at this site). Distinguishing between these two
models is important for furthering our basic understanding of HIV-1 infection in the
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brain, and in assessing the significance of the CNS as a sanctuary site during
HAART. The relative merits and implications of these models will therefore be
discussed further (Chapter 3)
1.9.3 Infected cell types in the brain
The predominant cell types infected by HIV-1 in the CNS are monocytes,
macrophages, and microglial cells (Koenig et al., 1986; Wiley et al., 1986). It is
thought that HIV-1 Env-directed fusion of these infected cells with uninfected
neighbouring cells gives rise to the characteristic syncytia that often accompany
HIVE. Some reports have suggested that HIV-1 infects a wider range of cell types in
the CNS including astrocytes (Cheng Mayer et al., 1987; Chiodi et al., 1987),
oligodendrocytes (Bagasra et al., 1996; Gyorkey et al., 1987), neurones (Pumarola
Sune et al., 1987; Bagasra et al, 1996), and microvascular endothelial cells (MVECs)
(Wiley et al, 1986; Pumarola Sune et al, 1987). The current consensus opinion is that
oligodendrocytes and neurones are not infected by HIV-1. Infection of astrocytes has
been demonstrated both in vivo and in vitro by a number of techniques, but viral
replication appears to be restricted, with often only accessory gene products
expressed (reviewed in Brack-Werner, 1999). The nature of this restriction is
incompletely defined but has variously been ascribed to a block in Rev function
(Ludwig et al., 1999; Neumann et al., 1995), defects in envelope processing
(Shahabuddin et al., 1996), and inefficient translation of structural gene products
(Gorry et al., 1999). In contrast, a study of primary human foetal astrocytic infection
by HIV-1 pseudotyped with Envs of amphotropic murine leukemia virus or vesicular
stomatitis virus showed a highly productive infection of these cells, suggesting
astrocyte infection by HIV-1 is restricted at the level of viral entry (Canki et al.,
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2001). Astrocytes do not express CD4, but subpopulations of astrocytes can express
CCR5 and CXCR4 (reviewed in Hesselgesser and Horuk, 1999; Gabuzda and Wang,
2000) . Therefore infection of astrocytes appears to be via a CD4-independent
mechanism. While CD4-independent X4 and R5 HIV-1 strains have been isolated
after viral passage in tissue culture (Kolchinsky et al., 1999; Dumonceaux et ah,
1998), and a number of CD4-negative cell types are sometimes found to be
susceptible to HIV-1 infection both in vivo and in vitro ( (Speck et ah, 1999) and
references therein), in the vast majority of cases infection of human cells with
naturally occurring HIV-1 isolates requires the presence of CD4. Consequently the
specific mechanism by which astrocytes are infected remains poorly defined.
MVECs also do not express CD4, but do express CCR5, CXCR4, DC-SIGN, and L-
SIGN (Mukhtar et ah, 2002). Our current understanding of HIV-1 infection of
MVECs is therefore incomplete for the same reasons described for astrocyte
infection. In the SIV/macaque animal model, which shares many common features
with HIV-1 infection in humans, neurovirulent strains of SIV have been identified.
One such strain (SIV/17E-Fr) was found to infect MVECs in a CD4-independent
manner (Edinger et ah, 1997). The occurrence of similar CD4-independent infection
of MVECs by HIV-1 is somewhat controversial. However, if true then this would
provide an easy portal for viral entry into the CNS, and may result in disruption of
BBB function, thereby contributing to the development of HAD.
1.9.4 HIV-1 induced damage in the CNS
HIV-l does not appear to infect neurones. Neurodegeneration in HIV-l infection is
therefore thought to be largely the result of indirect mechanisms, probably instigated
by factors released from activated or infected monocyte derived macrophages and
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microglial cells within the brain. One possible mechanism for neuronal damage is the
shedding of viral proteins by infected cells. Many HIV-1 gene products have been
shown to have toxic affects upon neurones and other CNS cell types (Kanmogne et
al., 2002; Shi et al., 1998; Adamson et al., 1999; Sabatier et al., 1991). Perhaps the
most likely candidate viral protein is gpl20, which is frequently shed by infected
cells. Both soluble and virion-associated gpl20 can trigger signal transduction
pathways by binding receptors such as CXCR4 and CCR5 present on neurones and
other cell types in the CNS, thereby affecting cellular functions and inducing
apoptotic death (Kaul et al., 2001). A further pathway to neuronal damage and
apoptosis is secretion of inflammatory cytokines and toxic factors by activated or
infected cells. Factors released in this manner are thought to establish a complex
cascade of inter- and intra-cellular signal transduction pathways and networks,
ultimately resulting in neuronal death (reviewed in Kaul et al, 2001). Molecules
implicated in this process include glutamate, quinolinic acid, platelet aggregating
factor, a- and (3-chemokines, interleukin-1 (3, tumour necrosis factor-cc, and free
radicals (Lipton and Gendelman, 1995).
1.9.5 HIV-1 nucleotide sequences in the brain
Little is known about the sequence relationships between viral variants present in
brain and lymphoid tissue during the asymptomatic period of infection. This is
primarily because the low HIV-1 proviral loads detected in the brain at this point
could be accounted for by the presence of infected cells in residual blood within the
tissue samples (Donaldson et al, 1994a; Donaldson et al, 1994b; Gray et al, 1992).
The availability of tissue specimens representing this stage of infection is also
relatively limited. In contrast, a large number of investigations have focussed upon
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determining the sequence relationships of virus from the brain and other
compartments in individuals who have died of complications associated with AIDS.
These comprise a diverse body of work with many differences in sample materials
and study designs, but some broad patterns have emerged. The majority of
investigations have focussed upon areas of the env gene (usually including the V3
region) as this is generally considered to be the primary determinant of HIV-1
cellular tropism. Many studies have found that virus in the brain of individuals with
HIVE is phylogenetically distinct from that in the lymphoid compartment (Epstein et
al., 1991b; Epstein et al., 1991a; Haggerty and Stevenson, 1991; Korber et al, 1994a;
Pang et al., 1991; Chang et al., 1998; Donaldson et al, 1994a; Gartner et al., 1997;
Gorry et al., 2001; Hughes et al., 1997a; Shapshak et al., 1999), although this is not
necessarily the case for every subgenomic region or study subject analysed (Hughes
et al., 1997b; Korber et al, 1994a). Inferences of coreceptor preference and cellular
tropism based on V3 sequences in brain almost invariably predict a CCR5-using,
macrophage tropic viral phenotype (Korber et al, 1994a; Wang et al, 2001;
Donaldson et al, 1994a; Chen et al., 2000). Viral variants similar to those present in
lymphoid tissue are sometimes sampled at lower levels in the brain, perhaps
representing a small amount of peripheral blood or recently infiltrating
lymphocytes/macrophages in tissue samples (Korber et al, 1994a; Gatanaga et al.,
1999; Hughes et al, 1997b). The overall viral sequence diversity within brain can
also be greater than is found within lymphoid tissue (Hughes et al, 1997b).
Furthermore, sequence similarities have also been noted between variants in brain
and those present in other macrophage-rich compartments such as the lung and colon
(Wang et al, 2001). Compartmentalisation between brain and lymphoid variants is
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sometimes reflected in other regions of the viral genome such as LTR (Ross et al.,
2001), and pol (Wong et al, 1997), although only a limited number of studies have
focussed on subgenomic regions outwith env. Many factors can lead to the
development of distinct viral subpopulations including adaptation to a specific
environment, physical isolation, and differences in replication rates. The relative
contributions of each of these factors are largely unknown for HIV-1 in the CNS.
It has been suggested that specific viral env sequences are associated with the
occurrence of dementia (Power et al., 1994; Power et al., 1998). Other studies have
failed to find such correlations between the presence of particular amino acid
signature sequences and the clinical presentation of HAD (Reddy et al., 1996; Di
Stefano et al., 1996). In general the only consistent finding between studies of HIV-1
in the brain is the presence of a low overall positive charge in the V3 loop, broadly
(although not always) consistent with macrophage tropism. Hence there does not
appear to be any clear set ofmutations that lead to a "neurotropic" or "neurovirulenf'
viral phenotype, although the question of whether such a phenotype may be
converged upon by many different constellations of mutations remains open.
1.9.6 Phenotype of HIV-1 in the brain
The presence of distinct genetic variants within the CNS gives rise to the possibility
that adaptive changes may occur within this virus population. For example local
immune responses and the phenotype of available target cells in the CNS
microenvironment may select for the outgrowth of particular viral variants.
Consistent with inferences based upon partial env nucleotide sequences, most HIV-1
variants obtained from brain tissue have a macrophage tropic phenotype (Cheng-
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Mayer and Levy, 1988; Li et al., 1991), and require both CD4 and CCR5 to enter
microglial cells (the resident CNS macrophages) (Albright et al, 1999; He et al,
1997; Shieh et al., 1998). HIV-1 infection of the CNS alone is not sufficient to cause
dementia (Bell, 1998; Power et al, 1994). Likewise, the formation of syncytia and
induction of apoptosis within the CNS does not occur in all individuals with evidence
of HIV-1 at this site (Bell, 1998). Moreover during in vitro cell culture infection
experiments only a subset of viruses produce syncytia in microglial cultures (Strizki
et al., 1996; Watkins et al, 1990), or induce neuronal apoptosis in primary brain
cultures (Ohagen et al., 1999; Power et al, 1998). These observations have led to the
proposal that "neurotropic" HIV-1 strains (as defined by ability to replicate in
microglial cells) are not necessarily "neurovirulent" i.e. do not cause the release of
factors that induce neuronal apoptosis (Power et al, 1998; Gorry et al., 2002a). No
consistent amino acid changes have been identified that can be used to predict
whether a particular R5 isolate will be able to replicate efficiently and/or induce
syncytia in microglial culture, or cause apoptosis in neighbouring neurones.
Therefore the determinants in Env that lead to these phenotypes appear to be
conformationally complex and context dependent.
Microglial cells and macrophages express lower levels of CD4 than is present on
CD4* T cells in the peripheral blood (Dick et al, 1997; Lewin et al., 1996). A
reduced dependence on CD4 for viral entry would therefore be a plausible adaptation
for enhanced HIV-1 infection of cells in the brain. With respect to this issue an
informative series of experiments have been performed in the laboratory of
Gonzalez-Scarano and colleagues (Strizki et al, 1996; Shieh et al., 2000; Martin et
al., 2001). During these experiments 27 primary virus isolates were obtained from
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acutely infected individuals and assessed for their ability to replicate in either
monocyte derived macrophages (MDM) or microglial cells (Strizki et al, 1996).
While most isolates replicated equally well in both, several strains replicated
preferentially in one of the two cell types. Serial passage of one isolate (HIV-Ibori-
15) in microglial cultures led to a 1000-fold increase in peak virus production (Strizki
et al, 1996). HIV-Ibori-is replicated to a higher titre in microglia and MDM than in
PBMCs and induced prominent syncytia, predominantly in microglia. This altered
phenotype was not due to a change in receptors used for virus entry, as the parental
and microglia-adapted virus each required the presence of both CD4 and CCR5
(Shieh et al, 2000). Generation of chimeric viruses revealed that the determinants for
the new syncytium-inducing phenotype were within Env, and sequence analysis of
the parental and microglia-adapted envelopes showed differences in eight amino acid
positions. Four amino acid differences were within the V1/V2 region of env, and two
of these eliminated potential N-linked glycosylation sites (Shieh et al, 2000). Further
characterisation of this strain demonstrated that the alterations in VI/V2 permitted
infection of cells expressing lower levels of CD4 (Strizki et al, 1996; Shieh et al,
2000). Infection experiments using cells expressing chimeric CCR5/CCR2b
coreceptor molecules established that differences between the microglia-adapted and
parental isolates also led to alterations in specific interactions with the coreceptor
molecule during viral entry, ercv-pseudotyped virus containing either the VI/V2
region of HIV-1Bori-i5 in the context of the parental isolate (rVl/V2), or the entire
env of HIV-Ibori-is (rB15) led to more efficient infection of cells expressing CCR5
with the third extracellular loop (ECF3) substituted for that of CCR2b than did the
parental env (rBORl). Differences in the dependence upon ECL3 were also seen
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between rVl/V2 and rB15, with rB15 demonstrating more efficient infection of cells
expressing CCR2b ECL3 in the context of CCR5 than did rVl/V2. Therefore the
four amino acid differences outwith V1/V2 in the microglia-adapted isolate also
affected specific interactions between Env and the coreceptor molecule. Differences
in infection efficiency between rBORI and rVl/V2 or rB15 were also found when the
N-terminal four amino acids were deleted from CCR5, with rBORI showing reduced
infectivity compared with both rVl/V2 and rB15 (Martin et al, 2001). Moreover the
microglial-adapted variants showed greatly increased susceptibility to neutralisation
by both a panel of human anti-HIV-1 antisera and the CD4-induced monoclonal
antibody 17b.
This adaptation to utilise lower levels ofCD4 along with changes in the specificity of
coreceptor interactions (possibly by alteration of the VI/V2 loop conformation) at
the expense of increased susceptibility to antibody neutralisation may be similar to in
vivo adaptations that occur in HIV-1 populations within the brain. In the periphery,
the exposure of neutralisation-sensitive epitopes sometimes associated with
adaptation to infect cells with reduced levels ofCD4 would probably be lethal to the
virus. In contrast, within the relatively immunoprivileged environment of the CNS,
concentrations of neutralising antibodies may be sufficiently reduced to allow this
adaptation to occur. While other studies have reported that tropism of HIV-1 isolates
for microglia and macrophages is similar (Ghorpade et al., 1998a; Hibbitts et al.,
1999), adaptations such as these may facilitate infection of both macrophages and
microglia in the brain. The phenotypic properties conferred by alterations in N-linked
glycosylation sites within V1/V2 are strongly context dependent. Similar patterns of
mutations can have different, or even opposite effects depending upon the overall
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genetic background of the envelope gene in which they are present (Dumonceaux et
al, 1998; Kolchinsky et al, 1999; Labranche et al., 1999; Ly and Stamatatos, 2000;
Gorry et al, 2002a).
With regard to evidence for in vivo adaptations of HIV-1 within the brain, a
neurotropic and neurovirulent isolate has recently been described (Gorry et al, 2001;
Gorry et al, 2002a), which was highly fusogenic in MDM and induced neuronal
apoptosis in primary brain cultures. Envelope clones from this isolate required only
low levels of both CD4 and CCR5 to function in cell-to-cell fusion and single-round
infection assays. These Envs also bound CCR5 with high affinity and could do so in
the absence of CD4, although they could not facilitate CD4-independent infection.
Consistent with the in vitro adaptive changes associated with microglial infection
described above, this primary virus isolate also was more susceptible to antibody
neutralisation (Gorry et al, 2002a). This isolate was also missing a predicted N-
linked glycosylation site in the VI/V2 stem of gpl20, the loss of which had
previously been demonstrated as sufficient to allow CD4-independent infection in
the laboratory isolate ADA (Kolchinsky et al., 2001a; Kolchinsky et al, 1999).
However in contrast to its effect on ADA Env, reintroduction of this N-linked
glycosylation site had no effect on CD4 independent CCR5 binding in the
neurotropic primary isolate (Gorry et al, 2002a). This provides further evidence for
the unpredictable and strain-specific effects that mutations in HIV-1 Env have upon
the conformationally complex interactions between Env and the cellular receptors
used for virus entry.
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1.10 Molecular Evolution
Molecular evolution comprises the study of rates and patterns of change occurring in
genetic material (or the products of this material such as proteins) through
evolutionary time, and the mechanisms responsible for these changes. This field of
study also encompasses molecular phylogenetics, which involves converting
information in sequences into an evolutionary tree for those sequences.
1.10.1 Distance Measures for Nucleotide Sequences
One method for estimating the amount of evolutionary change that has occurred
between two nucleotide sequences with a shared common ancestry is to calculate a
genetic distance. This is usually measured by the number of nucleotide substitutions
between the two sequences (pairwise distance). The simplest distance measure is the
p-distance, which corresponds to the proportion of sites at which the two sequences
compared are different. A p-distance is therefore obtained by dividing the number of
nucleotide differences by the total number of nucleotides compared. Because
multiple substitutions can occur at the same nucleotide position, a p-distance may
underestimate the actual amount of evolutionary change. Therefore a large number of
distance correction methods have been developed, which are designed to more
accurately represent the underlying molecular evolutionary processes. The methods
used in the investigations described in this thesis were the Jukes Cantor one
parameter distance (Jukes and Cantor, 1969) and the Kimura two parameter distance
(Kimura, 1980).
The one parameter method of Jukes and Cantor (J-C distances) compensates for
multiple substitutions at the same site, and assumes that the rate of nucleotide
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substitution is the same for all pairs of the four nucleotides (G, A, T, and C). J-C
distances therefore do not take into account differences in the frequencies of
transitions (purine to purine and pyrimidine to pyrimidine substitutions), or
transversions (purine to pyrimidine or pyrimidine to purine substitutions). This
model is suitable for the analysis of HIV sequences that have diverged within a
single infected individual, where pairwise distances are relatively small and
transitions are unlikely to have saturated to an extent that major underestimates of the
rate of sequence change would be made.
The assumption that all nucleotide substitutions occur randomly is unrealistic in
many cases, as transitions generally occur with more frequency than transversions.
To compensate for this bias the Kimura two parameter model takes into account
different rates of transitions and transversions per site (Kimura, 1980).
1.10.2 Molecular Phylogenetics
Evolutionary relationships between sequences are often depicted in the form of a
phylogenetic tree. Phylogenetic trees can be rooted or unrooted. In a rooted tree the
direction of evolution is indicated, with the root representing the common ancestor of
all the remaining sequences. An unrooted tree specifies the relationships among the
sequences but does not define an evolutionary path. Most phylogenetic methods
produce unrooted trees. However, a root may be added to an unrooted tree by
including an outgroup which is evolutionarily related to the sequences under study,
but diverged from the other sequences prior to their divergence from one another.
A large number of methods have been described for creating phylogenies from
nucleotide sequence data, and there has been extensive debate over which methods
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perform best in different circumstances (Page and Holmes, 1998a; Felsenstein,
1988; Felsenstein, 1988). Broadly, methods for creating phylogenies can be divided
into character-based methods and distance-based methods. Character-based methods
use the individual substitutions among sequences to determine the most likely
ancestral relationships. Distance-based methods first convert aligned sequences into
a pairwise distance matrix and then input that matrix into a tree building method.
Tree building methods can be divided into cluster methods and those that use
optimality criteria. Cluster methods follow an algorithm that considers each sequence
in turn and adds it to a growing tree (for example unweighted pair-group mean). The
second class of tree building methods use optimality criteria to assign a score to all
possible trees, and this score is a function of the relationship between tree and data
(for example maximum parsimony and maximum likelihood methods). A
disadvantage of this class of method is that as increasing numbers of sequences are
compared, the total number of possible trees rises rapidly. For example there are 945
possible rooted trees for 6 sequences, over 3 x 107 rooted trees for 10 sequences, and
the corresponding figure for 135 sequences is 2.1 13 x 10267 possible rooted trees.
This type of tree building technique is therefore extremely computationally intensive,
and becomes unusable with larger data sets.
For the investigations described in this thesis the Neighbour-Joining (N-J) distance-
based (clustering) method was used (Saitou and Nei, 1987), which is a simplified
version of the minimum evolution method (Saitou and Imanishi, 1989; Rzhetsky and
Nei, 1992). The minimum evolution method uses genetic distances that corrects for
multiple substitutions at the same site, and a topology showing the smallest value for
the sum of all branches is chosen as an estimate of the correct tree. The N-J method
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does not compute a value for the sum of all branches; instead the examination of
different topologies is embedded in the algorithm. Therefore only one final tree is
produced. This method produces an unrooted tree, and usually requires an outgroup
to find the root.
1.10.3 Statistical Significance of Tree Topologies
A number of different methods have been proposed for testing the reliability of a tree
topology. The most frequently used is the bootstrap test (Felsenstein, 1985).
Bootstrapping involves randomly resampling the data on which the tree was based to
generate a distribution of data sets (usually several hundred), each ofwhich is used to
determine a new tree. During each resampling usually one third of the varied sites are
removed and replaced by duplication of others in the same sequence. The frequency
that particular branches are observed in the resampled data set then allows
probability statements to be attached to the original tree. While there has been
extensive debate over the exact significance of bootstrap values, it has been
suggested that bootstrap values of 70% or higher may correspond to a 95%
confidence level (Hillis and Bull, 1993).
1.11 Aims
HIV-l is frequently detected in the CNS, where it can cause damage to neural cell
types by both direct and indirect mechanisms. Sequence analysis of HIV-l variants
in the brain, usually based upon relatively short regions of the env gene, often shows
that this subpopulation of virus is distinct from that present in the lymphoid system.
Many factors could lead to such divisions and it is not clear which underlies the
apparent genetic segregation observed in HIVE.
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Therefore one aim of this project was to further characterise the sequence
relationships between HIV-1 in the brain and lymphoid system. In particular, the role
of recombination between the two subpopulations was assessed by focussing upon
regions of the viral genome that lie both within, and outside the major determinants
ofHIV cellular tropism (V1/V2 and V3 regions). This analysis included entire HIV-1
envelope genes obtained at limiting dilution. If physical isolation or differences in
virus turnover rates are responsible for the separate virus populations observed in the
brain, then the same phylogenetic relationships between different variants should be
observed regardless of the subgenomic region analysed. However, if lymphoid
variants come into regular contact with those in the brain it may be expected that
recombinants between the two will arise frequently. These recombinants could then
be readily detected by their differing phylogenetic affinities in different subgenomic
regions. If this is the case then the genomic areas that maintain a tissue specific
grouping are likely to have been selected for, and thus represent a specific adaptation
for replication in the brain.
A second important issue regarding HIV sequence relationships in the context of a
single infection concerns the manner in which sequences are obtained. Sequence
analysis can provide many insights into HIV biology, for example by enhancing our
understanding of the viral adaptive processes associated with transmission, immune
evasion, development of antiviral resistance, and invasion of new cell and tissue
types. As technological advances allow longer sequences to be routinely obtained
and larger sequence data sets to be examined, it is likely that our knowledge of each
of these processes will be further enhanced. However, there are a number of in vitro
artefacts associated with polymerase chain reaction (PCR) and molecular cloning
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techniques commonly used to obtain HIV sequences. These include the incorporation
of point mutations during PCR, recombination during PCR, resampling of clones,
and modification of sequences during plasmid expansion in bacteria. Each of these
issues has the potential to affect both sequence analysis and interpretations based
upon that analysis. Moreover if the sequences are subsequently used in phenotypic
assays then the same complications could also arise in these downstream
applications. Therefore the second aim of this project was to quantify the effect of
each of these in vitro artefacts in the context of HIV-1 env gene amplification. The
results of this analysis demonstrated that all of these factors could lead to
considerable alterations in sequences obtained.
Taking into account the sequence alterations associated with PCR amplification and
cloning of HIV-1 env, and the complex, poorly defined, and often strain dependent
adaptations that may underlie HIV-1 neurotropism, it would be useful to have a
means of ensuring that in vitro artefacts are not present in env genes to be used for
phenotypic analysis. Therefore the third aim of this project was to develop a method
for generating env sequences suitable for transfection and expression in mammalian
cells that maintained the exact characteristics and genetic linkages present in vivo.
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2: Materials and methods
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2.1 Autopsy samples
Samples were obtained from the Medical Research Council Brain and Tissue Bank
of Edinburgh (Western General Hospital, Edinburgh). Frozen samples of lymph node
or spleen and several anatomically distinct regions of brain were obtained at
autopsies carried out within three days of death. Samples were cut into 1-2 cm3
sections and frozen at -40°C prior to DNA extraction.
2.2 Biological Safety when working with HIV
HIV is classified as a dangerous pathogen of hazard group 3. When working with
HIV it is therefore vital to ensure measures are in place that adequately protect
laboratory workers and other staff members. As a blood borne virus, infection with
HIV may occur via several routes by direct contact with clinical samples containing
virus such as blood, semen, vaginal secretions, cerebrospinal fluid, and tissue biopsy
material. The most frequent route of infection during laboratory procedures is
through cuts from contaminated "sharps" such as syringes, needles, scalpels, and
pointed scissors. This allows direct access of virus into the blood or lymphatic
system and therefore susceptible cells. Splashes of infectious material onto face and
skin can allow viral entry via mucosal membranes or through minor cuts or
abrasions. If in vitro culture of HIV is undertaken, the viral concentration in the
culture supernatant can greatly exceed levels typically found in blood of infected
individuals and may therefore pose additional infection risks. Acquisition of HIV
infection via ingestion or inhalation has not been documented in a non-laboratory
setting, although with high titre virus samples special care must be taken to reduce
these potential risks. General safety procedures when handling infectious samples
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included the use of a disposable plastic apron, arm cuffs, and two pairs of latex
gloves beneath a dedicated lab coat. Autopsy material was dissected using chainmail
gloves between two pairs of latex gloves and all sample manipulation was
undertaken within a class 1 microbiological safety cabinet. Pseudotype virus
production was confined to a class 2 microbiological safety cabinet within a
specifically designed category 3 laboratory. Laboratory surfaces were regularly
decontaminated with the application of 70% ethanol or 3% Tegador (Tego Hygiene).
Contaminated waste material was disposed of by initial chemical treatment where
possible with 3% Tegador followed by autoclaving (121°C for 30 minutes at 3
atmospheres) then incineration.
2.3 DNA Extraction
0.5-1 cm1 blocks were dissected from frozen autopsy material and added to 1.5 ml
eppendorf tubes containing 500 pi lysis buffer (0.11 M NaCh, 55 mM Tris pH 8.0,
1.1 mM ethylenediamine tetraacetic acid [EDTA] pH 8.0, 0.55% sodium dodecyl
sulphate [SDS], 1 mg/ml Proteinase K, 40 pg/ml poly A), mixed well by vortexing,
and then incubated at 65°C for two hours or until the material was completely
dissolved. After lysis, 450 pi of water saturated phenol (Sigma) was added to the
extraction eppendorf and vortexed for 5 minutes. The tube was then centrifuged at
room temperature for 10 minutes at 12000g. The upper aqueous layer was transferred
to a clean eppendorf tube and phenol extraction repeated as above. The aqueous layer
was transferred to a fresh eppendorf tube containing 450 pi chloroform/iso-
amylalcohol (Rathburn) 50:1, mixed by vortexing for 2 minutes and centrifuged at
room temperature for 10 minutes at 12000g. The aqueous layer was then transferred
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to a fresh eppendorf tube containing 40 pi 3 M sodium acetate (NaAc) pH 5.2 and
800 pi cold (-20°C) 100% ethanol (BDH). This tube was mixed by inversion and
then left overnight at -20°C to allow precipitation of nucleic acid. After precipitation
the tube was centrifuged at 0°C for 10 minutes at 12000g and the supernatant
discarded. The pellet was then washed with 80% (v/v) ethanol and centrifuged at 0°C
for 10 minutes at 12000g. The supernatant was discarded and the pellet dried at 37°C
for 5 to 10 minutes. The DNA pellet was re-suspended in 50 pi of sterile
(DNAase/RNAase free) water and left at room temperature for at least 10 minutes
before use to ensure adequate solubilisation of the nucleic acid.
2.4 Quantitation of Extracted DNA
The concentration and approximate purity of DNA in each sample was quantified
using spectrophotometric absorbance readings at wavelengths of 260 nm and 280
nm. Samples were diluted 1 in 200 with sterile water and absorbance measured in a
spectrophotometer (GeneQuant II, Pharmacia Biotech). The concentration of DNA
was calculated from the equation: A260 x D x 50 = DNA concentration (pg/ml),
where A260 = OD values at 260 nm, D is the dilution factor (200), and 50 is
equivalent to the concentration (pg/ml) of double-stranded DNA at A260 of 1.0. The
ratio of optical density (OD) at 260 nm to 280 nm gave an indication of DNA purity
in each of the extracted samples. Pure DNA preparations have an A260/A280 ratio of
approximately 1.8.
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2.5 Polymerase Chain Reaction
2.5.1 General procedures
The nested polymerase chain reaction is an extremely specific and sensitive
molecular technique allowing the amplification of a single target molecule within a
complex mixture of DNA sequences. While ideal for a wide range of biological
applications the high sensitivity of this procedure gives rise to an inherent risk of
sample contamination by exogenous DNA during laboratory procedures. To
minimise this risk all buffers for PCR reactions were prepared in a dedicated room
where no nucleic acid extractions were performed. Primary and secondary PCR
reactions and the cloning and subsequent amplification of PCR products were all
undertaken in separate rooms with dedicated lab coats. Latex gloves were changed
frequently throughout procedures. Known positive and negative DNA controls and
an additional negative control containing no DNA were included in every set of
reactions to provide a comprehensive test for contamination of samples or buffers.
All thermal cycling reactions were performed on a Genius PCR machine (Techne).
Where nested PCR was performed, 2 pi of primary PCR product was transferred for
amplification with second round primers and the same reaction conditions were used
for primary and secondary PCRs. All reactions were overlaid with 1 drop of mineral
oil prior to thermal cycling to prevent evaporation of reaction mixtures.
2.5.2 Primer sequences
General considerations when designing oligonucleotide primers for PCR include
primer length (generally between 15 and 30 bases), close sequence identity with the
template DNA sequence (especially when heterogeneous DNA templates are being
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amplified), and avoidance of mismatches with template DNA at the 3' base position.
If possible similar annealing temperatures for forward and reverse primers, 40-60%
G + C content, avoidance of runs of Gs or Cs (to reduce internal secondary
structure), and avoidance of complementary sequences between primers (to avoid
primer-dimer formation) is also desirable. The sequences of the oligonucleotide
primers used in this study are shown (Table 2.1) along with the 5' base position of
the primer-binding site on the relevant template molecule.
Code Primer Sequence (5' to 3') Binding site
531 GCGAGAGCGTCAGTATTAAGCGG 1012: pl7gagl
532 GGGAAAAAATTCGGTTAAGGCC 1052: pl7gag
533 CTTCTACTACTTTTACCCATGC 1528: pl7gag
534 TCTGATAATGCTGAAAACATGGG 1577: pl7gag
401 GAGGATATAATCAGTTTATGG 7372: V1/V2
402 CATCAAAGCCTAAAGCCATG 7393: V1/V2
403 CAATAATGTATGGGAATTGG 7883: V1/V2
333 AATGTACTGTGCTGACATT 7969: V1/V2
332 TACAATGTACACATGGAATT 7964: V3
306 TGGCAGTCTAGCAGAAGAAG 8019: V3
307 CTGGGTCCCCTCCTGAGG 8422: V3
308 ATTACAGTAGAAAAATTCCCC 8475: V3
G AGATCTTCAGACTTGGAGGAGG 8798: gp41
I GAGTAAGTCTCTCAAGCGGTGG 9795: gp41
ENV A GGCTTAGGCATCTCCTATGGCAGGAAGAA 6622: env
ENV B AGAAAGAGCAGAAGACAGTGGCAATGA 6972: env
ENV M TAGCCCTTCCAGTCCCCCCTTTTCTTTTA 10473: env
ENV N CTGCCAATCAGGGAAGTAGCCTTGTGT 10554: env
N1 AGCAGTAGCTGAGGGRACAGATAG 9978: nef
NEF F TGCTRTAAGATGGGTGGCAAGTGG 10082: nef
NEF F2 TAAGATGGGTGGCAAGTGGTCAAA 10087: nef
N4 CTGGCCCTGGTGTGTARTTCTGCC 10576: nef
NEF R TGGAAAGTCCCCAGCGGAAAGTCC 10989: nef
NEF RO GCTGCTTATATGCAGGATCTGAGG 11099: nef
GFP1 GTGGATAACCGTATTACCGCCATGC 4705: pEGFP-Cl2
GFP2 CCGCTAGCGCTACCGGTCGCCACC 589: pEGFP-Cl
GFP3 CTACTTGTACAGCTCGTCCATGCCG3 1332: pEGFP-Cl
GFP4 GGATTTTGCCGATTTCGGCCTATTG 1739: pEGFP-Cl
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LUC F GGTAAAGCCACCATGGAAGACGCC 268: luciferase4
LUC F2 CCATGGAAGACGCCAAAAACATAA 278: luciferase
LUC R2 GCGATCTTTCCGCCCTTCTTGGCC 1925: luciferase
LUC R GAATTACACGGCGATCTTTCCGCC 1935: luciferase
3.1FO GATTTTGCCGATTTCGGCCTATTG 4926: pCR3.T
3.IF GCGCGCGTTGACATTGATTATTGAC 1: pCR3.1
3.1R CTGCGTTATCCCCTGATTCTGTGG 1067: pCR3.1
3.1RO TTACGGTTCCTGGCCTTTTGCTGG 1113: pCR3.1
T7 TAATACGACTCACTATAGGG 638: pCR3.1
BGH TAGAAGGCACAGTCGAGG 790: pCR3.1
Table 2.1. Oligonucleotide primer sequences and 5' nucleotide binding sites
on template DNA.
'HIV sequence positions correspond to the HXB2 genome on the Los Alamos
National Laboratory HIV Database. "pEGFP-Cl, genbank accession U55763.
3Shaded bases represent alteration of vector sequence to incorporate a stop
codon.4Luciferase gene in pGL3-control vector, genbank accession U47298.
5pCR3.1-Uni mammalian expression vector (numbering corresponds to Invitrogen
literature).
2.5.3 PCR of p179ag , V1/V2, V3, nef and EGFP
The enhanced green fluorescent protein (EGFP) gene (both with and without
flanking promoter and poly [A] sequences) was amplified using 2 pi of a 10"3
dilution (approximately 10 ng) of pEGFP-Cl vector (Clontech) as template for PCR
with a single set of primers. HIV subgenomic regions were amplified by nested PCR
using template DNA extracted from autopsy samples.
Reagents
Tag polymerase in storage buffer B (Promega) - 5 Units/pl enzyme, 20 mM Tris-
HC1 (pH8), lOOmM KC1, 0.1 mM EDTA, 1 mM DDT, 50% glycerol, 0.5% Nonidet-
P40, 0.5% Tween 20
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10 x PCR reaction buffer with MgCL2 (Promega) - 100 mM Tris-HCl (pH 9.0), 500
mM KC1, 15 mM MgCl2, 1% Triton X-100
Protocol
Reaction mixtures contained 5 pi of 10 x reaction buffer, 30 pM of each dNTP
(dGTP, dATP, dTTP, and dCTP), 1 Unit (U) of Taq polymerase, 0.25 pM of each
primer and between 1 and 5 pi of sample DNA. All PCR mixes were set up in 50 pi
reactions with the final volume made up with nuclease free water. Primers used to
amplify primary and secondary reaction products are shown (Table 2.2).
Thermal cycling conditions
pi7gag and nefregions
94°C for 18 sec, 55°C for 21 sec, 72°C for 1.5 min x 30 cycles followed by 72°C for
10 min x 1 cycle
V1/V2 and V3 regions:
94°C for 18 sec, 50°C for 21 sec, 72°C for 1.5 min x 25 cycles followed by 72°C for
10 min x 1 cycle
EGFP:
94°C for 45 sec, 55°C for 45 sec, 72°C for 3 min x 25 cycles followed by 72°C for
10 min x 1 cycle
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Sequence Amplified Primary PCR Secondary PCR
Forward Reverse Forward Reverse
p 17gag 531 534 532 533
V1/V2 401 333 402 403
V3 332 308 306 307
env ENV A ENV N ENV B ENV M
nef N1 NEFRO NEFF NEFR
Promoter-EGFP-poly (A) GFP1 GFP4 - -
EGFP GFP2 GFP3 - -
Luciferase LUCF LUCR - -
Table 2.2. Primers pairs used in PCR and sequencing reactions.
2.5.4 PCR of full-length env and Luciferase genes
PCR of the env gene was performed using template DNA extracted from autopsy
samples or control clones. Control clones used were CAM-1 (full-length molecular
clone of the Cambridge isolate also referred to as C-HIV-1) and LAI (full-length 12
Kb insert of HIV-1 LAI) kindly provided by Dr Karpas and Dr Becket respectively
via the NIBSC Centralised Facility for AIDS Reagents supported by EU Programme
(contract BMH4 97/2515) and the UK Medical Research Council. Plasmid DNA was
extracted as in section 2.8.5 and quantified by V3 limiting dilution PCR (see 2.5.3).
Several aliquots were made whereby either a single genotype or an equimolar mix of
the two genotypes (approximately 3 x 104 copies of each) was added to 1 pg of HIV
negative peripheral blood mononuclear cell (PBMC) DNA. Various dilutions of
these mixes were then used as templates for env PCR reactions (as described in
Chapter 4). The same reaction conditions were used in a single round PCR reaction
to amplify the firefly luciferase gene (luc+) using 2 pi of a 10"5 dilution
(approximately 100 pg) of pGL3-control vector (Promega) as template.
Ill
Reagents
10 x PCR reaction buffer (with MgCh) (Roche)
Expand High Fidelity Polymerase (Roche) - 3.5 U/pl enzyme, 20 mM Tris-HCl (pH
7.5), lOOmM KC1, 1 mM DTT, 0.1 mM EDTA, 0.5% Tween 20, 0.5% Nonidet-P40,
50% glycerol
Protocol
Reaction mixtures contained 5 pi of 10 x reaction buffer with MgCF, 60 pM of each
dNTP, 2 units of Expand High Fidelity Polymerase, 0.5 pM of each primer and
between 1 and 5 pi of sample DNA with the final volume of 50 pi made up with
nuclease free water.
Thermal cycling conditions
94°C for 45 sec, 50°C for 45 sec, 72°C for 4 min x 20 cycles, then 94°C for 45 sec,
50°C for 45 sec, 72 °C for 4minl5 sec x 15 cycles, followed by 72°C for 10 min x 1
cycle
2.6 Agarose gel electrophoresis
Reagents
10 x TBE - 108g Tris base (BDH), 55g boric acid (Molecular Biology certified;
Kodak), 40ml 0.5M EDTA (Molecular Biology certified; Kodak). Made up to 1 litre
with distilled water
Agarose gel - Agarose (Sigma), made with 1 x TBE containing ethidium bromide
(0.1 pg/ml)
6 x loading buffer - 15% Ficoll 400, 0.03% bromophenol blue, 0.03% xylene cyanol,
0.4% orange G, 10 mM Tris-HCl (pH 7.5), 50 mM EDTA
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Protocol
DNA was fractionated according to size in a 1-2% agarose gel using flatbed
apparatus and 1 x TBE as electrophoresis buffer. Gels were run at 150V for 20
minutes to 2 hours depending on the expected size of the DNA. Ethidium bromide
was included in the gel to act as an intercalating agent, binding to DNA and
fluorescing under short wave (254 nm) ultra violet light therefore allowing PCR
products, restriction digests, and clones to be visualised as discrete bands. DNA
samples were suspended in a final concentration of 1 x loading buffer prior to
electrophoresis and 100 bp or 1 Kb DNA ladders (Promega) were run beside samples
to assess the length of products.
2.7 Quantitation of HIV-1 proviral DNA
HIV-l DNA was initially semi quantified by using nested PCR on serial 10-fold
dilutions of extracted DNA with V3 primers known to be capable of detecting a
single proviral copy. In some cases this was followed by the more accurate limiting
dilution PCR method (Simmonds et al., 1990). Ten PCR replicates were performed at
the last positive dilution and the proviral load was estimated assuming a Poisson
dilution by the formula -In (l-p)/d (where p = proportion of positive samples and d
= dilution). The number of proviral copies per million cells was calculated on the
basis that a human diploid cell contains 6.6 pg DNA.
2.8 Cloning of PCR products
The cloning of PCR products was performed using a unidirectional eukaryotic TA
cloning kit (Invitrogen). This kit contains pCR3.1, a vector allowing TA cloning of
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complete open reading frame PCR products in the correct orientation for expression
when the resultant clones are transfected into eukaryotic cells. The left hand arm of
pCR3.1 does not have a 5' phosphate group and in order for ligation to occur the
PCR products must be amplified with forward primers that have a 5' phosphate
group chemically or enzymatically added, therefore assuring correct (forward)
orientation of insert.
2.8.1 Phosphorylation of PCR products
5' phosphates were added to forward primers either chemically during primer
synthesis (Oswel) or enzymatically using T4 polynucleotide kinase. The enzymatic
phosphorylation reaction contained 50-100 pmoles of forward primer, 1 pi of 10 x
kinase buffer (500 mM Tris-HCl (pH 7.5), 100 mM MgCh, 50 mM dithiothreitol, 1
mM spermidine), 1 pi 10 mM ATP, and sterile water to make up to 9 pi total
volume. One pi of T4 polynucleotide kinase (10 U/pl) was added and the reaction
mixed gently then incubated at 37°C for 30-40 minutes. The reaction was then
incubated at 94°C for 5 minutes to inactivate the kinase and prevent phosphorylation
of the reverse primer during PCR. Enzymatically phosphorylated primers were used
for PCR immediately after production.
2.8.2 Ligation reaction
The amount of PCR product needed to ligate with 60 ng (20 fmoles) of pCR3.1 was
calculated using the formula X ng PCR product = 2 (Y bp PCR product) (60 ng
pCR3.1 vector)/ (size in bp of the pCR3.1 vector: 5020) where "X" ng is the
amount of PCR product of "Y" bp to be ligated for a 1:2 (vector:insert) molar ratio.
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The ligation reaction was composed as follows:
Fresh PCR product (Less than 1 day old) Xpl
10 x Ligation Buffer - 60 mM Tris-HCl (pH 7.5), 60 mM MgCL, 50
mM NaCl, 1.0 mg/ml bovine serum albumin, 70 mM P-mercaptoethanol,
1 mM ATP, 20 mM dithiothreitol, 10 mM spermidine
1 pi
PCR3.1-Uni vector (30 ng/pl) 2 pi
Sterile water To a final volume of 9 pi
T4 DNA ligase (4 units/pl) 1 Pi
Table 2.3. Composition of ligation reaction.




SOC Medium - 2% Tryptone, 0.5% yeast extract, 0.005% NaCl, 2.5 mM KC1, 10
mM MgCL, 10 mM glucose
LB (Luria-Bertani) Medium - 1% Tryptone (Difco), 0.5% Yeast extract (Gibco), 1%
NaCl, made up to 1 litre with distilled water
LB agar plates - 1% Tryptone, 0.5% Yeast extract, 1% NaCl, 1.5% agar, made up to
1 litre with distilled water
One Shot TOP10F' competent cells - genotype: F'{/acIq Tn10 (TetR)}mc/-AA (mrr-
hsdRMS-mrcBC) (f>80/<3cZAMl5 AlacX74 deoR recAl araD\39 A (ara-leu)l697
gall] galK rpsL endA1 nupCs
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Protocol
One vial containing 50 pi of competent cells was thawed on ice for each
transformation reaction. Two microlitres of ligation reaction was added to the
competent cells and the mixture gently stirred before incubation for 30 minutes on
ice. The vials were then heated for exactly 30 seconds at 42°C and immediately
placed back on ice. Two hundred and fifty pi of room temperature SOC media was
added to the tubes and the vials were incubated at 37°C for 1 hour at 225 rpm in a
shaking incubator. Between 10 and 50 pi of the transformed cells were then plated
onto LB agar plates containing 50 pg/ml ampicillin and left at room temperature for
20 minutes. The plates were then inverted and incubated at 37°C overnight before
storage at 4°C.
2.8.4 Colony Screening
Bacterial colonies transformed with V1/V2 ligations were PCR screened for the
presence of insert using primers 402 and 403. Colony screening for the presence of
env gene clones required two separate PCR reactions. The first reaction included
primers Env B and 403, therefore verifying the presence of the 5' end of the gene.
The second reaction included primers N2 and ENV M, indicating the 3' end of the
gene was also present. A small proportion of a bacterial colony was picked with a
sterile toothpick and added directly into PCR reaction mixtures for amplification.
PCR reaction mixture composition (with the exception of primers) and thermal
cycling parameters were as for amplification of V3 (Section 2.5.3).
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2.8.5 Plasmid DNA Mini-preps
Bacterial cultures for plasmid mini-preps were prepared by inoculating 2-3 ml of LB
media containing 50 pg/ml of ampicillin with a single colony in a 15 ml sterile tube
to ensure adequate aeration for growth. The culture was incubated at 37°C with
shaking for 12-16 hours. A plasmid mini prep kit (Hybaid) was then used to extract
the plasmid DNA from the bacteria as follows:
Reagents
Pre-Lysis buffer - (50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 100 pg/ml RNAase A
Alkaline Lysis Solution - 200 mM NaOH, 1% SDS (w/v)
Neutralising Solution - Containing acetate and guanidine hydrochloride
Binding Buffer - Containing silica gel matrix
Wash Solution - Containing ethanol, NaCl, EDTA, and Tris-HCl
Protocol
One ml of bacterial culture was transferred to an eppendorf and centrifuged at 6000g
for 5 minutes. The supernatant was completely removed and discarded then the
bacterial pellet was resuspended in 50 pi pre-lysis buffer. To lyse the cells 100 pi of
alkaline lysis solution was added and mixed thoroughly into the cell suspension. A
total of 75 pi neutralising solution was added and the tube vortexed to ensure
complete mixing of contents. The tube was then centrifuged for 2 minutes at 12000g
to pellet the white precipitate and the supernatant removed and transferred to a spin
column. Binding buffer was shaken before use to resuspend the silica gel matrix and
250 pi of this buffer was added to the spin filter and mixed with the plasmid DNA
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supernatant. The spin tube was centrifuged for 1 minute at 12000g to collect the
liquid at the bottom of the vial. Three hundred and fifty pi of wash solution was
added and the spin filter was centrifuged again for 1 minute. In order to dry the
pellet, the liquid in the collection vial was discarded and the spin filter was
centrifuged for 1 minute at 12000g. The spin filter was then transferred to a new
catch tube and 50 pi of sterile water was added to the membrane. The tube was
sealed, vortexed briefly, and centrifuged for 30 seconds to collect plasmid DNA in
the catch tube.
2.8.6 Plasmid DNA Midi-preps
For isolation of up to 100 pg of plasmid DNA larger bacterial culture volumes were
required. A culture of 2-3 ml LB media containing 50 pg/ml ampicillin was
inoculated with a single colony and cultured in a sterile 15 ml tube for approximately
8 hours at 37°C with vigorous shaking (>200 rpm). This starter culture was diluted
1/500-1/1000 and used to inoculate 25 ml of LB medium with 50 pg/ml ampicillin in
a sterile container of at least 100 ml total volume. The second culture was grown at
37°C for 12-16 hours with vigorous shaking. A QIAfilter plasmid midi kit (Qiagen)
was used to extract plasmid DNA as follows:
Protocol
The bacterial cells were harvested by centrifugation at 6000g for 15 min at 4°C after
which the supernatant was discarded and the pellet resuspended in 4 ml buffer PL
Four ml of buffer P2 was then added to lyse the cells and the lysate mixed by
inverting the tube 4-6 times before incubation for 5 minutes at room temperature.
Four ml of chilled buffer P3 was added to the lysate and the tube inverted 4-6 times
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to precipitate genomic DNA, proteins, and cell debris. The lysate was then poured
into a QIAfilter cartridge and incubated at room temperature for 10 minutes. A
QIAGEN-tip 100 was equilibrated by applying 4 ml of buffer QBT and allowing the
column to empty by gravity flow. The cell lysate was filtered through the QIAfilter
cartridge into the equilibrated QIAGEN-tip 100 and allowed to enter the resin by
gravity flow. The tip was washed twice with 10 ml of buffer QC then the plasmid
DNA eluted with 5 ml of buffer QF. DNA was then precipitated by mixing 3.5 ml
room temperature isopropanol with the eluted DNA and centrifuging at 15000g for
30 minutes at 4°C. The supernatant was decanted off and the DNA pellet washed
with 2 ml room temperature 70% ethanol before centrifugation at 15000g for 10
minutes. The ethanol was then removed and the pellet air-dried for 10 minutes before
redissolving the DNA in 100 pi sterile water.
2.9 Restriction digests
2.9.1 Pme I digest
pCR3.1 contains two Pme I sites, one on each side of the insert. This restriction
enzyme was used to cut the vector and verify that clones contain inserts of an
appropriate size.
Reagents
Pme I restriction enzyme (New England Biolabs) - 10 U/pl Pme I enzyme in storage
buffer (100 mM NaCl, 10 mM Tris-HCl (pH7.4), 0.1 mM EDTA, 1 mM
dithiothreitol (DTT), 200 pg/ml BSA, and 50% glycerol)
119
10 x New England Biolabs buffer 4-50 mM potassium acetate, 20 mM Tris acetate,
10 mM magnesium acetate, 1 mM DTT
Protocol
2 pi cloned DNA was mixed with 2 units of Pme I, 1 pi 10 x reaction buffer 4, 0.1
pg/ml final concentration of Bovine serum albumin (BSA), and the final volume of
10 pi made up with sterile water. The reaction was incubated for 4 hours at 37°C and
run on an agarose/ethidium bromide gel for visualisation of products.
2.9.2 Hind III and Xmn I single and double digests:
Full-length env PCR products were cleaved with Hind III, Xmn I, or a combination of
both restriction enzymes.
Reagents
Hind III restriction enzyme (Promega) - 10 U/pl Hind III enzyme in storage buffer
(10 mM Tris-HCl, (pH7.4), 250 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mg/ml
BSA and 50% glycerol)
Xmn I restriction enzyme (Promega) - 10 U/pl Xmn I enzyme in storage buffer (10
mM Tris-HCl (pH7.5), 100 mM NaGlutamate, 0.1 mM EDTA, 1 mM DTT, 0.5
mg/ml BSA, and 50% glycerol)
10 x reaction buffer B (Promega) - 60 mM Tris-HCl (pH7.5), 500 mM NaCE, 10
mM DTT
Protocol
Single and double digests were performed in 30 pi total volumes. Digests were set up
with 8 pi of secondary PCR product (approximately 800 ng DNA), 3 pi of 10 x
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reaction buffer B, 2 units of (each) enzyme, 0.1 pg/pl concentration of BSA with the
final reaction volume made up with sterile water. The reaction was incubated at 37°C
for 4 hours and products visualised under UV light after electrophoresis on an
agarose/ethidium bromide gel.
2.10 Overlap Extension PCR reactions
Linear expression constructs (LECs) were produced by overlap extension PCR
reactions. Detailed diagrams of vectors used and PCR primer binding sites are shown
in chapter 5.
2.11 PCR using ligation reactions as template
pCR3.1 ligation reactions were set up as described in section 2.8.2 for EGFP, luc+,
nef and env genes amplified by PCR. In each case 2 pi of a 10"J dilution of the
ligation reaction products was used as a template for further PCR reactions. Two
separate overlapping single round PCR reactions (PCR A and PCR B) were set up
with each ligation product. The PCR conditions were the same as those for the env
gene amplification but Taq polymerase and the appropriate 10 x buffer replaced
Expand High Fidelity Polymerase and buffer. The primers used for amplification of
these products are shown in Table 2.4.
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Template Ligation Primers for PCR A Primers for PCR B
EGFP 3.1FO and GFP3 GFP2 and 3.1RO
Luciferase 3.1FO and LUCR2 LUCF2 and 3.1RO
nef 3.1FO and N4 NEFF2 and 3.1RO
env 3.1FO and 332 308 and 3.1RO
Table 2.4. Primer pairs used in construction of linear expression constructs
2.12 Extension reactions
Extension reactions were performed for EGFP and Luciferase by mixing 5 pi of PCR
product A with 25 pi of product B, 1.5 nmol of each dNTP and 1 unit of Taq
polymerase, nefand env extensions were composed by adding 5 pi PCR product A to
5 pi product B, 5 pi 10 x reaction buffer B, 3 nmol of each NTP, and 2 units of Taq
polymerase with the final reaction volume of 60 pi made up with sterile water.
Extension mixtures were then cycled at 94°C for 24 sec, 72°C for 4 min x 10 cycles
followed by 72°C for 10 min x 1 cycle.
2.13 Final Amplification
Extension products were subjected to a final amplification reaction using primers
3. IF and 3.1R. For EGFP and luciferase genes 1 pi of extension reaction was taken
for further amplification, for nef and env genes 10 pi of extension reaction was
carried over. Extended products were added to 5 pi 10 x reaction buffer B, 1.5 nmol
of each dNTP, 10 pmol of each primer and 1 unit of Taq polymerase with 50 pi final
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volume made up with sterile water. The mixtures were overlaid with 1 drop of
mineral oil and thermal cycled at 94°C for 45 sec, 55°C for 45 sec, and 72°C for 4
min 15 sec x 15 cycles followed by 72°C for 10 min x 1 cycle.
2.14 PCR product purification
Prior to transfection into eukaryotic cells, linear expression constructs were purified
using a QIAquick PCR purification kit (Qiagen). This procedure involves binding the
DNA to a silica-gel membrane within a spin column. After binding to the membrane
the DNA is washed to remove impurities such as salts, enzymes, unincorporated
nucleotides, oils, and detergents that may interfere with transfection procedures. The
DNA can also be concentrated during the purification process by adding the contents
of several PCR reactions onto a single membrane before elution. In this case three 50
pi amplification reaction products were added to a single column for elution in 50 pi
of sterile water.
Protocol
5 volumes of buffer PB was mixed with 1 volume of PCR sample and the mixture
added to a QIAquick spin column. The column was then centrifuged at 12000g for
30-60 seconds and the flow-through discarded. 0.75 ml of wash buffer PE was added
to the column and it was centrifuged at 12000g for 30-60 seconds. The flow-through
was discarded and residual wash buffer removed by centrifuging the column again at
12000g for 30-60 seconds. The column was then placed in a clean tube and 50 pi of
sterile water was added to the membrane. Finally the tube was centrifuged at 12000g




Manual DNA sequencing was performed using a thermo sequenase radiolabeled
terminator cycle sequencing kit (USB). This kit is based upon the chain termination
method of Sanger (Sanger et al., 1977) using cycle sequencing (Murray, 1989). The
procedure uses a thermostable polymerase to extend a single primer along a DNA
template by thermal cycling with the inclusion of P radiolabeled 2',3'-
dideoxynucleoside-5'triphosphate nucleotide analogues (ddNTPs) as chain
terminators. This results in both the radioactive labelling of the extended DNA
strand, and the production of different lengths of DNA. Sequencing products can
then be separated by electrophoresis on a polyacrylamide gel. After running, the gel
is incubated beside photographic film and bands visible upon development of this
film correspond to the presence of the same base in the target DNA sequence as the
ddNTP added to that reaction. Thus when the four separate sequencing reactions
corresponding to each base (ddGTP, ddATP, ddTTP, and ddCTP) are run side by
side, the original sequence of the DNA template can be read.
Reagents
Thermo sequenase DNA polymerase - 4 U/pl thermo sequenase DNA polymerase
enzyme, 50 mM Tris-HCl (pH 8.0), 1 mM DTT, 0.1 mM EDTA, 0.5% Tween-20,
0.5% Nonidet P-40, 50% glycerol
Reaction buffer (concentrate) - 260 mM Tris-HCl (pH9.5), 65 mM MgCh
dGTP nucleotide master mix - 7.5 pM dGTP, 7.5 pM dATP, 7.5 pM dTTP, 7.5 pM
dCTP
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ddGTP - 0.3 pM (ct-33P) ddGTP
ddATP - 0.3 pM (a-33P) ddATP
ddTTP - 0.3 pM (a-33P) ddTTP
ddCTP - 0.3 pM (a-33P) ddCTP
Stop solution - 95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05%
xylene cyanol FF
Shrimp alkaline phosphatase (SAP, Amersham) - lU/pl enzyme, 25 mM Tris-HCl
(pH 7.5), 1 mM MgCh, 0.1 mM ZnCF, 50% glycerol
Exonuclease I (Amersham) - 10 U/pl enzyme, 20 mM Tris-HCl (pH 7.5), 0.5 mM
EDTA, 5 mM 2-mercaptoethanol, 50% glycerol
Protocol
For sequencing of PCR products the product was first treated with a combination of
SAP and Exonuclease I to eliminate any primer or dNTPs, which were not
incorporated into the PCR product. One pi of SAP and 1 pi of exonuclease I was
added to 5 pi of PCR and the mixture incubated at 37°C for 15 minutes followed by
80°C for 15 minutes. Termination mixes were made by adding 2 pi of dGTP master
mix to 0.5 pi of each ddNTP (ddGTP, ddATP, ddTTP, and ddCTP - one for each per
sequence). Four tubes were labelled ("G", "A", "T", and "C") and 2.5 pi of each
termination mix was added. Reaction mixture composed of 0.5 pi reaction buffer,
0.75 pi DNA, 10 pmoles primer, 0.5 pi thermo sequenase enzyme, and 3.1 pi sterile
water was added to each termination tube, mixed well and covered with 10 pi of
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mineral oil. The reactions were subjected to 30 cycles at 94°C for 30 seconds, 55°C
for 30 seconds, and 72°C for 1 minute. After thermal cycling 6 pi of each reaction
was transferred to a fresh tube containing 4 pi of stop solution.
2.15.2 Acrylamide Gel Electrophoresis
Reagents
10 x Sanger TBE - 324 g Tris base, 85 g boric acid, 19 g EDTA, made up to 2 litres
with distilled water
6% acrylamide gel - 21 g Urea (BDH), 6 ml Sequagel XR concentrate (National
Diagnostics), 5 ml 10 x Sanger TBE, 0.05 g ammonium persulphate (APS) (Sigma),
made up to 50 ml with distilled water then 20pl N,N,N',N'
Tetramthylethylenediamine (TEMED, Sigma) added
Protocol
The sequencing reactions were run on a 6% acrylamide gel. Glass plates were
cleaned with methanol then acetone and a pair of flat spacers were used to assemble
the plates. The gel mixture was poured carefully to avoid producing bubbles and left
to polymerise for at least 2 hours. The gel was pre run at 75 volts for 10 minutes
using 1 x Sanger TBE as the electrophoresis buffer. Samples were heated at 90°C for
5 minutes and loaded on the gel, which was run at 75 volts for 0.5-1.5 hours. After
electrophoresis the gel was disassembled and dried before exposure to X-ray film
(Kodak) for 1-2 days depending on the intensity of radioactive signal.
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2.15.3 Automated Sequencing
Automated sequencing reactions were performed using the ABI Prism BigDye
Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems) and run on
an ABI Prism 3100 genetic analyser (Perkin Elmer ABI biosystems). This system
follows the same principle as manual cycle sequencing. However, each termination
nucleotide analogue is labelled with a different fluorescent marker, allowing
sequencing reactions to be performed in a single tube. Primers used for sequencing
of env gene and subgenomic regions are shown in figure 2.1.
T7 ENV B 402 306 G N1
gpl20 gp41 nef
M^—
403 307 i ENV M BGH
Figure 2.1. Schematic representation of primer binding sites on env gene.
Primers used to sequence env PCR products. For sequencing of clones T7 and BGH
were used instead of ENV B and ENV M respectively.
Reagents
Terminator Ready Reaction Mix - A-Dye Terminator labelled with dichloro[R6G],
C-Dye Terminator labelled with dichloro[ROX], G-Dye Terminator labelled with
dichloro[Rl 10], T-Dye Terminator labelled with dichloro[TAMRA],
deoxynucleoside triphosphates (dATP, dCTP, dITP, dUTP), AmpliTaq DNA
polymerase, MgCh, Tris-HCl buffer (pH 9.0)
Protocol
Reactions were composed of 4 pi of Terminator Ready Reaction Mix, 50-500 ng
DNA, 1.6 pmol of primer, and the final reaction volume of 10 pi made up with
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sterile water. The mixture was overlaid with 1 drop of mineral oil and subjected to 25
x cycles of 96°C for 30 sec, 50°C for 15 sec, and 60°C for 4 minutes. After thermal
cycling the products were transferred to a clean tube and ethanol precipitated by
addition of 25 pi cold (-20°C) 100% ethanol and 1 pi of sodium acetate (pH 4.5).
The contents were mixed and the tube incubated for 3-16 hours at -20°C before
centrifugation at 12000g for 30 minutes at 4°C. The supernatant was removed and
the DNA pellet washed by addition of 125 pi of cold 70% ethanol then centrifuged at
12000g for 10 minutes at 4°C. Ethanol was then removed completely and the pellet
allowed to air dry before being sent for automated sequencing.
2.16 Sequence Analysis
Sequencing gels were read and manually aligned using the Simmonic 2000 computer
package developed by Professor Peter Simmonds. Automated sequencing files were
first manually edited using the Chromas ABI sequence editor package (version 1.42)
before importing into Simmonic 2000.
Phylogenetic trees were created from the aligned sequences using the Molecular
Evolutionary Genetic Analysis (MEGA) computer package (Versions 1.1 and 2.1). A
genetic distance based method was used to create data sets for the construction of
neighbour-joining phylogenetic trees. Because of the small number of possible
nucleotides at any given position in a DNA sequence (four: G, A, T, and C) there is
the problem that evolutionary convergence into the same state by two unrelated
sequences occurs relatively frequently. The result of this is a significant
underestimation of genetic distances, a bias that increases as the sequences compared
become more divergent. It is therefore not sufficient to adopt a measure based
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entirely on the observed similarity between strains and it is essential to estimate the
real divergence from the data by using an estimator that corrects for multiple
substitutions at each nucleotide site. In the case ofHIV sequences that have diverged
during a single infection there are comparatively few nucleotide substitutions and the
relatively simple "one parameter" model of Jukes and Cantor is sufficient. In this
model it is assumed that any nucleotide is equally likely to be substituted by any
other and the estimated number of nucleotide substitutions (K) that have occurred
since the two sequences diverged is given by the formula K = -3/4 In (1-4/3X) where
X is the observed fraction of sites at which the two sequences differ.
Phylogenetic inferences were made by the construction of a Neighbour-Joining (N-J)
tree from the distance matrix. This method is a simplified version of the minimum
evolution method (Saitou and Imanishi, 1989; Rzhetsky and Nei, 1992) and uses a
complex algorithm to construct a tree from the distance matrix. Since this method
produces an unrooted tree, orientation is provided by including an outgroup in the
form of an epidemiologically unlinked sequence that is equally divergent from all of
the sequences included for analysis. The robustness of the observed groupings is
determined by a bootstrap resampling procedure. This method has the advantage
over more traditional means of determining variability in that no theoretical models
or mathematical assumptions are required. In the bootstrap procedure the original
data set of data is considered as a parent population from which repeated samples are
taken. The same number of nucleotides as the actual number used for constructing
the tree are randomly sampled with replacement from the original data set, and a NJ
tree is produced from this set of resampled nucleotide data. The topology of the tree
is then compared with the original NJ tree and any interior branch of the NJ tree that
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gives the same partition of sequences as that of the bootstrap tree is given a value of
1, whereas other interior branches are given 0. The process is repeated several
hundred times and the percentage of times each interior branch of the NJ tree
receives a value of 1 is computed. This bootstrap confidence limit is displayed on
each branch and values greater than 70% are considered to be significant. MEGA
was used to create distance matrices from the DNA sequences and Neighbour-
Joining phylogenetic trees from these matrices.
With most studies of HIV involving PCR and cloning procedures there is the
possibility of laboratory contamination leading to erroneous results and
interpretations. To address this possibility, all newly generated sequences were
initially included on a phylogenetic tree along with those of standard reference
strains and local isolates. In all cases the branches containing sequences from a
single individual were monophyletic, indicating that the contamination of samples
with exogenous DNA had not occurred. This procedure also demonstrated that the
patients used in this study were not superinfected with several viral strains of
different origins, a situation that also confuses evolutionary analysis of HIV DNA
sequences.
HIV-1 envelope sequences were assessed for inter-tissue recombination events using
a new group-scanning method developed by Professor Peter Simmonds and
described in detail in chapter 4. Nucleotide sequence alignments were edited in
Simmonic to reduce alignment gaps and sequences labelled in groups according to
tissue origin. Sequences were gap-stripped then bootstrap resampled J-C distance
matrices and N-J phylogenetic trees for each window position were generated using
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components within the Phylogeny Inference Package (PHYLIP: Felsenstein, 1989).
A number of sequences were also assessed by the bootscanning method (Salminen et
al., 1995) in the Simplot program (version 2.5). This method uses a sliding window
moving in steps across the alignment. A tree is constructed for every window and
bootstrap values calculated for the clusters. Values corresponding to the percentage
of bootstrap resampled trees that a test sequence clusters with each user-defined
group of sequences are plotted for each window position. This method was
developed for the identification of inter-subtype HIV recombinant sequences, where
the suspected recombinant sequence is compared with a representative sequence,
consensus sequence, or set of sequences from each of the HIV-1 group M subtypes.
In the region of the crossover point the bootstrap value first drops for the cluster that
contains the recombinant. At some point after this, the sequence will move from its
cluster into a new one, and the bootstrap value for this cluster should then increase as
the sliding window moves past the crossover point. For env sequence analysis
(Chapter 4) groups of sequences were assigned according to tissue origin (right
occipital, left temporal, or lymph node), and test sequences sequentially removed
from their group, bootscanned, then replaced. Bootscans were performed using as
close parameters as possible to group-scan analysis, with a 500 bp window moving
in 100 bp steps and trees generated with 50 bootstrap resamplings. As J-C distances
are unavailable in Simplot Kimura 2 parameter distances were used to generate the
distance matrix, with transversions scored at double the value of transitions.
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2.17 Eukaryotic cell culture
2.17.1 Growth medium and Cell Lines
Cell lines used in this study are listed (Table 2.5). The 293T human embryonic
kidney cell line was used for DNA transfection and NP2 (Soda et al„ 1999) human
glioma cell lines expressing different HIV receptors were used for infection with
pseudotype virus. Cells were grown in Dulbecco's Modified Eagle's Medium
(DMEM) (Invitrogen) supplemented with 10% foetal calf serum (FCS, Sigma), 100
U/ml penicillin (Merck), 100 pg/ml streptomycin (Sigma), and 2 mM L-glutamine.
Geneticin (G418, Life Technologies) and/or Puromycin (Life Technologies) was
added to NP2 cells where appropriate. All cells were grown at 37°C in a humidified
atmosphere containing 5% CO2.
Cell Type CD4/coreceptor expressed Selective medium
293 T - -
NP2-CD4 CD4 1 mg/ml Geneticin
NP2-CD4/CCR5 CD4, CCR5 1 mg/ml Geneticin, 1 pg/ml Puromycin
NP2-CD4/CXCR4 CD4, CXCR4 1 mg/ml Geneticin, 1 pg/ml Puromycin
Table 2.5. Mammalian cell lines used for transfection experiments, HIV-1
receptors expressed and selective media required for maintenance of expression.
2.17.2 Thawing Cells
Frozen aliquots of cells were removed from liquid nitrogen storage and thawed
rapidly at 37°C. 10 ml of cold media was then added dropwise to the cells in a 20 ml
universal container. The universal was centrifuged at 500g for 5 minutes to pellet
cells. The media was removed and the cells resuspended in 5 ml fresh media before
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transfer into a 25 cm3 tissue culture flask. Cells were then checked daily and split/fed
as required.
2.17.3 Passaging Cells
Cells were kept at less than 80% confluency at all times, split every 3-5 days at a
ratio of 1:5-l :8, and discarded after 15 passages. Cells were grown in a 25 cm3 tissue
culture flask and split by first removing the media and washing the monolayer with
Phosphate Buffered Saline (PBS: 7.02 mM Na2HPC>4, 1.47 mM KH2PO4, 0.137 M
NaCl, 2.68 mM KC1) to remove FCS. Two ml of 0.02% versene (Sigma) was added
and passed over the cells for 1 minute then removed and the process repeated with 2
ml of 0.05% trypsin (Invitrogen). The flask was incubated at 37°C until cells had
detached from the plastic and 5 ml of fresh media was added to inactivate the trypsin.
Cells were then diluted in media and added to a fresh tissue flask.
2.17.4 Freezing cells
Cells were pelleted by centrifugation at 500g for 5 min and resuspended in FCS
containing 10% dimethyl sulphoxide (Merck) at a concentration of 106-107 cells/ml.
1 ml aliquots were dispensed into cryotubes (Nunc), which were placed in a freezing
box and placed at -70°C (cooling cells at approximately 1°C per minute) overnight
before transferring to liquid nitrogen for long-term storage.
2.18 Electroporation of 293 T cells
293 T cells were treated with trypsin and versene then suspended in media as in
section 2.17.3. If at low concentration, cells were pelleted by centrifugation at 500g
for 5 minutes and resuspended to a concentration of 106 cells/ml. DNA for
133
transfection was mixed with 800 pi of these cells and the mixture transferred to a 0.4
cm electrode gap Gene Pulser Cuvette (Biorad). The cuvette was placed in an
electroporator (Biorad, Gene Pulser) and the cell/DNA mix subjected to a single
pulse at 250V and 960 pFD capacitance. Electroporated cells were then removed and
mixed with 5 ml of media in a universal container. For EGFP and luciferase assays
cells were then transferred to a single well in a six well tissue culture plate (Nunc),
for nef assay 1 ml of diluted cells was added to a well in a 24 well tissue culture
plate. Plates were incubated for 2 days before analysis.
2.19 Fluorescent Microscopy
293 T cells electroporated with EGFP gene were observed under an inverted
fluorescent microscope 48 hours after transfection. EGFP within cells was observed
by excitation at 488 nm resulting in emission of light at 507 nm. Pictures were taken
using a Hamamatsu digital camera and then edited using the Openlab computer
package.
2.20 Luciferase Assay
Expression of luciferase in 293 T cells was assessed 48 hours after electroporation of
293 T cells with luc+ gene. Luciferase activity was measured using components from
the Dual-Luciferase Reporter Assay System (Promega). Cells were disassociated
from the plastic of the six well tissue culture plate and resuspended in 1 ml media as
in section 2.17.3. Cells were then transferred to a sterile eppendorf tube and pelleted
by centrifugation at 6000g for 1 minute. The media was removed and the cells
resuspended in 100 pi of passive lysis buffer. The tube was then incubated for 15
134
minutes at room temperature to ensure complete lysis of cells. After incubation 10 pi
of the lysate was added to a 96 well plate, which was then placed in a Luminoskan
RT luminometer. 25 pi of Luciferase assay reagent II (containing the firefly
luciferase substrate luciferin) was then mixed with the lysate and light production
measured. The readings were blanked individually for each lysate prior to substrate
addition in order to prevent strongly positive samples from creating artificially high
readings in adjacent wells.
2.21 Nef Immunostaining
Expression of the electroporated nef linear expression construct in 293 T cells was
detected by immunocytochemistry using components from the Streptavidin ABC
Complex/HRP kit (Dako). A Nef specific monoclonal antibody (EVA3067.2 kindly
provided by Dr K Krohn via the NIBSC Centralised Facility for AIDS Reagents) was
added to monolayers, followed by a biotinylated rat-anti-mouse secondary antibody.
The signal was amplified with a horse radish peroxidase labelled Streptavidin-Biotin
Complex (ABC) and visualised by addition of the chromogen diaminobenzidine
(DAB).
293 T cells were fixed 2 days after electroporation with water or nef LEC. Growth
media was removed and cells washed with 500 pi PBS. After removal of PBS cells
were fixed by addition of 500 pi 2% paraformaldehyde and incubated for 4 hours at
room temperature. Paraformaldehyde was removed and cells washed once with 500
pi 3 x PBS and three times with 500 pi 1 x PBS. Cells were then blocked by addition
of 200 pi PBS containing 3% bovine serum albumin (BSA) and incubated at room
temperature for 45 minutes. 200 pi of primary antibody diluted 1/40 in PBS
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containing 3% BSA was added to each well and incubated for 1 hour at room
temperature. Cells were then washed twice with 500 pi of PBS then 200 pi of
biotinylated secondary antibody diluted 1/200 with PBS + 3% BSA was added and
the plate incubated for a further 45 minutes at room temperature. After incubation
with secondary antibody cells were washed twice with 500 pi PBS then 200 pi of
streptavidin-biotin complex (ABC) was added to each well. Cells were washed twice
with PBS and 200 pi ofDAB (Vector laboratories) was added to each well. The plate
was then incubated at room temperature until brown foci developed (approximately 5
minutes). Cells were washed twice with 500 pi of distilled water and 200 pi of
distilled water was added to each well. Photographs were taken under a light
microscope at 40x magnification and edited using the Corel Photo-Paint 8 computer
package.
2.22 Pseudotype Virus Production and Analysis
Several control clones were required for the production of pseudotype virus (Fig
2.2). The viral proteins needed were provided by the HIV backbone clone
pNL4.3Ae«vGFP (Fig. 2.2.C), a construct based upon the tissue culture adapted,
sincitium inducing, CXCR4 using strain NL4.3.
This construct has a defective env gene produced by filling in the NdeI site indicated,
therefore causing a frameshift (He et al, 1997). The backbone clone also has green
fluorescent protein inserted into nef. The positive control env expressing clones used
in this study were YU2 env (derived from a CCR5 using virus), and HXB2 env
(derived from a CXCR4 using virus) (Fig. 2.2.B). These two control env constructs
had previously been introduced into the pSVIII vector (Choe et al, 1996).
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Figure 2.2. Vectors used for pseudotype virus production. A) env gene cloned
into pCR3.1-unidirectional vector. B) The CCR5 positive control env clone YU2 in
the vector pSVIlI. C) pNL4.3Ae«vGFP proviral backbone clone (in the pSVIII
vector). When co-transfected with an Env expressing clone this env defective
construct provides the additional HIV proteins required for virion formation. In
addition to a frameshift in env it also contains GFP in place of nef which is








All control clones used in this study were kindly provided by Dr Paul Clapham.
Patient derived envelopes were either cloned into pCR3.1 (Fig. 2.2.A), or generated
by ligation into this vector with subsequent amplification of linear expression
constructs (Section 2.10).
For pseudotype virus production an env expressing genetic element (either a clone or
a linear expression construct) was cotransfected along with an env deficient proviral
backbone into 293T cells by calcium phosphate transfection. The cells were
incubated for 48 hours then the supernatant harvested and filtered (0.45 pm) to
remove cellular debris. Serial 10-fold dilutions of harvested virus were added to NP2
indicator cells expressing either CD4 alone, or in conjunction with CCR5 or CXCR4.
After incubation for 48 hours infection of these cells was detected directly by
observing GFP expression with fluorescent microscopy or indirectly by p24
immunocytochemistry.
2.23 Calcium Phosphate Mediated Transfection:
Prior to transfection, DNA was ethanol precipitated. Ten pg of pNL4.3Ae«vGFP was
mixed with 4 pg of envelope gene (plasmid or LEC), 0.1 volume of sodium acetate
(pH 4.5) and 2.5 volumes of cold (-20°C) 100% ethanol in a 1.5 ml eppendorf tube.
This mixture was centrifuged at 12000g for 30 min at 4°C, the supernatant removed,
and the DNA pellet washed by addition of 125 pi 70% ethanol. The tube was
centrifuged again at 12000g for 5 minutes at 4 °C, the ethanol removed, and DNA air
dried for 5 minutes. DNA was then resuspended in 263 pi sterile water.
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Calcium phosphate transfections were performed using the ProFection Mammalian
Transfection System - Calcium Phosphate (Promega). 293 T Cells were plated out
the day before transfection onto a 6 well tissue culture plate at a density of 106
cells/well. This seeding density provided a monolayer of cells at approximately 60%
confluency on the day of transfection. Three hours prior to transfection the media
was removed from cells and replaced with 5 ml fresh growth medium. For each
transfection the DNA and 2 x HEPES-Buffered saline (HBS) solutions were
prepared in separate sterile tubes. In the first tube the DNA was mixed well with 37
pi of 2M CaCE- Working in a tissue culture hood the second tube containing 300 pi
of 2 x HBS was vortexed gently at a speed allowing addition of the prepared DNA
solution. Whilst continuing to vortex the CaCE/DNA solution was slowly added
dropwise. The solution was then incubated at room temperature for 30 minutes. After
incubation the transfection solutions were vortexed and added dropwise to 293 T
cells. The cells were then incubated for 24 hours, and the media containing CaPCE
removed and replaced with 5 ml fresh DME media. Cells were incubated for a
further 24 hours before harvesting of pseudotype virus. Media was removed from
cells and filtered through a 0.45 pM filter (Nunc) to remove any floating cells and
cellular debris. Several 1 ml aliquots were then transferred to cryotubes and stored at
-70°C before use. This pseudotype virus was then used to infect NP2 cells to detect
production of functional virus and analyse coreceptor usage.
2.24 Viral Infectivity Assays
NP2 cells were seeded the day before infections at a density of 1.5 x 104 cells/well in
a 48 well tissue culture plate (Costar). Frozen aliquots of virus were thawed at room
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temperature and DME media used to set up 10-fold serial dilutions (from undiluted
to 10"5). The media was removed from NP2 cells and 100 pi of each dilution of virus
was added to a separate well in the tissue culture plate. The plate was incubated
overnight (16 hours) then 400 pi of DME media was added to each well (without
removal of virus). Plates were incubated for a further 48 hours and analysed by
fluorescent microscopy (as in section 2.19) or immunostaining using anti-p24
monoclonal antibodies.
2.25 p24 immunocytochemistry
Cells infected with pseudotype virus were stained with a 1:1 ratio of mouse anti
HIV-1 p24 monoclonal antibodies EVA365 and EVA366 kindly provided by Dr B
Wahren via the NIBSC Centralised Facility for AIDS Reagents. Primary antibodies
were stained with goat anti-mouse P-galactosidase conjugated monoclonal antibody
(Southern Biotechnology). p24 positive cells were then visualised by using the P-
galactosidase reporter gene staining kit (Sigma).
Three days after addition of virus, media was removed from wells and the cells fixed
by addition of cold (-20°C) methanokacetone (1:1). After 2 minutes
methanol/acetone was removed and 500 pi of PBS containing 1% FCS was added to
each well. PBS was removed and 100 pi of anti-p24 antibodies diluted 1/200 in PBS
containing 1% FCS was added. Cells were incubated for 1 hour at room temperature
with anti-p24 antibody. The cells were then washed twice by aspirating off liquid
from cells and adding 500 pi of PBS containing 1% FCS. The second wash was
removed and 100 pi of goat anti-mouse P-galactosidase conjugated antibody diluted
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1/400 in PBS containing 1% FCS was added to each well. The plate was incubated
again for 1 hour at room temperature then washed 3 times in PBS only. PBS was
removed and 200 pi of substrate (0.5 mg/ml 5-Bromo-4-chloro-3-indolyl-(3-D-
galactopyranosidase (X-gal), in PBS containing 1 mM MgCF, 3 mM K3Fe (CN)6, 3
mM K4Fe (CN)e) was added to cells. The plate was then incubated at 37°C until blue
foci developed (approximately 1 hour). Plates were then washed once with PBS and
200 pi PBS was added to each well before storage at 4°C. Foci of infection were
counted by eye under light microscopy at 20 x magnification. Focal forming units
present in the initial harvested media was calculated by taking the average number of
foci of infection present in the last two positive wells and multiplying by the dilution
factor.
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Chapter 3: Results (i)
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3.1 Introduction
Central nervous system abnormalities are common among HIV-1 infected
individuals (Snider et al., 1983). Approximately 80% of AIDS patients experience
some form of neurological or psychiatric symptoms and large post mortem studies
have found neuropathological abnormalities in 79-94% of brains from individuals
who died of AIDS (Burns et al., 1991; Bell, 1998). Clinical presentations include
motor and cognitive deficits along with behavioural changes and other symptoms
that eventually progress to HIV associated dementia (HAD) in approximately 10%-
30% of untreated infected individuals (Price, 1996; Bell et al., 1998; Gray et al,
1996). This manifestation of disease is therefore a major cause of morbidity in AIDS
patients and may develop as the predominant clinical abnormality at advanced stages
ofHIV-1 infection (Navia and Price, 1987).
HIV encephalitis, often characterised by the presence of multinucleated giant cells in
the brain, is observed in approximately 10%-50% of AIDS autopsies (Shaw et al.,
1985; Bell, 1998). The major cellular reservoir for HIV-1 at this site is monocyte
derived macrophages and microglial cells (Wiley et al, 1986; Bagasra et al, 1996),
although a number of other cell types may also be infected at lower levels (Bagasra
et al, 1996; Ranki et al., 1995; Wiley et al, 1986; Bell et al., 1993; Gyorkey et al,
1987). HIV-1 induced damage to neuronal cell types can occur by at least two
mechanisms; shedding of toxic viral proteins by infected cells (Kaul and Lipton,
1999; Lipton, 1993; Nath et al., 1996; Sabatier et al, 1991), and secretion of
inflammatory cytokines and other molecules by infected or activated macrophages
and microglial cells (Lipton and Gendelman, 1995; Giulian et al., 1990; Yeh et al.,
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2000). In addition to the pathological effect that HIV-1 can have within the brain, the
poor penetration of several antiretroviral agents into the CNS (Enting et al., 1998)
has led to concerns that it may serve as a "sanctuary site", allowing continued virus
replication despite effective suppression elsewhere in the body. As the lifespan of
HIV-1 infected individuals is extended by the use of antiretroviral drugs, this
continued virus replication in the CNS could be sufficient to instigate a neurological
decline culminating in dementia. Moreover the presence of sub-optimal drug
concentrations in the CNS may provide an ideal environment for the evolution of
drug resistant HIV-1 variants, which could then re-seed the peripheral blood and
lymphoid system.
A central question in determining the importance of the CNS as an anatomical
reservoir for HIV-1 concerns the time that this site is stably infected. One possibility
is that at some point before the onset of AIDS, HIV-1 establishes an autonomous,
self-sustaining infection of the CNS that is not dependent upon continued
replenishing by newly infiltrating infected cells. HIV-1 in the brain may therefore be
outwith the reach of current antiviral therapies, and concerns over the role of the
CNS as a sanctuary site could be well founded. A second possibility is that
autonomous replication of HIV-1 within the brain is only established at, or around,
the onset of AIDS. If this is true then effective suppression of virus in the peripheral
blood and lymphoid organs during the asymptomatic period of infection should be
sufficient to prevent complications associated with HIV-1 in the brain. These early
and late entry models each have supporting evidence, and determining the relative
contribution of each is important for enhancing our understanding of HIV-1 within
the CNS.
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As mentioned, an early entry model suggests that the brain is stably infected before
the onset ofAIDS, possibly soon after transmission. Low levels ofHIV replication or
viral latency would then follow, before eventual reactivation of HIV in this site,
perhaps facilitated by the general immunosuppression associated with the onset of
AIDS. In support of this model is the detection ofHIV proviral DNA in the brains of
seropositive but asymptomatic individuals who died of AIDS-unrelated causes (Gray
et al, 1996; An et al., 1996), and the appearance of HIV in the brain within 2 weeks
of accidental iatrogenic infection (Davis et al, 1992; Palmer et al, 1994). These
observations have been confirmed in the closely related simian immunodeficiency
virus (SIV)/macaque model, where SIV can be detected in the brains of infected
animals within 2 weeks of peripheral inoculation (Smith et al., 1995). A late entry
model suggests that large-scale autonomous viral replication in the brain is the result
of single or multiple seeding of the CNS from the periphery during AIDS, when
there is a high viral load and the integrity of the blood brain barrier may be
compromised (Dallasta et al., 1999). This hypothesis is supported by the fact that
HIVE is absent before the onset of AIDS, and severe neurological impairment
invariably occurs late in infection (Price et al., 1988; Bell et al, 1993; Gray et al,
1992). HIV-1 infected cells in the brain are also frequently perivascular in location,
suggestive of recent immune infiltration (Vazeux, 1991).
A second issue concerning HIV-1 in the brain is the frequently observed genetic
segregation between viral variants present in the brain and lymphoid system (Korber
et al, 1994a; Ball et al, 1994; Di Stefano et al, 1996; Epstein et al, 1991b; Wong et al,
1997; Vantwout et al, 1998; Hughes et al, 1997b), usually based upon partial env
sequences. Factors that could lead to the development of a separate virus
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subpopulation in the brain include the original seeding of this site being followed by
a long period of physical isolation between brain and lymphoid variants. This would
amount to a founder event, allowing the two populations to diverge by genetic drift.
Another possibility is that virus in the brain has a lower turnover rate than in the
lymphoid system, due for example to a relative lack of potential host cells or longer
periods of latency. Brain-derived virus may then consist of archival sequences, the
remnants of previously abundant viral variants present in the lymphoid compartment.
The relatively immunoprivileged nature of the CNS may also lead to comparatively
weak immune-mediated selective sweeps against particular viral variants, possibly
allowing more genetic drift to occur. Alternatively, the genetic segregation may be a
result of adaptation to the particular microenvironment and available host cells
within the brain. If this is the case then lymphoid variants may enter the brain
relatively frequently, but be poorly equipped for prolonged survival in the unique
environment of the CNS.
A final and more complex hypothesis is that viral variants present in different
anatomical sites of the body, such as the colon (Wang et al, 2001) or bone marrow
(Gartner and Liu, 2002; Gartner, 2000; Liu et al., 2000), have diverged from those in
the lymphoid system because of circumstances particular to those tissue sites, and
subsequently entered the brain. One possible reason for this divergence may be the
development of HIV-1 variants specifically adapted for infection of tissue
macrophages as opposed to CD4' T lymphocytes (Wang et al, 2001). Virus that has
adapted to infect these cells may then also be pre-adapted for infection of
macrophages and microglia within the brain. Trafficking of virus or virally infected
cells from these sites into the brain could then seed an infection with the genetically
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distinct virus subpopulation that evolved elsewhere in the body. If this is the case
then the putative anatomical site that the genetic divisions emerged is shifted, but the
question of which underlying factors are responsible for the outgrowth of distinct
viral subpopulation within the brain remains.
While direct evidence for recombination between HIV-1 variants that have diverged
during a single infection is currently limited (Jung et al, 2002), the large number of
reports describing recombination between more divergent HIV-1 strains suggests that
the former may be a common event (Carr et al, 1998; Bobkov et al, 1998; Liitsola et
al, 1998; Liu et al, 2002; Diaz et al, 1995). Therefore one potential means of
assessing the underlying factors leading to apparently tissue-specific HIV-1
populations is to look for evidence of recombination between viral variants in
different compartments. If recombination has occurred then physical isolation or
differences in replication rates are unlikely to have given rise to the separate
populations. Moreover, the observation of recombination in this case would also
provide more general insights into the adaptive and evolutionary mechanisms
associated with HIV-1 compartmentalisation. Recombination can be detected by the
presence of phylogenetic relationships between sequences that vary depending upon
the particular region of the viral genome analysed. This may include the observation
of clearly discordant phylogenetic relationships based upon different subgenomic
regions, or a marked reduction in sequence diversity in one subgenomic region that is
not apparent elsewhere in the viral genome (Brown and Cleland, 1996).
Therefore in this study the genetic relationships manifest in different HIV-1
subgenomic regions were assessed, both within brain and between brain and
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lymphoid sequences. The two subgenomic regions chosen for this analysis were
pl7gag and V3. pl7gag sequences have previously proved useful in ascertaining the
evolutionary relationships of HIV-1 variants both between (Holmes et al., 1993;
Kasper et ah, 1995) and within (Hughes et al, 1997b; Wang et al, 2001) HIV-1
infected individuals. The investigation of haemophiliacs infected from a common
batch of clotting factor concentrate has allowed the rate of sequence change in pl7gag
to be calculated (Kasper et al, 1995). This in turn may be used to calculate
approximate times of divergence for any pair of sequences. Thus if pl7gag sequences
were found to segregate between brain and lymphoid variants, then an approximate
divergence time of the two viral subpopulations could be calculated, providing
information on timing of infection of the brain. The V3 region encoding the V3 loop
of gpl20 has been implicated as the major determinant of several viral properties
such as cell tropism (Hwang et al, 1991), coreceptor preference (Speck et al, 1997),
ability to produce syncytia (Fouchier et al, 1992; Fouchier et ah, 1995b), and as the
principal neutralising epitope of host humoral responses (Wolfs et ah, 1990; Palker et
ah, 1988; Rusche et ah, 1988). HIV-1 V3 sequences have also been found to
segregate with some frequency between brain and lymphoid compartments in HIV-1
infected individuals (Korber et al, 1994a; Chen et al, 2000; Epstein et al, 1991b).
3.2 Aims
1) Amplify and sequence the V3 and pl7gag regions of the HIV-1 genome using
template DNA from lymphoid and brain tissue of infected individuals with evidence
ofHIV encephalitis.
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2) Compare the sequence diversity and phylogenetic relationships of virus present in
brain and lymphoid tissue in the two subgenomic regions and where possible
calculate approximate divergence times based upon pl7gag distances.
3) Search for evidence of discordant phylogenetic relationships (indicative of
recombination) in the different genome regions between virus derived from separate
tissue sections.
3.3 Clinical details of study subjects
Samples of LN or spleen and several anatomically distinct regions of brain from four
individuals with HIV giant cell encephalitis were stored at -40°C at autopsy. Risk
group, CD4 counts, and brain pathology of study subjects are summarised (Table
3.1). Subject NA128 had received zidovudine monotherapy for 17 months up to
approximately 1 year before death; ddC was used for 1 month, finishing 3 months
before death.
The other study subjects had received minimal antiviral treatment: for NA234, a
single course of zidovudine for a duration of 1 month at 1 year before death; for
NA021, zidovudine intermittently over 1 year at 5 years before death and
zidovudine-ddC for 1 month at 1 year before death; for NA173, zidovudine for 4
months at 2 years before death and then for 1 month at 1 year before death. None of
the study subjects showed evidence for genotypic resistance to zidovudine or other
antiviral agents (P Strappe pers comm). The brains were examined pathologically as
previously described (Bell et al, 1993). Assessment of pathology findings was













PV WM GM BG BS Cere pathology
NA173 34 MH 1 0 -p-p Mj- Toxoplasma
NA021 49 IVDU 300 K7 1 + r f P -»■7 +
NA128 48 MH 12 4 +/- -f-p-p -f-t" -P-P Toxoplasma
NA234 28 IVDU 90 30 "P + + -p + -P Lymphoma
Table 3.1. Clinical background and pathology appearance of study
subjects. aMH, male homosexual; IVDU, intravenous drug user. bScored as -
(no pathology), +/- (sparse pathology), + (slight pathology), ++ (medium
pathology), or +++ (severe pathology in different brain compartments). PV,





Mean Error Rank" Mean Error Rank
Within hrain NA021 (1.034 (1.1)00 3 0.015 O.fHkK 4
NA173 0.035 0.010 a 0.017 0.008 3
NA12.S 0.012 0.006 4 0.035 0.011 1
NA234 0.042 0.011 1 0.028 0.010 2
Brain-lvmphoid tissue NA021 0.040 0.009 3 0.043 0.014 3
NA173 0.040 0.011 "> 0.031 0.011 4
NAI2K 0.023 0.1 HIS 4 o.oso 0.018 I
NA234 0.057 0.013 1 0.072 0.018 2
Table 3.2. pl7gag and V3 sequence divergence. aMean J-C distance between
variants within brain or between brain and lymph node or spleen (excluding
choroid plexus). bRank of variability (1 = most variable).
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3.4 Methods
A full description of methods is provided (Chapter 2). In brief, DNA was extracted
from each sample by the phenol/chloroform method and quantified
spectrophotometrically. HIV proviral DNA was semiquantitated by nested PCR
amplification using the pl7gag primers on serial 10-fold dilutions of DNA, with the
last positive dilution used to indicate the minimum proviral load in the sample.
Samples were used for sequence comparison only if proviral frequencies were >100
copies/106 cells. Low proviral levels were detected in two atrophied LN samples
from NA128, and lymphoid sequences were therefore obtained from the spleen.
pl7gag and V3 regions were then amplified by nested PCR using 1 pg aliquots of
DNA as template and directly sequenced manually. Alison Morris, a co-worker in
the laboratory, provided all sequences from NA234 by cloning and sequencing of
single or multiple clones from each region as described in (Morris et ah, 1999).
Phylogenetic analysis was performed with the MEGA program (Kumar et ah, 1993).
Each set of sequences from the four study subjects was monophyletic in both
genomic regions and distinct from those of the published sequences of subtype B
(GenBank accession numbers in parentheses): HIVSF2 (K02007), HIVRF
(Ml7451), HIVOYI (M26727), HIVLAI (K02013), HIVJRFL (M74978), HIVYU2
(M93258), HIVCAM1 (D10112), HIVNY5CG (M38431), HIVHAN (U43131),
HIVWMJ22 (Ml2507), and HIVSFAAA (M65024). This comparison provided no
evidence for coinfection with more than one epidemiologically unrelated HIV strains
or for intersample or exogenous laboratory contamination. Previous sampling
problems associated with using a single small tissue section to reflect the total virus
population in a large solid organ (Hughes et al, 1997b) were partially overcome by
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using several anatomically distinct regions of brain for sequence analysis. Various
samples were also taken from both left and right areas of brain to allow comparison
of virus present in areas that have equivalent cellular components but are physically
separate.
3.5 Results
3.5.1 V3 and p179ag tree topology
NA021
The pl7ga§ tree topology for subject NA021 displayed three bootstrap supported
lineages (Fig. 3.1.A). Lineage A contained only the sequences from the right
temporal and right occipital lobes, and lineage B contained sequences from the
remainder of brain samples and the two lymph nodes.
The third, less pronounced lineage demonstrated that the two lymph node sequences
were more closely related to each other than to the remaining sequences in lineage B.
The mean synonymous J-C pairwise distance between lineages A and B was 0.0585
(mean standard error +/- 0.0270). On the basis of the previously established mean
rate of sequence change in this region of gag (0.6 to 0.7 % per site per year: Hughes
et al, 1997b; Kasper et al, 1995), these distances suggested a time of divergence
between lineages A and B of 4.43 years +/- 2 years, compared to the onset of AIDS
in this subject of 2 years before death and a CD4 count of 300 cells/pl one year
before death. This implied that at least some of the virus (within the RO and RT
regions) present in the brain of this study subject during late stage HIV infection
originally diverged from the lymphoid virus population before the individual
progressed to AIDS.
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Figure 3.1. Phylogenetic analysis of \i\lgag and V3 sequences from subject
NA021. A) pl7gag phylogenetic tree, B) V3 phylogenetic tree. Sequences available from
GenBank listed in Methods were used to root each clade. Neighbour-joining trees were
plotted using the indicated scale of J-C distances. All bootstrap values >75%, generated
with 100 resamplings, are indicated on branches. Labels indicate sequences from LN:
lymph node, RT: right temporal, LT: left temporal, RO: right occipital, LO: left
occipital, RF: right frontal, LF: left frontal, CP: choroid plexus, BS: brain stem, RP:
right parietal, LP: left parietal, BG: basal ganglia, RC, right cerebellum, LC: left
cerebellum. Symbols indicate sequences derived from brain (•), from lymph node (o),
or from choroid plexus (□).
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V3 sequences derived from the same DNA samples produced a tree containing two
bootstrap supported lineages (Fig. 3.IB). In marked contrast to the pl7gag tree,
lineage C contained all brain-derived sequences, and lineage D contained only the
sequences derived from the two lymph nodes. Virus from the right occipital and right
temporal lobes was therefore distinct from other brain sequences in pl7gag but closely
related in V3, with the converse being true for lymph node-derived virus. One
interpretation of this finding is that the virus found in the right temporal and right
occipital lobes represents a pre-AIDS seeding of the brain, with the remainder of the
brain regions being infected later by the predominant virus in the lymphoid system at
that time. The observed similarity in V3 sequences among brain isolates may then
subsequently have arisen by strong convergent evolution. However, both
synonymous and non-synonymous mutations in V3 were shared by brain but not
lymphoid sequences (Fig. 3.5.A, and data not shown). Therefore recombination
between brain- and lymphoid-derived virus is the most likely explanation for the
observed discordant phylogenies.
NA128
For subject NA128 the pl7gag relationships were monophyletic (Fig. 3.2.A).
However the V3 phylogenetic tree exhibited a pronounced bifurcation (Fig. 3.2.B),
with Lineage A containing sequences derived from left and right frontal lobes along
with that from lymphoid tissue (spleen), and Lineage B containing the remainder of
brain sequences.
NA173
pl7gag sequences from study subject NA173 produced a tree with three bootstrap






























Figure 3.2. Phylogenetic analysis of pl7^flg and V3 sequences from
subject NA128. A) pl7gag phylogenetic tree. B) V3 phylogenetic tree.
Outgroup, labels, symbols, and bootstrap method as for Fig 3.1. Lymphoid
sequences were in this case obtained from spleen (SPL).
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Figure 3.3. Phylogenetic analysis of pl7gag and V3 sequences
from subject NA173. A) pl7gag phylogenetic tree. B) V3
phylogenetic tree. Outgroup, labels, symbols, and bootstrap method
as for Fig 3.1.
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Figure 3.4. Phylogenetic analysis of pl78"8 and V3 sequences from subject
NA234. A) pl7gag phylogenetic tree. B) V3 phylogenetic tree. Outgroup, labels,
symbols, and bootstrap method as for Fig 3.1. Sequences from NA234 were
obtained from individual clones of amplified DNA rather than by direct
sequencing; single representative clones from each sample or multiple clones for
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Figure 3.5. Comparison of inferred V3 region amino acid
sequences of variants from study subjects. A) NA021, B) NA128, and
C) NA173. Lymph node or spleen sequences were used as reference.
Horizontal lines divide bootstrap-supported (>75% of data sets)
phylogenetic groupings of nucleotide sequences. Dots signify sequence
identity with lymphoid sequence. Sequences are numbered by their
position in the HIVlai gpl20 alignment.
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Lineage A contained the lymph node and right temporal sequences, lineage B
contained sequences from the right parietal and right cerebellum regions, and lineage
C contained sequences from the basal ganglia and brain stem. The remainder of
sequences was interspersed between these supported lineages. This topology is
suggestive of several independent infiltrations into the brain from the periphery. As
for the other study subjects, V3 sequences from this individual displayed a different
tree topology than that of pl7gag, being monophyletic with no bootstrap supported
clades present (Fig. 3.3.B).
NA234
The phylogenetic tree constructed with pl7gag sequences from study subject NA234
had two major supported lineages (Fig. 3.4.A), and several supported divisions
within these lineages. Sequences in lineage A were solely brain derived and virus in
these anatomical sites had common ancestors distinct from those in lymphoid tissue,
more recent times of divergence can be inferred. Variants within lineage A may
therefore have originated from the spread of HIV within the brain rather than from
multiple seedings from the peripheral circulation and thus differ in origin from brain
derived variants in lineage B (left frontal, right parietal, and brain stem). The mean
synonymous J-C pairwise distance between the two lineages was 0.1098, suggesting
a divergence time of 8.32 years +/- 2.8 years, compared with the individual
progressing to AIDS approximately 3 years before death. The V3 phylogenetic tree
displayed similar topology to that of study subject NA021, with lymphoid sequences
grouping separately from all brain derived sequences with the exception of some
choroid plexus sequences, including those that grouped with LN sequences in the
pi 7gag region (Fig. 3.4.B).
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3.5.2 Sequence divergence and pathology appearance
The severity of HIVE varied between the study subjects (Table 3.1), ranging from
infrequent giant cells confined to perivascular regions (NA173) to widespread
pathology affecting both white and grey matter (NA128). The extent and type of
HIV-induced pathology correlated with the degree of V3 but not pl7gag sequence
diversity between brain regions and in the extent to which V3 sequences from the
brain differed from those in lymphoid tissue. The mean J-C distances for V3 and
pl7gag sequences both within brain and between brain and lymph node derived virus
are shown (Table 3.2). V3 sequences from NA173 (who showed minimal HIV-
related pathology) were largely undifferentiated from those detected in lymph node,
with only an alanine-arginine change segregating by tissue (Fig. 3.5). At the other
extreme, the spleen-derived sequence from NA128 had a predicted syncytium-
inducing phenotype and differed in multiple sites from the nonsyncytium-inducing
variants in the brain. However, in the pl7gag region sequences from NA173 were the
most variable, and those from NA128 were the least variable.
3.6 Discussion
3.6.1 Timing of viral entry into the CNS.
This study documents the complex genetic interrelationships ofHIV-1 populations in
vivo, findings that have several implications in understanding mechanisms of tissue
adaptation and the timing of entry of HIV-1 into the CNS. The different sequence
relationships between brain-derived and lymphoid variants from the four study
subjects suggest that entry of HIV-1 into the CNS can occur at different times. Clear
genetic segregation in pl7gag sequences from subjects NA021 and NA234 between
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lymphoid and non-lymphoid containing lineages allowed the mean synonymous J-C
pairwise distances and therefore approximate divergence times to be calculated. In
both cases the time since divergence of the two lineages pre-dated the individuals
progression to AIDS, implying that the virus predominating in the brain during late
stage HIV-1 infection may have originally entered the CNS before the subject
advanced to AIDS. Intrinsic to this type of calculation is the assumption that the
virus sampled has not undergone significant periods of latency before reactivation,
although if this had occurred then it would result in an underestimation of viral
divergence times. The interpretation of a pre-AIDS entry of HIV-1 into the CNS of
these two subjects as predicted by an early entry model of HIV-1 infection of the
brain is therefore still valid. A more complex proposal that viral variants present in
the brain originally diverged from those in the lymphoid compartment at a third
anatomical site before trafficking into the CNS (Gartner and Liu, 2002; Gartner,
2000; Liu et al, 2000) cannot be corroborated or discounted on the basis of this data.
Therefore the possibility that the time since divergence of variants in the brain and
lymphoid compartment does not correspond to the time of HIV-1 invasion of the
brain remains open.
The poor penetration of antiretroviral agents such as protease inhibitors and some
nucleoside analogues into the CNS (Lewis et al., 1996; Yarchoan et al., 1988) make
the presence of this replication competent viral reservoir in the brain problematic for
several reasons. Firstly the life expectancy of HIV infected individuals HAART may
be greatly extended. However it is not yet clear whether the persistence and possible
replication of HIV in the CNS of these individuals will eventually lead to the
neurological symptoms generally associated with progression to AIDS. The presence
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of sub-optimal concentrations of antiviral drugs in the CNS also provides ideal
conditions for the development of antiviral resistance mutants, perhaps leading to re-
seeding of the lymphoid system with drug resistant virus from the brain and failure
of antiviral therapy. Finally, one potential aim of therapeutic interventions against
HIV is the complete eradication of virus from infected individuals, ultimately
allowing cessation of therapy. The presence of anatomical reservoirs containing
replication competent virus such as the CNS represents a significant barrier to these
endeavours.
Evidence for the contribution of late-entering variants to HIVE is provided by
sequences from NA173, where a distinctive pathology appearance comprising HIV-
expressing infiltrating macrophages confined to the perivascular regions was evident
(Table 3.1). The hypothesis of recent entry of HIV-infected cells into the brain
parenchyma was supported by the observation of close sequence similarity in the V3
region of brain derived variants with those obtained from lymphoid cells (Table 3.2.
and Fig. 3.3.B). This late entry picture contrasted strongly with the distribution of
HIV infection in NA128, in which HIV was widely dispersed in white and grey
matter, while V3 sequences were largely distinct between spleen and brain and
heterogeneous within brain (Table 3.1, and Fig.3.2). However this correlation was
not supported by sequence comparisons in the pl7gag region where sequence
diversity was greatest in NA173 and least in NA128 (Table 3.2). The increased
within-brain heterogeneity of V3 sequences in putative early-entry variants could
possibly be the result of a less-vigorous humoral immune response within the CNS
allowing increased genetic drift.
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One possible explanation for these contrasting results regarding timing of entry into
the brain in different individuals is that HIV-1 invasion of this organ is similar to that
proposed for HIV in CSF (Price, 2000). Where it was suggested that during the
asymptomatic period virus in CSF infiltrates from blood in a "transitory" infection
and as the individual progresses to AIDS a more "autonomous" infection in the CSF
is established. In some cases, such as in subjects NA021 and NA234, this transitory
infection may be sufficient to establish a persistent infection in the brain before the
onset of AIDS. In others, such as NA173, an autonomous infection is not established
until the onset ofAIDS.
3.6.2 Identification of in vivo recombination events in the
evolution of regional viral populations.
When sampling gene sequences from an asexually reproducing population where
recombination has not occurred, the evolutionary relationships exposed by analysis
of one gene would usually be representative of those determined using other genes
from the same organisms. If the population is sexually reproducing or exchanges
genetic information by recombination, then different genes from the same organism
can have distinct evolutionary histories. In this study the different degrees of
variability and the discordant phylogenetic relationship between pl7gag and V3
regions in each study subject indicated a lack of genetic linkage between these two
subgenomic regions and supports the hypothesis of frequent recombination in vivo.
The differing relationships between samples in the pl7ga§ and V3 regions also imply
that the frequently observed tissue segregation in regions of the env gene is not solely
the result of compartmentalisation or differences in viral turnover rates in the CNS
compared with that in the lymphoid tissue. If this were the case then sequence
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relationships in other regions of the viral genome such as pl7gag would be expected
to reflect those in V3. The existence of recombination also provides an explanation
for the discordant phylogenies between pl7gag, V1/V2, and V3 observed between
brain (in the left frontal region) and lymph node sequences in other studies
(Donaldson et al, 1994b; Hughes et al, 1997b; Hughes et al, 1997a). While sequences
in V3 were tissue specific, sequences in the pl7gag and VI/V2 regions were diverse
in their relationships between tissues.
Greater degrees of sequence complexity may partly originate from the presence of
different infected cell types in a tissue sample. HIV sequences amplified from the
choroid plexus ofNA234 showed the greatest diversity in the V3 region, containing
variants corresponding to those from lymphoid tissue and brain (Fig. 3.4), consistent
with the presence of virus from blood-derived cells and brain parenchyma. Several
previous studies have implicated the choroid plexus as a potential entry point for
HIV into the CNS (Petito et al., 1999; Falangola et al., 1995) and an investigation
based upon V3 sequences found viral genotypes corresponding to both brain and
spleen variants in this site (Chen et al, 2000), similar to the results presented here.
The proximity of these different cell types in the choroid plexus therefore may
provide an opportunity for recombination to occur, in addition to its potential role as
a site of entry ofHIV into the CNS.
The diversity of V3 sequences in different brain regions of the four study subjects
was similar to a previous comparison of variants infecting different brain regions
(mean pairwise distance between brain regions, 0.021 (Chang et al, 1998), excluding
sequences from the left frontal region that were highly divergent in sequence and
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failed to group phylogenetically with sequences derived from other regions of the
brain in one study subject). In this specific instance the left frontal sequences may
have originated from exogenous contamination of the PCR, or corresponded to an
epidemiologically unlinked isolate in the case of a mixed infection. In either case, the
observed degree of sequence divergence was unlikely to have originated from
sequence change over the course of infection within the study subject.
The diploid nature of retroviruses suggests that recombination serves a central
function in their replication and evolution. Potential advantages of recombination
include the expansion of genetic diversity, and the rescue of replication defective
viruses. A large number of investigations using in vitro assay systems have
established that given the correct conditions, recombination between genetically
distinct retroviral isolates is a common event (Clavel et al, 1989; Yu et al, 1998; Hu
and Temin, 1990a; Jetzt et al, 2000; Zhuang et al, 2002; Hu and Temin, 1990b).
Likewise there is abundant evidence for frequent inter-subtype recombination
between quite divergent strains of HIV-1 (Carr et al, 1998; Bobkov et al, 1998;
Liitsola et al, 1998; Gao et al, 1998; Liitsola et al, 2000; Montavon et al, 1999), and
in many cases this has led to substantial spread of circulating recombinant forms
(Gao et al, 1996b; Gao et al, 1998). Evidence for any selective advantage that these
frequently observed recombinants might have (for example in allowing more
efficient passage through a particular human population) is currently lacking. Thus at
a population level recombinant HIV genomes may represent broadly equivalent viral
phenotypes, in which case the differing prevalence of particular recombinants would
correspond to stochastic events rather than selective advantages. In contrast the
indirectly inferred high rate of recombination between HIV-1 variants that have
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diverged within a single infected individual as described here and in other studies
(Dykes et al, 2000; Brown and Cleland, 1996), and the recent direct demonstration of
the same phenomenon (Jung et al, 2002), could have a profound influence on the
adaptive potential of HIV-1 variants in vivo. Frequent recombination would provide
a powerful mechanism for adaptation to several simultaneously acting selective
pressures. For example, a prominent feature of the natural course ofHIV infection is
continuously high levels of virus production and immune-mediated destruction (Ho
et al, 1995; Wei et al, 1995; Perelson et al, 1996; Perelson et al, 1997). Selection
pressures imposed by cytotoxic T lymphocytes, humoral immune responses, and
other immune effecter mechanisms may each act upon the products of different HIV
subgenomic regions. Reshuffling of genetic information by recombination may allow
different collections of mutations that bestow some protection from these selection
pressures to come together, thereby providing a selective advantage to the resultant
chimeric genome. Similarly, patterns of mutations that confer resistance to different
antiretroviral agents are often complex (Jacobsen et al., 1995; Winters et al., 1998;
Larder and Kemp, 1989; Richman et al, 1994). Tissue culture infection experiments
have shown that recombination can bring together different collections of drug
resistance mutations present in separate HIV-1 strains, and thereby produce a new
multi-drug resistant vims variant (Moutouh et al., 1996). Frequent in vivo
recombination such as described here would be expected to allow the occurrence of
similar events.
In the specific context of HIV-1 in the brain, recombination between brain and
lymphoid virus populations could provide a number of adaptive advantages. It has
been suggested that the genetic compartmentalisation often evident upon comparison
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of env sequence segments between brain and lymphoid-derived HIV-1 viral variants
may be a result of adaptation for replication in the unique microenvironment and cell
types within the brain (Strizki et al, 1996; Shieh et al, 2000; Power et al, 1994; Power
et al, 1998; Gorry et al, 2001; Gorry et al, 2002a). If this is the case then
recombination between brain and lymphoid viral populations may provide a simple
method for viral variants in the brain to acquire CTL escape mutations or antiviral
resistance mutations that evolved in the lymphoid system, while still retaining the
genetic determinants of their neuroadapted phenotype. The converse may also be
true, with sub-optimal drug concentrations in the CNS potentially providing an ideal
environment for the development of drug resistant variants (Lewis et al, 1996;
Yarchoan et al, 1988). However, alterations in Env-receptor interactions associated
with neuroadaptation may result in a concomitant increase in susceptibility to
neutralising antibodies (Gorry et al, 2001; Gorry et al., 2002b; Martin et al, 2001).
Therefore recombination between brain and lymphoid-derived HIV-1 variants may
allow lymphoid virus to acquire constellations of mutations associated with drug
resistance from virus in brain, while still maintaining their lymphoid-adapted
phenotype.
Identifying at higher resolution the specific sites and frequencies of recombination
events between HIV-1 genomes that have diverged within single individuals requires
the sequencing of longer, variable, regions of the viral genome derived from single
viruses present in vivo. This subject was the topic of further research (Chapter 4).
Understanding what contributes to neurotropism will illuminate the selective
pressures (if any) that produce the recombinant viruses observed in this study.
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Chapter 4: Results (ii)
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4.1 Introduction
HIV-l virions are covered with non-covalently associated heterodimeric
glycoprotein spikes comprising a cell-surface attachment protein (gpl20), and a
membrane spanning fusion protein (gp41) arranged as trimers in the viral envelope.
Infection of cells by HIV-l usually takes place via a sequential series of events
beginning with gpl20 binding to CD4 on target cells (Maddon et al, 1986;
Klatzmann et al, 1984b; Dalgleish et al, 1984), leading to a conformational shift in
the envelope glycoproteins allowing binding to a second cell surface (coreceptor)
molecule (Feng et al, 1996; Alkhatib et al, 1996b; Choe et al, 1996; Deng et al, 1996;
Doranz et al, 1996; Dragic et al, 1996). This second interaction exposes domains in
gp41 allowing fusion of the viral and cellular membranes followed by entry of the
viral core into the target cell. gpl20 and gp41 are encoded by the envelope (env)
gene, consequently this gene contains the principle determinant of receptor usage
(Speck et al, 1997; Ross and Cullen, 1998; Chan et al., 1999; Bieniasz et al., 1997),
and therefore the differential cellular (Hwang et al, 1991) and potentially tissue
tropism displayed by HIV. The infidelity of reverse transcriptase (Preston et al,
1988) coupled with the high level of HIV replication throughout infection (Ho et al,
1995; Wei et al, 1995), and the long duration of infection, make genetic mutations in
this region extremely common. These mutations can lead to alterations in viral
properties such as receptor usage (Bjorndal et al., 1997), cellular tropism
(Schuitemaker et al., 1992) and the susceptibility of the virus to specific immune
responses (Wolfs et al, 1990).
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Perhaps the most well-documented of these effects are the genetic mutations leading
to positively charged residues at specific sites in the V3 loop that are associated with
the change in co-receptor usage from CCR5 to CXCR4 (Bjorndal et al, 1997; Speck
et al, 1997; Schuitemaker et al, 1992; Chesebro et al., 1992), a phenotypic switch
observed during disease progression in approximately 50% of individuals infected
with HIV-1 group M subtype B strains. These mutations correlate to some extent
with the ability ofCXCR4 using (X4) syncytium inducing (SI) primary viral isolates
to infect transformed CD41 T cells in culture (T-tropic), and CCR5 using (R5) non-
syncytium inducing (NSI) variants to infect macrophages in culture (M-tropic). A
wide range of alternative coreceptors can also facilitate HIV-l entry (at least in
vitro), and use of these additional coreceptors has proved more difficult to map to
specific amino acid residues. Genetic determinants of coreceptor usage or cellular
tropism have variously been mapped to the V1/V2 (Cho et al, 1998; Hoffman et al.,
1998; Ross and Cullen, 1998; Koito et al, 1994; Boyd et al., 1993; Groenink et al,
1993), V3 (Cann et al., 1992; Hung et al., 1999; Hwang et al, 1991; Kato et al., 1999;
Hoffman et al, 1998; Speck et al, 1997), and V4/V5 (Cho et al, 1998) regions of env,
most frequently in conjunction with specific sequences in other regions of gpl20. For
example the ability of particular chimeric HIV-l envelope proteins to mediate
CCR3-dependent infection is determined by VI/V2 sequences in conjunction with a
CCR5 tropic V3 loop (Ross and Cullen, 1998). Certain mutations in CD4-
independent HIV-l strains generated in tissue culture map to other regions of env
including C2, C3 (Dumonceaux et al, 1998), and C4 (Labranche et al, 1999),
consequently mutations at these or other sites may allow entry of viral variants into
CD4-negative cells in vivo. A number of other receptors such as DC-SIGN
I7l
(Geijtenbeek et al, 2000a), DC-SIGNR (Pohlmann et al, 2001b), Gal-C (Harouse et
al, 1991), and heparan sulphate (Patel et al, 1993) may be important for aiding HIV-1
adsorption to cells. Differences in affinity for these molecules could affect cellular
tropism by allowing certain HIV-1 variants to preferentially adhere to cell types that
express them. For example a higher V3 positive charge provides an enhanced
interaction between gpl20 and polyanionic molecules such as heparan sulphate
(Moulard et al, 2000). Moreover HIV-1 isolates often vary both in their entry
receptor density requirements (Kozak et al, 1997; Kabat et al, 1994), and in the
precise manner that they interact with coreceptor molecules for entry (Picard et al,
1997; Brelot et al, 1999). Envelope determinants of tropism are therefore complex
and may often be conferred by several, discontinuous, regions of the env gene.
Target cell factors in addition to the presence of particular viral receptors also appear
to influence viral tropism in a complex manner. For example macrophages and
microglia express CXCR4 and may be infected by many X4 primary viral isolates
but not tissue culture lab adapted X4 viruses (Simmons et al, 1998; Strizki et al,
1996; Ghorpade et al, 1998a; Verani et al., 1998). This may be connected to low
levels of CD4 expression on macrophages (Kozak et al, 1997; Piatt et al., 1997), or
the relatively poor ability of CXCR4 to associate with CD4 on these cells compared
with CCR5 (Lapham et al, 1999; Dimitrov et al., 1999). Alternatively, the inefficient
replication ofmany X4 strains in macrophages may be due to post-entry factors, such
as the inability of gpl20-CXCR4 binding on these cells to activate a requisite signal
transduction pathway allowing productive infection (Schmidtmayerova et al., 1998).
The conformation that coreceptors adopt may also vary in a cell type specific manner
(Lee et al, 1999a), such as the formation of CCR5 dimers (RodriguezFrade et al.,
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1999) or other cell surface receptor interactions (Mellado et al., 1999). Issues such as
this may be especially significant when examining HIV in the brain, where
genetically distinct viral populations are frequently observed (Ball et al, 1994; Di
Stefano et al, 1996; Donaldson et al, 1994a; Epstein et al, 1991b; Haggerty and
Stevenson, 1991; Korber et al, 1994a; Steuler et al, 1992) and several different cell
types appear to be infected. These cell types include those that do not express CD4
such as astrocytes (Bagasra et al, 1996; Ranki et al, 1995; Wiley et al, 1986), which
leaves open the possibility that individual viruses derived from this organ would
display a range of subtly different entry receptor requirements depending upon the
cell type they are specific for. Further alterations of viral phenotype in the brain
compared to the lymphoid system may be mediated by the microenvironment within
this organ. For example neutralising antibodies may be less abundant in the brain
than elsewhere in the body, potentially allowing viral envelopes at this site to adopt a
more "open" or "pre-triggered" conformation with an increased affinity for
coreceptors and a reduced requirement for CD4 (Martin et al, 2001; Gorry et al,
2002a). The presence of fewer immune cells may also lead to lower concentrations
of inhibiting factors such as the p-chemokines macrophage inflammatory protein
(MlP)-la, MIP-ip, and regulated upon activation normal T cell expressed and
secreted (RANTES) as compared with the lymphoid system. Overall, it is clear that
the cellular tropism of HIV is dependent upon both the infecting viral strain and
target cell/tissue type.
Furthermore at a genetic level the importance of different in vivo viral evolutionary
mechanisms in the adaptation to new cell and tissue types is still unclear.
Recombination clearly has a central role in production of new variants on a global
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scale (Robertson et al, 1995; Gao et al, 1996b) yet it has proved difficult to ascertain
the specific sites and frequencies of recombination over the course of a single
infection. The majority of investigations have indirectly inferred the occurrence of
recombination between variants that diverged in a single infected individual (Morris
et al, 1999; Dykes et al, 2000; Brown and Cleland, 1996). It would therefore be
useful to further characterise this phenomenon in order to assess its possible
relevance to escape from antiviral drugs or immune responses, and its potential for
aiding viral expansion into new cell/tissue types.
Given these complex interactions, it is of central importance that any genetic or
phenotypic study of HIV env uses envelope sequences that accurately reflect those
present in vivo. Currently the preferred method for amplifying genes from HIV is the
polymerase chain reaction (PCR), as this does not lead to the immediate and intense
selection of small subsets of virus associated with cell culture systems
(Sanchezpalomino et al., 1993). However, PCR is also known to produce in vitro
artefacts, most significantly the artefactual recombination of parent strands during
amplification (Meyerhans et al., 1990; Yang et al., 1996; Zylstra et al., 1998; Judo et
al., 1998; Fang et al., 1998) and the incorporation of single nucleotide errors by the
DNA polymerase used in the reaction (Saiki et al., 1988; Bracho et al., 1998; Smith
et al, 1997; Bracho et al, 1998). Making every effort to avoid the resulting potential
for scrambling of hypervariable regions and incorporation of point mutations is
critical to any study attempting to identify discrete genetic or phenotypic properties
of specific viral populations. Moreover, molecular cloning is often used subsequently
to PCR to allow sequencing and expression of amplified genes yet this method may
also lead to artefactual results and erroneous interpretations. If small numbers of
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template molecules are present in the beginning of a PCR reaction, or if preferential
primer binding has led to the disproportionate amplification of certain templates,
then several clones may be derived from a single virus or provirus (Liu et al., 1996).
This procedure can therefore result in misrepresentation of the genetic diversity
within a sample. Considering the importance of env in understanding many areas of
HIV pathogenesis, and the large volume of research focussing on this gene, we
aimed to quantify each of these artefactual effects and if possible reduce or eliminate
them thus providing genuine in vivo HIV-1 env sequences for analysis.
4.2 Aims
1) Individually assess the significance of a range of in vitro artefacts associated with
the PCR amplification and subsequent cloning of the HIV-1 env gene.
2) Develop methods for eliminating these artefacts and generating sequences that are
representative of those present in vivo.
3) Further previous observations of in vivo recombination by analysing env
sequences obtained at limiting dilution from separate tissues.
4.3 Materials and methods
As described in Chapter 2.
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4.4 Results
4.4.1 Nucleotide misir.corporation during PGR
One problem associated with use of PCR is the introduction of mutations resulting
from nucleotide misincorporations during amplification. We therefore investigated
the extent to which this occurred in a nested PCR encompassing the entire env gene
of HIV-1 along with the first 300 bp of nefusing previously described primers (Gao
et al., 1996a). 30 copies of either full-length HIV-1Lai or HIV-Icami (of known
sequence) were amplified in three separate env PCR reactions and a total of seven
clones derived from these reactions were fully sequenced (3 clones each from 2 PCR
products and 1 clone from the 3rd PCR product). An average of 1.57 mutations/clone
was identified (11 mutations in 7 clones) giving an overall frequency of nucleotide
misincorporation in final product clones of 1 per 1839 bp. Calculating the error rate
for a polymerase requires the real number of DNA duplications during PCR to be
known, as opposed to the number of thermal cycles the DNA is subjected to (70 in
total for this nested PCR). Given an average weight of 660 g/mole per base-pair for
double stranded DNA, one mole of env (2887 bp) has a mass of 1.9 x 106 g, therefore
a single molecule of env has a mass of 3.16 ag (1.9 xl06/6.022 x 1023 = 3.16 x 10"18
g). Assuming an input number of 30 molecules and 5 pg of end product DNA, then
the total amplification achieved by PCR is approximately 5 x 1010 (i.e. 5 x 10"6/ (30 x
3.16 x 10"18) = 5.27 x 1010), corresponding to approximately 36 duplications of DNA
(5 x 1010 is approximately 2l6). 1.57 errors per 1 x 10^ incorporations (2887 x 36)
gives an error rate for Expand High Fidelity polymerase (a mixture of Pwo and Taq)
in this PCR of 1.51 x 10"5, lower than that reported for other thermostable
polymerases (Smith et al, 1997) but still potentially harmful for studies of the
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amplified clones. For example 7/11 of the polymerase misincorporations identified in
this study resulted in predicted amino acid changes (Fig. 4.1). These included a
mutation within the V2 region of env (position 552) and the replacement of a
conserved cysteine residue essential for maintaining the di-sulphide bond of the V3
loop with a tyrosine residue (position 1075). Mutations of this type are likely to
result in translated glycoproteins that display altered biological properties from the
original templates and may also produce non-functional proteins.
4.4.2 In vitro recombination during amplification by PCR
A second problem associated with the PCR amplification of genetically distinct
templates is the production of artefactual recombinant molecules. Therefore a study
was undertaken to determine if entire env gene PCR amplification of heterogeneous
HIV templates leads to significant in vitro recombination and final products that are
chimaeras of the original sequences. A system was devised to assess the frequency of
recombination in vitro using the two genetically distinct HIV-1 template clones
HIVlai and HIVcami- These contain unique Hind III and Xmn I restriction sites




























Figure 4.1. Schematic representation of mutations that occurred
during env PCR using cloned viral templates. A summary ofmutations
identified in seven env clones derived from 3 PCR reactions using cloned
HIV-1 genomes as template. These mutations are due to
misincorporations by the Expand High Fidelity PCR System (a mixture
ofPwo and Taq) used for amplification. Amino acid changes due to non-
synonymous changes are shown above and synonymous nucleotide
changes below the env diagram. Numbering is from the start of env and
refers to nucleotide position.
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Figure 4.2. System for detecting recombination during env PCR amplification.
A) Positions of Hind III and Xmn I restriction sites in env PCR amplicons derived from
HIVlai or HIVcami- If the two genotypes are mixed and the env gene amplified by PCR
then no recombination would lead to the presence of only parental genotypes in the final
product. Recombination during PCR between the two restriction sites spaced 1285 bp
apart would produce sequences with neither restriction site (5' end HIVlai, 3' end
HIVcami), leading to an uncut band of 2918 bp upon Hind IIIIXmn I digestion, or both
restriction sites (5' end HIVcami, 3' end HIVlai), producing bands of 665 bp, 1285 bp,
and 968 bp upon digestion. The ratio of the four products revealed by enzymatic
cleavage indicates the frequency of recombination during PCR.
B) Hind III and Xmn I double restriction digest on env PCR products derived from only
HIVcami (lane 2), or HIVlai (lane 3) demonstrating the expected restriction pattern for
each, a 1 Kb DNA ladder is also shown (Lane 1).
A) env PCR product
HIV,
(1950 bp)















Therefore if the two clones are mixed before amplification of the env gene by PCR,
products generated by an in vitro recombination event between the two sites can be
easily identified by possession of either both or neither restriction site. Hind III and
Xmn I double digests on env PCR products derived from only HIVcami or HIVlai
templates demonstrated the expected restriction pattern for each (Fig. 4.2.B). It has
been previously suggested that in vitro recombination may occur more frequently
where large numbers of target DNA molecules are initially present in the reaction
(Meyerhans et al, 1990). Hence, equimolar mixtures containing 3000, 300 or 30
copies of each clone as template were prepared and amplified by env PCR. HIV-
negative peripheral blood mononuclear cell DNA was also added to the reactions
prior to amplification in order to more closely simulate amplification of proviral env
genes from DNA extracted from infected cells. These products were cleaved with
Hind III and Xmn I in a double restriction digest and the bands sized by agarose gel
electrophoresis (Fig. 4.3.A). The detection of visible recombinant bands of
approximately 2.9 Kb and 1285 bp corresponding to sequences containing neither or
both of the restriction sites indicated that in vitro recombination had occurred at a
relatively high frequency between the two restriction sites on the parent DNA
strands. Note that the 2.9 Kb uncut band appears more intense than the 1285 bp
doubly cleaved band. This is likely to be due to the re-annealing of fully extended
products competing significantly with primer binding in the latter stages of the PCR,
leading to the formation of heterodimeric molecules that are refractory to restriction
digestion. Therefore the presence of the 1285 bp restriction fragment is the more
rigorous indication of recombination.
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Figure 4.3. Detection of recombinant env PCR products.
Recombinants were identified by restriction mapping after amplification of different
concentrations of the MIVcami/HIVlai genotypic mix. The levels of the 2918 bp and
1285 bp bands (the presence ofwhich demonstrates that recombination has taken place)
are also indicated.
A) Lanes 1 and 7: 1 Kb DNA ladder, Lanes 2 and 6: 100 bp DNA ladder, Lanes 3, 4,
and 5 represent Hind III/Xmn I restriction digest products of PCR reactions that
contained 3000, 300, or 30 copies respectively of each clone as template. Bands at 2.9
Kb and 1285 bp are evident in each of the digested reaction products.
B) Digests of PCR products amplified from the HIVcami/HIVlai mix after dilution to
near PCR end point. Lanes 1 and 13: 1 Kb DNA ladder, Lanes 2 and 12: 100 bp DNA
ladder, Lanes 3-11: digests of replicate PCR reactions (see text for information on the
final composition of each of these reaction products).
C) Digests of replicate PCR products amplified from a further 1 in 3 dilution of template
shown in B. Lane 1: 1 Kb ladder, Lanes 2-10 replicate PCR products digested with both










To assess the arte factual recombination frequency when low numbers of template
molecules are amplified by PCR this genotypic mixture was then diluted out to near
PCR end point and PCR replicates were performed at the last positive (10-fold)
dilution. Reaction products were again digested with both Hind III and Xmn I to
characterise their genetic composition (Fig. 4.3.B). Lane 5 represents a negative PCR
result, as would be expected when approaching limiting dilution. Assuming a
Poisson distribution it was calculated that each replicate contained an average of
approximately 2.2 sequences from the original HIVcami/HIVlai mix. Reactions 4
and 7 contained only HIVcami and HIVlai respectively and the remaining 5 reactions
contained genotypic mixes of the two original templates and displayed varying
intensities of the 1285 bp recombination indicator band. The genotypic mix was then
further diluted 1 in 3 and figure 4.3.C shows digested products derived from this
dilution, which yielded 7 positive reactions from 9 tested. This resulted in varying
outcomes: 4 isolated HIVlai sequences (lanes 2, 6, 7, and 8), 1 of HIVcami (lane 9),
2 HIVcami/HIVlai recombinant patterns (lanes 3 and 10) and 2 negative replicates
(lanes 4 and 5). The replicate in lane 3 containing both HIVlai and HIVcami
sequences produced approximately equimolar amounts of the 4 possible restriction
patterns and the replicate in lane 10 displayed a less intense recombinant pattern than
that indicative of the original sequences present in the reaction. These results implied
a loss of genetic linkage between the restriction sites 1285 bp apart under these PCR
conditions, and demonstrated that recombination in PCR can also occur at high
frequency with low numbers of input molecules. All PCR replicates performed on
more concentrated dilutions than in figure 4.3.C demonstrated the presence of both
genotypes along with varying intensities of recombinant bands. Any PCR positives
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observed at lower dilutions than that in figure 4.3.C demonstrated the presence of
only a single genotype by restriction analysis (data not shown). The isolation of
single genotypes in certain PCR replicates also suggested that the sensitivity of the
env PCR is sufficient for the amplification of single proviral molecules at limiting
dilution from an original genotypic mix, a procedure permitting the elimination of
artefactual recombination
4.4.3 Limiting dilution env PCR
To confirm that the limiting dilution technique could be applied to the env PCR, the
sensitivity of this reaction was compared with that of a PCR using primers spanning
the V3 region, which had previously proven sensitive enough for use on single
proviral templates (Donaldson et al, 1994a). Cloned HIVLAi DNA was titrated in a 3-
fold dilution series and whole env and V3 PCRs were both performed in triplicate
reactions on each of the dilutions in the series (Table 4.1). The results indicated that
with cloned DNA as template the whole env PCR had similar sensitivity to that of
V3. An additional sensitivity comparison between the V3 and env PCRs was then
undertaken using DNA extracted from an autopsy specimen recovered from the brain
of an individual with giant cell encephalitis (right occipital lobe of NA021, Chapter
3). Serial 10-fold dilutions of the DNA were analysed by both V3 and env PCR, and
replicate PCR reactions using both sets of primers were then performed at limiting
dilution (Table 4.2). The sensitivity of whole env PCR was similar to PCR using V3
primers although there were approximately five-fold fewer positive end point
replicates using the env PCR.
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PCR method Number of positive replicates/number tested
*300 100 30 10 3 1 0.3
V3 primers 3/3 3/3 3/3 3/3 1/3 1/3 0/3
env primers 3/3 3/3 3/3 2/3 2/3 1/3 0/3
Table 4.1. Sensitivity comparison of env PCR with V3 PCR using cloned HIV
proviral DNA as template. *Approximate number ofDNA copies added to PCR.
PCR method DNA dilution
Undiluted 10'1 102 10"3*
V3 primers + + + 14/30
env primers + + + 3/30
Table 4.2. Sensitivity comparison of env PCR with V3 PCR using HIV proviral
DNA extracted from autopsy tissue as template. *30 replicate reactions carried out at
end point dilution for each PCR with frequency of positives indicated.
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The majority of DNA extracted from autopsy tissue was present as a high molecular
weight (> 10 Kb) species (data not shown) therefore autolysis or cleavage of
template DNA during extraction is unlikely to account for this small difference in
sensitivity. It is possible that less of the 3 Kb env template was present in a form
suitable for PCR amplification compared with the shorter 350 bp V3 template.
4.4.4 Genetic diversity comparison between limiting dilution
and cloning
Resampling error occurs when low input copy numbers or preferential primer
binding during PCR results in cloned sequences that significantly under-represent the
genetic diversity within an original DNA sample. Resampling due to low input copy
number is related to the number of templates added to a PCR reaction and the
number of clones derived from that reaction, allowing the probability of resampling
at least one original template to be calculated (Liu et al, 1996). For example if 25
input templates are added to a PCR reaction, and 10 clones derived from that reaction
are sequenced then there is an 88% probability of resampling at least one of the
original templates (Liu et al, 1996). This effect can be reduced by first quantifying
the amount of template in a sample then ensuring that a large number of template
molecules are added to the PCR. However, the issue of preferential primer binding
cannot be effectively accounted for by varying template copy number. Furthermore,
the exponential amplification involved in PCR means that even small differences in
primer affinity to template DNA can result in a minority sequence becoming the
most abundant genotype at the end of a PCR reaction.
To specifically address this issue 9 env sequences were amplified at limiting dilution
from the right occipital lobe of patient NA021 as described above and the VI/V2
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region sequenced. In parallel the VI/V2 region was directly amplified by PCR from
the same DNA sample in a reaction containing over 1000 original HIV-1 proviral
DNA templates using Taq DNA polymerase. Taq polymerase was used in order to
more closely imitate the majority of similar investigations using PCR and cloning
techniques reported in the literature. The single V1/V2 PCR product was cloned and
11 individual clones were isolated and fully sequenced. Given an input DNA copy
number of over 1000 with 11 clones sampled, the average number of clones that
should be derived from unique templates is over 10.9 and the probability of one or
more resampling events occurring is less than 0.054, or 5.4% (Liu et al, 1996).
Therefore resampling of clones is unlikely to be evident and the genetic diversity
observed within the cloned V1/V2 sequences should be very similar to that observed
in limiting dilution PCR products. Note that sporadic polymerase errors are more
likely to have occurred in the VI/V2 PCR than the V1/V2 region of an env PCR
product. This is due to the lower fidelity Taq polymerase used for V1/V2
amplification, and to the greater number of polymerase incorporations that will have
occurred during generation of the VI/V2 final PCR product compared with the
V1/V2 region of the longer env PCR product. The previously determined number of
misincorporations during env PCR leads to an expected 1 polymerase error in the
entire data set of V1/V2 sequences from limiting dilution PCR products, a figure that
is likely to be greater in the directly amplified VI/V2 PCR products described here.
N-J phylogenetic trees using J-C distances were created with each data set using






































Figure 4.4. Phylogenetic trees constructed with V1/V2 sequences
obtained by cloning or limiting dilution PCR. Upper panel: Cloned
sequences, Lower panel: PCR product sequences. Divergence between
nucleotide sequences was estimated using Jukes Cantor distances (scales
indicated below trees), and trees were constructed from the distance
matrices by the neighbour-joining method. The robustness of observed
groupings was tested by bootstrap resampling of 500 data sets with values
over 75% indicated on branches. The subtype B isolate HIVmn was used as
an outgroup to root the tree. Lineage A corresponds to the set of closely
related cloned sequences referred to in the text.
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The tree produced from cloned sequences appeared less diverse than that from
limiting dilution PCR products. This impression was largely due to one lineage (Fig.
4.4, Lineage A) displaying a marked reduction in genetic diversity compared with
the topology of the rest of the tree and that of limiting dilution PCR sequences. The
sequences within this lineage were remarkably similar and contributed to a median
number of nucleotide differences compared with the 60% majority sequence
(ignoring insertion/deletion events) per sequence of 1 for cloned sequences in
contrast to 7 for limiting dilution PCR products (Fig. 4.5). The number of differences
compared to the consensus was a somewhat arbitrary value because if resampling
had occurred then these duplicated sequences would also contribute towards the
composition of the consensus sequence. However, other possible measures such as
comparing the mean genetic distances within each group of sequences were not
appropriate as the presence of a few divergent "outlier" strains would potentially
compensate for other, more similar sets of sequences elsewhere in the data set.
Clones ROc7 and ROcll each had an identical change that was shared with
sequences from limiting dilution PCR products (position 151). These two cloned
sequences were therefore probably not derived from the same template as the
remainder of sequences in Lineage A, although it is possible that they were derived
from the same sequence as each other. Clones ROc3, ROc4, ROc5, and ROc6
contained only two nucleotide mutations in total. These mutations (position 60 in
ROc4, and position 181 in ROc6) were unique within the data set and unprecedented
within the Los Alamos National Laboratory HIV sequence database. Hence these
two mutations probably represented polymerase misincorporations.
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GAT CAA AGC CTA AAG CCA TGT GTA AGA TTA ACC CCA CTC TGT GTT ACT TTA AAT TGC ACT GAT GTT AAT TTC AAT GGT ACT GAT GTG AAG
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R05 ... G.. G.. .C. G G. GAC ACT GAT ACT GAT G A G
A A T A . . .SDTDTD. .G.S.R
Figure 4.5. V1/V2 nucleotide and predicted amino acid sequences obtained
either by cloning or by limiting dilution PCR. Clones: ROc, Limiting dilution
PCR products: RO. The 60% majority consensus is used as a reference sequence.
Dots indicate residues identical to reference sequence, and dashes indicate alignment
gaps. Arrows mark nucleotide positions referred to in the text. Sequences have been
grouped according to similarity and the number of nucleotide differences in each
sequence as compared to the consensus (ignoring insertion/deletion events) is
provided at the end of each sequence. Continued overleaf.
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TGC TCT TTC AAT ATT ACC ACA CGC CTA AGA GAT AAG GTG CAG AAA GAA TAT GCA CTT TTT TAT AAA CTT GAT GTA GTA CCA ATA GGA •
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Given that the original proviral templates were fairly diverse in V1/V2, as
demonstrated by the "correct" sequences from limiting dilution PCR products, the
four cloned sequences: ROc3, ROc4, ROc5, and ROc6 are most likely derived from
a single original template.
Significantly this result did not simply reflect a lack of original template molecules in
the PCR. The same V1/V2 PCR used prior to cloning was also used to quantify the
original number of amplifiable templates, an approach that is essential for adequate
template numbers to be assured (Rodrigo et al., 1997). PCR amplification of DNA
containing over 1000 of these amplifiable template molecules with 11 clones
sequenced is unlikely to have produced a single resampling event because of lack of
input DNA. Therefore the resampling of clones documented here likely reflects
preferential primer binding or random events during the PCR leading to an over
representation of certain genotypes in the final product. Such events are difficult to
account for completely, even when primers are designed to correspond to fairly
conserved regions of the HIV genome.
4.4.5 Sequence Analysis of limiting dilution env sequences
Given that the sensitivity of the env PCR had proven sufficient for amplification
from single HIV-1 proviral templates, this approach was used to amplify and directly
sequence the envelope genes from two regions of brain and one lymph node obtained
at autopsy from an HIV infected individual displaying giant cell encephalitis (study
subject NA021, Chapter 3). The right occipital and left temporal lobes were chosen
for this analysis because they had previously been shown to contain virus genetically
distinct or similar respectively to lymph node virus in pl7gag yet each were
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completely segregated from lymph node in the V3 region (Chapter 3). Therefore
upon closer examination of the env gene perhaps would display unpredictable
interrelationships and further evidence of recombination between virus present in
different tissues. A total of 9 sequences were obtained from the right occipital lobe
(RO), 8 from left temporal (LT), and 8 from lymph node (LN, or LN2 as described in
Chapter 3). An example of several final env PCR products obtained at limiting
dilution is shown (Fig. 4.6). Each product formed a discrete band of approximately 3
Kb, demonstrating the specificity obtained using this PCR. It is also noteworthy that
while the Poisson formula may be used to predict the average number of molecules
per reaction, it is still possible for positive reactions that appear to be at limiting
dilution to contain more than one proviral molecule. Two of the PCR products
originally generated displayed completely ambiguous sequences across the VI/V2
and V4/V5 hypervariable regions, probably due to the presence of two or more
original templates containing length polymorphisms in these genomic regions. These
two sequences were accordingly excluded from the current analysis. Remaining PCR
products did not display any such length polymorphisms and were unambiguous
during individual sequencing, thereby providing additional confidence that they were
indeed derived from single original proviral copies.
The predicted amino acid sequence of the isolated env (gpl60) genes is shown (Fig.
4.7) with relevant domains annotated.
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Figure 4.6. Example of env PCR products amplified from single
proviral templates. Template DNA was extracted from either lymph node
(LN) or right occipital lobe (RO) tissue samples. 1 Kb and 100 indicate 1
Kb and 100 bp DNA ladders respectively, level of 3 Kb band is marked.
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Figure 4.7. Predicted Env (gpl60) amino acid sequences of PCR products
amplified at limiting dilution from different tissue samples obtained at autopsy. A
60% majority consensus sequence is included for comparison. Dots indicate residues
identical to reference sequence, dashes indicate alignment gaps, "x" indicates ffameshift
mutations, and stars indicates stop codons. RO: right occipital lobe, LT: left temporal
lobe, and LN: lymph node. Hypervariable regions and other important structural features
are labelled. Red asterisks indicate sites for CD4 binding and blue asterisks indicate sites
where substitutions are critical for CCR5 binding. These binding sites are taken from a
previously published alignment (Yamaguchi-Kabata and Gojobori, 2000) and are based
upon the X-ray crystal structure of a gpl20-CD4 complex (Kwong et al., 1998), and
mutational analysis of specific amino acid residues in gpl20 (Rizzuto et al., 1998)
respectively. Green triangles indicate sites in the V3 region where the occurrence of
positively charged amino acids strongly correlates with CXCR4 usage. Figure is
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No two sequences were entirely identical although some, most notably from the LT
region were closely related to each other. There also appeared to be a broad
segregation between the lymph node and brain-derived sequences. One sequence
(LN6) contained a stop codon in the cytoplasmic domain of gp41 (position 810)
predicted to cause a premature truncation 74 amino acids from the C-terminus. A
single nucleotide deletion (frameshift mutation) was present in both LN4 (position
206) and R07 (position 770), but the remainder of the open reading frames appeared
intact. As expected, the gpl20 coding region was more variable than gp41, and the
greatest genetic diversity was present within the hypervariable regions. In the V1/V2
region lymph node sequences contained a variety of length polymorphisms whereas
only one brain-derived sequence (R05) had a relative insertion event (Position 152-
156). The V3 region was relatively homogeneous with no mutations completely
segregating between the separate tissues, although one relative N-W/A change
present in the 5' V3 flanking sequence (position 301) did distinguish between LN
and brain populations. Sites 324 and 340 in the V3 region are positions where the
presence of a positively charged amino acid is strongly indicative of CXCR4 usage.
Both of these sites contained uncharged or acidic amino acids, thus all of the Envs in
this data set are derived from viruses that would be expected to use CCR5. The
limiting dilution V3 sequences described here also correspond well to the consensus
V3 sequences described in Chapter 3 that were obtained from the same tissues. In V4
the RO sequences were most variable and two sites consistently segregated between
LN and brain-derived sequences (positions 415 and 416). In V5, sequences were also
diverse but appeared to group broadly with others from the same tissue. One
sequence (LN6) had a relative R—>1 mutation in the fourth amino acid of the usually
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highly conserved (R/L-X-K/R-R) gpl20/gp41 cleavage site (position 534-537), and
thus may represent a biologically unviable virus. The beginning of gp41 was much
more conserved than the majority of gpl20, perhaps in part as a result of purifying
selection at the nucleotide level mediated by the presence of the Rev response
element (RRE) at this point. Other areas of specific functional importance were also
relatively conserved. Three sequences contained single sporadic mutations in the
gp41 membrane-spanning domain (position 710-733), and the Y-X-X-L endocytosis
motif (position 739-742) was a region of complete identity among all sequences.
One way of detecting potentially biologically important differences in brain or
lymphoid sequences is to identify those sites known to be important for receptor
binding or have been specifically shown to alter receptor usage in laboratory
experiments. If such sites are significant for tissue tropism then there may be
segregating or mostly segregating mutations at these positions separating brain and
lymph node derived sequences. Some of the sites important for CD4 and CCR5
binding as identified by X-ray crystal structure (Kwong et al, 1998) or site directed
mutagenesis experiments (Rizzuto et al., 1998) are also labelled on the Env amino
acid alignment. These sites are mainly conserved within all sequences, probably
reflecting the importance of gpl20-receptor interactions. One site important for CD4
binding (position 301) did segregate between brain and lymph node sequences, with
an asparagine residue present in all brain derived sequences but no lymph node
sequences, and may therefore represent an adaptive mutation. Several sequences
contained an arginine instead of lysine at position 121, an important site for CCR5
binding, but not in a tissue specific manner, this difference is therefore unlikely to
represent an important adaptive mutation. Alteration of N-linked glycosylation
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signals may also alter the properties of translated glycoproteins. One report
documenting the spontaneous adaptation in tissue culture of an HIV-1 CCR5 using
variant (isolate ADA) for replication in CD4-negative cells describes the movement
or loss of an N-linked glycosylation site as a necessary and sufficient factor in the
altered viral phenotype (Kolchinsky et al, 1999). This mutation in the VI/V2 stem
(env amino acid 197 on the HXB2 genome or position 215 in this study) also
provided enhanced CD4-independent infection in conjunction with mutations
elsewhere in ADA env. These alterations, when introduced into YU2 or the CXCR4-
using ADA (MMM) glycoproteins did not generate a similar CD4-independent
phenotype, suggesting that the effect was restricted to ADA Env. However, in the
current study all lymph node derived sequences contained this N-linked
glycosylation site and all but three brain-derived sequences did not, due to a relative
N—»D substitution (amino acid position 215). Other changes noted in the prior study
were not present in this data set but the naturally occurring loss of this glycosylation
site may to some extent mirror CD4-independence in cell culture isolates by
enhancing direct gpl20-CCR5 binding and negating or more likely reducing the
requirement for CD4 in these interactions. Such alterations in brain-derived isolates
may be expected given the apparent infection of cell types that do not express CD4,
or express only low levels of this molecule.
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A) Tat exon 2
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consen RPASQPGGDP TGPKESKKKV ERETETDPVH *
R01 R Q *
R03 *
R04 Q *
R05 R Q *
R06 *
R07 R Q x *
R08 *
R09 *
R016 R Q *
LT1 *
LT2 *
LT3 R Q *
LT4 R Q *












B) Rev Exon 2
RNA binding
and Nuclear Activation
D Localisation Oligomerization Domain
consen PPPSQEGTRQ ARRNRRRRWR ERQRQIRSIS EWILSNHLGR PAEPVPLQLP PLERLTLDCN EDCGTSGTQG VGSPQILVES PTVLESGTKE
R01 . L. . P F
R03 K
R04 F
R05 . L. . P F V
R06
R07 . L. . P X...F V
R08
R09 A. .
R016 . L. . P F P
LT1 Y V
LT2 Y V
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LN1 H.H S... .A...P
LN4 H.H N A...P
LN5 H V N...S... .P...P
LN6 H.H V R A. . .P
LN7 H.H L N...F... .A...P
LN22 H.H N...S P
LN26 S
LN35 H.H A...P
Figure 4.8. Predicted amino acid sequences of the second exons of Tat
and Rev, encoded within the gpl60 open reading frame. A) Tat exon 2. B)
Rev exon 2. Sequence labels are as for Figure 4.7. The "x" in each R07
sequence indicates a frameshift that is present in all three overlapping open
reading frames. Several important functional domains are also annotated in
the Rev alignment.
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The second exons of Tat and Rev are present in overlapping open reading frames
towards the 3' end the gp41 coding sequence. As selection pressure on tat or rev
sequences may directly alter the env sequence, predicted amino acid sequences of the
second exons of Tat and Rev are shown (Fig. 4.8). The amino acid sequence of Tat
exon 2 shows no complete tissue segregation, although positions 27 and 29 near the
C terminus do show a separation of brain from lymph node sequences with the
exception of LN26. Of interest in Rev exon 2 is the almost complete conservation of
the putative nuclear localisation and RNA binding domain, and the leucine-rich
activation domain (encoding the nuclear export signal) with only one
nonsynonymous mutation present in each (notwithstanding the previously mentioned
frameshifit in R07). Again no specific amino acid motif serves to completely
distinguish virus from different anatomical sites. It therefore appears that if a strong
selection pressure acting upon one of these alternative reading frames has led to
alterations in the env coding sequence it will not have done so in all the sequences
from a single tissue sample.
For further assessment of the relationships between env sequences from different
anatomical sites a N-J, J-C distance phylogenetic tree was constructed using the env
(gp 160) sequences (Fig 4.9). The most obvious segregation was between brain and
lymph node, with two clearly distinct lineages present. Within the brain lineage left
temporal sequences were generally separate from those present in the right occipital
lobe, with the exception of LT1 and LT2, which grouped with RO sequences. A
number of bifurcations were supported by large bootstrap values (>75%) providing








































Figure 4.9. Phylogenetic tree constructed with limiting dilution
env (gpl60) nucleotide sequences. The tree was generated as described
in the legend of figure 4.5 with the HIVmn sequence used as an
outgroup. Bootstrap values over 75% are indicated on branches. RO:
right occipital lobe, LT: left temporal lobe, and LN: lymph node. Brain
and lymph node sequences group separately and these two major
lineages are labelled.
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This observation of HIV sequences in the brain being broadly genetically distinct
compared to the lymphoid system concurs with preliminary analysis using V3
consensus sequences obtained from the same individual (Chapter 3) in addition to a
large number of previous reports. However, such general interpretations provide little
information on how the virus present in the brain has acquired the observed variation
and whether this apparent segregation is consistent along the length of the sequence
as would be expected if representatives of an isolated replicating population had been
sampled. An alternative hypothesis as described in Chapter 3 is that a significant
amount of recombination occurs during the evolution of regional viral populations.
In which case overall segregation between env sequences from different anatomical
regions may obscure more subtle associations between sequences from different
tissues. Closer examination would in that case reveal a more complex
interrelationship between variants from different anatomical sites depending upon the
specific portion of sequence used for analysis as was found between pl7gag and V3 in
this and three other infected individuals (Chapter 3).
The relationships between these sequences from different tissue samples were
analysed using a new method named "group scanning". This method involves the use
of a sliding window moving in steps across the alignment and at each step a grouping
value is determined which indicates the amount of association a test sequence has
with other user-defined groups in the alignment. The principle is similar to
bootscanning (Salminen et al, 1995) although the trees generated are unrooted, so
difficulties associated with rooting a phylogenetic tree correctly with an appropriate
outgroup acting as the ancestral sequence are removed. Also a bootstrap percentage
value is not plotted, and instead for a given placement of a test sequence within the
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tree a score is assigned to each user-defined group depending on the number of nodes
separating this sequence from each other sequence in the data set. Thus the sequence
or set of sequences separated from the test sequence by one node is assigned a score
of 0.5, the sequence (s) separated by 2 nodes, 0.25, by 3 nodes, 0.125 etc. The sum of
scores for each of the individual sequences within a group is calculated. Each group
is therefore assigned a part of the total score of 1 based upon its degree of grouping
with the test sequence. The tree is then recreated with bootstrap resampling and the
process repeated with the average grouping value for each set of bootstrap resampled
trees providing the final grouping score of the test sequence with each of the groups
of sequences in the data set. The window then slides 1 step and the whole process is
repeated across the sequence alignment.
Here the groups were assigned according to tissue (right occipital, left temporal, and
lymph node), and a 500 bp window with 50 bootstrap replicates per window and 100
bp steps was used. Each sequence was compared in succession with the remainder of
sequences in its own group and all sequences in the other two groups. The grouping
score of each individual sequence was then plotted against genome position. The
group-scan results for each of the individual env sequences are shown (Figs. 4.10 to
4.12).
Sequences ROE R03, R05, R06, R07, and R016 each grouped with other right
occipital sequences across the entire env alignment, and were more closely related to
left temporal sequences than lymph node sequences in the majority of positions (Fig.
4.10).
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Figure 4.10 Group-scan plots for right occipital limiting dilution env sequences.
Each group-scan plot was generated with a 500 bp window moving in 100 bp steps, with
50 bootstrap replicates in each step (see text for more details of method). Vertical axis
represents grouping score, horizontal axis represents window position in env sequence.
A diagram ofEnv showing the positions of hypervariable regions within gpl20 (V1-V5)
and the transmembrane domain of gp41 (TM) is presented above each column.
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Figure 4.11. Group-scan plots of left temporal (LT) limiting
dilution sequences. Method as for figure 4.10.
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Figure 4.12. Group scan plots of lymph node (LN) limiting dilution
sequences. Methods as for figure 4.10
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Sequence R04 was more closely related to left temporal sequences at several points
around the V3 region but otherwise grouped with those from right occipital. The
most complex interrelationship of a right occipital sequence with those from different
tissues was displayed by R08. This sequence was similar to others from the right
occipital lobe until the end of V3, after which it grouped strongly with lymph node
until the beginning of gp41. Across the external domain of gp41 R08 then grouped
with either left temporal or right occipital sequences until approximately the
transmembrane region where again it groups strongly with other right occipital
sequences. R09 was generally similar to other right occipital sequences apart from at
the beginning of gp41 where it grouped with left temporal sequences, and at the end
of the Env open reading frame where a brief grouping with lymph node sequences
was evident. Left temporal sequences displayed a general association with others
from the same tissue and closer relationships to right occipital than lymph node
sequences across the majority of the env gene (Fig. 4.11). LT1 and LT2 were each
more similar to RO sequences from the beginning of V1/V2 to the beginning of V3,
then similar to others from left temporal until just after the end of gpl20. A brief
association with lymph node then right occipital sequences was evident around this
point before a return to LT grouping at the transmembrane region of gp41 and for the
remainder of the alignment. LT3 and LT4 were similar to other left temporal
sequences at all points apart from a single window position beginning in V2 where
an association with right occipital sequences was evident. Sequence LT5 grouped
slightly more with RO sequences than LT at two positions in gp41, and sequences
LT6, LT7, and LT8 each grouped with right occipital sequences in a section of the
coding region for the cytoplasmic domain of gp41. Lymph node derived env
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sequences grouped closely with other LN sequences in almost every case, with low
RO and LT grouping scores across the alignment for the majority of LN test
sequence comparisons (Fig. 4.12). In marked contrast to other LN sequences, LN26
presented a much more complex set of grouping scores. This sequence associated
strongly with LT sequences at the extreme 5' end of the alignment and grouped with
both sets of brain sequences more than LN from around V5 to the transmembrane
spanning region of gp41.
Several of these sequences therefore appeared to display distinct evolutionary
histories depending upon the particular segment of the env gene analysed. The most
likely explanation for these complex interrelationships is the occurrence of
recombination between variants present in different tissues. Inclusion of recombinant
sequences in phylogenetic analysis can lead to difficulties because most models for
reconstructing evolutionary relationships implicitly assume that recombination has
not taken place. The potential recombinants in this nucleotide alignment may
therefore have altered the branching pattern of trees where other sequences were
being tested. To investigate this possibility, sequences that showed clear inter-tissue
association differences across the alignment were excluded from groups, then each
sequence was re-analysed against the new groups. No significant differences were
observed in the re-analysed group-scans indicating that the possible presence of
recombinants had not affected the original results (data not shown). Another
potential difficulty in this analysis is that the algorithm for scoring grouping values is
new. Therefore necessarily the robustness of this method and has not been
determined as thoroughly as older, more established means of determining
mosaicism in sequences such as bootscanning (although methods such as those have
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their own limitations as described above). To assure that these results were not due to
some factor peculiar to this particular method of analysis, a number of sequences
were also tested against the same groups using the bootscanning method (see Chapter
2 for details). Results of bootscan analysis were broadly similar to the group-scan
results, although some variation reflecting differences in the underlying algorithms
and methods was apparent (data not shown). However, these differences were not
sufficient to undermine any of the interpretations of group-scan results described
here. A representative comparison of group-scan and bootscan results for one
apparent non-recombinant sequence (LN4), and one potentially recombinant
sequence (LN26) is shown (Fig 4.13). Both methods produced similar (although not
identical) plots when used to analyse the same sequence, indicating that the
discordant phylogenetic relationships across the env gene identified here by group-
scanning are valid and representative of those obtained using a distinct method for
identification of recombinants. Additionally the amino acid sequence signatures (Fig.
4.7) and synonymous substitutions (data not shown) in the potentially recombinant
regions support this interpretation.
The most complex and apparently recombinant sequence relationships were found in
R08, LT1, LT2, and LN26, all of which grouped with sequences from each of the
three tissues at some point in the alignment. Interestingly sequence LN26 was
present as an outlier group from the main lymphoid lineage in the tree generated
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Figure 4.13. Comparison of group-scan with bootscan. Group-scan graphs
are shown in grey, bootscans in white. Two sequences analysed with both
methods are shown. The left panel shows a sequence that appeared non-
recombinant by groupscanning (LN4). The right panel shows a potential
recombinant as identified by group-scanning (LN26). In both cases bootscan
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This type of grouping is characteristic of recombinant sequences, where they do not
fit well within defined clades and their final position in the tree is often defined by
the proportion of each parental sequence that they contain rather than a clear
representation of their evolutionary history. Similarly LT1 and LT2 were the only
left temporal sequences to group with those from right occipital in the env tree and
closer investigation of these two sequences revealed that they contained large
sections of right occipital-like sequence. The remainder of the brain sequences
grouped only with others from the same tissue, or showed minor grouping swaps
between the two brain regions. This minor swapping to an alternative group, where
the scores for the two tissues are very similar probably reflects a natural divergence
of the test sequence from both groups of brain sequences (i.e. in both RO and LT) at
these points, or possibly recombination with a separate lineage not represented in this
data set, and does not necessarily indicate a recombination event between members
of the three sampled virus groups (RO, LT, and LN). One possible exception is near
the 3' end of LT6, LT7, and LT8, where grouping scores between RO and LT
sequences are more distinct, thus it is possible that these sequences were generated
by recombination. Apart from the identification of recombinant sequences these
results demonstrated that intra-tissue association of most LN sequences across the
env gene was stronger than that within either of the two brain-derived tissue groups.
Moreover in most cases non-recombinant brain sequences were more associated with
those from the other region of brain than with lymph node sequences.
4.4.6 Consensus pseudotype virus production
In order to functionally characterise envelope sequences, limiting dilution PCR
reactions were cloned into a eukaryotic expression vector (pCR3.1) and colonies
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were PCR screened to verify that they possessed both the 5' and the 3' ends of the
insert and therefore contain the entire HIV env open reading frame (ORF). This was
necessary because without the screening process in some cases >80% of the resultant
colonies contained plasmids with truncated inserts (data not shown), possibly a result
of the unintended expression of the env sequences in E. coli (Cunningham et al,
1993) coupled with the toxicity of this gene product (Cunningham et al, 1993; Peden,
1992) leading to the death or poor growth of cells containing full-length env ORFs.
Having obtained full-length, recombination free env clones, we next devised a
strategy to avoid the harmful effect of nucleotide misincorporation on the biological
properties of the clones. Although misincorporation cannot be prevented, we
prepared consensus clones for biological characterisation that were each composed
of 10 individual clones derived from the PCR product of a single molecule
amplification (Fig. 4.14). As described above it was empirically determined that
individual env clones contain a mean of 1.57 misincorporations in the env coding
sequence. The probability of every one of the ten individual clones combined
containing a misincorporation error was therefore reduced to approximately 10.7%.
This figure is obtained by applying the average of 1.57 mutations/clone to the
poisson formula so: 1.57 - -In (fo), where fo is the observed frequency of clones with
no mutations. Therefore -1.57 = In (fo), and e"! 57 = 0.2, giving a frequency of clones
with no mutations as 0.2 or 20%. The probability of a single clone containing at least
1 polymerase misincorporation mutation is then 80% (1 - 0.2 = 0.8), and the
probability of every one of 10 clones having an artefactual mutation is 10.7% (0.810
= 0.107). In addition the possibility of separate clones containing identical
misincorporations is small. In the worst case of a copying error occurring in the first
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round of the PCR, only 25% of resulting clones will contain this sequence change,
while the possibility of two identical but independent nucleotide mutation events
occurring at the same site is remote. Consequently ten individual bacterial colonies,
all derived from a single limiting dilution reaction were picked, grown overnight
separately to equivalent concentrations, and then mixed in equal proportions before
extraction of the plasmid DNA. The validity of this approach in generating env gene
clones for use in subsequent phenotypic analysis was assessed by the production of
pseudotype virus. Consensus clones were calcium phosphate co-transfected into 293-
T cells along with NL4.3Ae«vGFP (an env defective HIV-1 proviral backbone clone
in the vector pSVIII) (Fig. 4.14). Pseudotype virus was harvested after two days and
used to infect NP-2 cells (Soda et al, 1999) expressing CD4 and one of the HIV co-
receptors CCR5 or CXCR4 in a single round infection assay. Each of the consensus
env clones produced viable pseudotype viruses that used CCR5 and not CXCR4 in
conjunction with CD4 for entry into cells (Table 4.3). However, the virus produced
by the consensus clones had approximately 10-fold reduced infectivity when
compared to that generated with the control envs YU2 and HXB2 (Table 4.3).
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Clone* Cell type* Average FFU/ml*
pNL4.3Ae«vGFP CCR5 0
only CXCR4 0
YU2 CCR5 9.5 x 104
CXCR4 0
HXB2 CCR5 0
CXCR4 3.25 x 104
ROl CCR5 2.1 x 103
CXCR4 0
R03 CCR5 1.75 x 103
CXCR4 0
R06 CCR5 4.1 x 102
CXCR4 0
R08 CCR5 3.3 x 103
CXCR4 0
R09 CCR5 1.27 x 103
CXCR4 0
R016 CCR5 4.3 x 102
CXCR4 0
Table 4.3. Result of pseudotype single round infection assay using consensus
env clones. Clones used in conjunction with pNL4.3AenvGFP to create pseudotype
virus. YU2 and HXB2 were controls for CCR5 and CXCR4 usage respectively. RO
refers to consensus clones derived from limiting dilution env PCR products. +NP2
cells expressing both CD4 and either CCR5 or CXCR4 were used to determine
pseudotype virus co receptor usage. "'Focal forming units/ml present in the initial
harvested media was calculated by taking the average number of foci of infection in
the last two wells (in a 10-fold dilution series) showing evidence of infection and
multiplying by the dilution factor.
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4.4.7 Plasmid rearrangements during expansion in E. coli
Detection of large numbers of truncated env inserts after initial cloning of PCR
products indicated a severe instability of these clones when propagated in E. coli.
This effect was observed despite the use of different growth media, culture volumes,
or growth temperatures for bacterial expansion (data not shown). Three different
reck\ (-) E. coli strains were also tested as hosts yet none improved the genetic
stability of env containing plasmids (data not shown). This occurrence was clearly
evident when individual glycerol stocks of each of the ten component clones present
in a single consensus clone were prepared, then re-grown from a single bacterium in
accordance with good microbiological practice. Original consensus clones (5' and 3'
PCR screened at colony stage) used to create the glycerol stocks appeared to be of
correct length upon restriction digestion (Fig. 4.15.A) and homogeneous when
sequenced. However, after mixing, plasmid extraction, and restriction digestion of
clones re-grown from glycerol stocks a range of truncated inserts was present (Fig.
4.15.B). This difference probably reflects the increased number of bacterial and
plasmid divisions during culture from a single bacterium without screening as
compared with from a colony in which the presence of plasmid containing full-length
insert has already been verified. A greater number of cell/plasmid divisions provides
additional opportunities for deletion events to occur within the env inserts and
subsequent selection of the more "fit" bacteria containing these altered sequences.
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Figure 4.15 Example of env clone instability in E. coli.
A) Pme I digested mini-preps of consensus clones. These clones were PCR
screened at the colony stage to verify that they contained both the 5' and 3'
end of inserts. The 5 Kb vector and 3 Kb insert restriction fragments both
form discrete bands. Lanes 5 and 6 are 100 bp DNA ladder and 1 Kb DNA
ladder respectively. Lane 1: ROl, Lane 2: R03, Lane 3: R04, and Lane 4:
R05 consensus clones.
B) Pme I digested mini-preps of the same consensus clones shown above
but after re-growth of a single bacterium from glycerol storage at -70°C.
Digests of consensus clones after re-growth display a number of restriction
fragments larger than 5 Kb. In some cases this could indicate the loss of
one restriction site. Multimerisation of uncut plasmid due to the loss of
both restriction sites may explain the presence of visible bands over 8 Kb.
A large number of fragments smaller than 3 Kb were also present,
probably reflecting the truncation of insert or vector. Lane 1: 1 Kb DNA
ladder, Lane 2: ROl, Lane 3: R03, Lane 4: R04, and Lane 5: R05.
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The procedure of mixing ten individual clones, grown in separate culture media and
derived from a single limiting dilution PCR product is likely to make the instability
of these clones more evident, but highlights the complications relating to env
sequence amplification in E coli.
4.5 Discussion
The genetic and functional analysis of primary HIV-1 envelope glycoproteins is
central to our understanding ofmany aspects ofHIV biology. This study investigated
some of the important artefacts associated with PCR amplification and cloning of
HIV-1 env genes and provides means of circumventing them. One such issue is the
incorporation of errors during amplification by the DNA polymerase used. Single
nucleotide misincorporations during PCR amplification of viral sequences has often
been mistaken for genuine in vivo genetic diversity. Previous investigations into this
effect (Smith et al, 1997; Bracho et al, 1998) have identified a number of studies
where the majority of nucleotide diversity observed in cloned PCR products
amplified from hepatitis C virus (HCV) or HIV RNA sequences falls within that
expected from polymerase error alone (Martell et al., 1994; Martell et al., 1992;
Najera et al., 1995). Indeed these misincorporations are likely to be present to some
extent in the vast majority of studies based upon PCR and cloning. Difficulties arise
when counter intuitive results likely to be due to this artefact are presented as
genuine sequences. For example as previously identified (Bracho et al, 1998) one
study into hepatitis G virus (HGV/GBV-C) phylogenetic relationships reported that
the genetic diversity of sequences within a single individual obtained by PCR and
cloning was greater than that found by direct sequencing of PCR products from
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different patients from around the world. This type of result is likely to reflect PCR
misincorporation errors in clones rather than genuine viral genetic diversity and if
observed should be verified by direct sequencing of (preferably limiting dilution)
PCR products. Clearly if PCR derived clones are used for expression experiments
then these difficulties can be transferred to subsequent phenotypic assays, where
small changes may lead to significant differences in biological function. The
availability of thermostable DNA polymerases with higher fidelities than Taq such as
Vent (New England Biolabs), Tbr (NBL Gene Sciences), Pwo (Boehringer
Mannheim), Pfu (Promega), and polymerase mixtures such as Expand High Fidelity
PCR system (Boehringer Mannheim) allow DNA amplification with several times
the fidelity of Taq alone. However, with a large number of thermal cycles often used
in nested PCR procedures, and increasing sequence lengths amplified with this
method, polymerase misincorporation is still a significant source of artefactual
results. In this study the nested PCR amplification of an approximately 3 Kb region
including the entire env open reading frame using 30 full length HIV-1 genome
clones as template resulted in an error rate for Expand High Fidelity Polymerase of
1.51 x 10"5, or one error in 6.6 x 104 incorporations, compared with the previously
reported one error in 1.18 xlO5 incorporations (Barnes, 1994). This discrepancy may
be due to differences in the specific PCR conditions used in the two studies, or
perhaps because of additional alterations incorporated into the env sequence during
expansion in bacteria (see below). In any case the observed error rate is less than that
obtained with standard Taq alone (2.6 x 10"5 or 1 error per 3.8 xlO4 incorporations).
Approximately 64% (7/11) of misincorporations identified in clones from env PCR
reactions resulted in changes in the predicted amino acid sequence (Fig. 4.1), and
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some of these changes may alter the biological function of resulting Env
glycoproteins. Potentially important changes included one in the V2 region, and the
loss of a cysteine residue essential for maintenance of the V3 loop. Both the V1/V2
and V3 regions of env are known to influence cellular tropism and receptor binding
of HIV-1, therefore the inclusion of such altered sequences in phenotypic analysis
may result in observed properties that are not indicative of the original templates.
Another important issue associated with the use of PCR to amplify genetically
distinct templates is that of artefactual recombination. Recombination during PCR
has proven to be present wherever heterogeneous sequences are amplified in a single
reaction, whether this is in multigene families, repetitive sequences, or heterogeneous
RNA virus populations. The effect was first noted soon after the development of
PCR (Saiki et al, 1988; Olsen and Eckstein, 1989) and has since been more
comprehensively characterised (Meyerhans et al, 1990; Yang et al, 1996; Zylstra et
al, 1998; Judo et al, 1998; Fang et al, 1998; Odelberg et al., 1995; Wang and Wang,
1997; Sinkora et al., 2000; Shafikhani, 2002). Observed frequencies of in vitro
recombination have so far been shown to range from 1% (Judo et al, 1998) to 45%
(Sinkora et al, 2000) depending on the specifics of amplification and detection
methods. The most important factors appear to be the length of the amplified
product, the number of amplification cycles, the DNA polymerase used, and the
amount of template DNA initially present.
In the current study mixing either 3000, 300, or 30 copies each of two genetically
distinct full-length HIV-1 genome clones followed by env PCR and restriction
mapping indicated a relatively high frequency of recombination over a 1285 bp
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region (Fig. 4.3.A). These results are similar to those of previous studies (Yang et al,
1996; Sinkora et al, 2000) and highlight the significance of in vitro recombination
when amplifying sequences from heterogeneous virus populations (such as HIV) by
PCR. An analogous experiment was performed at near limiting dilution of the
HIVcami/HIVlai mix with an average of 2.2 initial template molecules present at the
beginning of each reaction (Fig. 4.3.B). In several of the replicate reactions that
contained at least one template copy of each genotype this resulted in a restriction
pattern indicating the presence of approximately 50% recombinants (the maximum
possible with this detection system) implying a complete lack of genetic linkage
between the two markers. The same characterisation procedure was performed on
replicate env PCR products derived from a further dilution of the genotypic mix and
resulted in recombinants in 2/9 replicates and the retrieval of single genotypes in 5/9
replicates (Fig. 4.3.C). Thus this study represents the first demonstration that
recombination in PCR can occur even when very few template copies are present at
the beginning of a reaction. These observations discount the theoretical possibility
that in vitro recombination is significantly increased by high initial target copy
numbers leading to competition of partially elongated transcripts with primers at
earlier stages in the reaction (Meyerhans et al, 1990).
One study investigating the importance of retroviral recombination in the acquisition
of linked mutations leading to increased viral resistance to zidovudine included
information on the background level of recombination due to PCR and cloning
procedures (Kellam and Larder, 1995). The authors reported that a 16% artefactual
recombination frequency with 100 ng of cloned template DNA became only 5.5%
when the amount of input DNA was reduced to 0.1 ng. A subsequent report
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describing the amplification of reverse transcriptase for antiviral resistance profiling
used this information as a basis to disregard any concerns of artefactual
recombination in their PCR procedure (Shi and Mellors, 1997), despite the use of
different primers and PCR conditions. The rational being that if 100 pg of input DNA
led to 5.5% recombination in PCR then using 1 pg as in their assay would result in a
frequency of less than 5.5%. However, as described here a high frequency of
recombination may occur even when only a few amplifiable template molecules are
present in the PCR reaction. Thus the frequency of artefactual recombination cannot
be predicted simply on the basis of input copy numbers and must be empirically
determined for each set of reaction conditions. It is also noteworthy that the
recombination frequency documented here using the template clones HIVcam-i and
HIVlai would be an expected underestimation of that observed when amplifying
many different but more closely related DNA templates such as may be present in a
single sample from an HIV infected individual. Recombination during PCR is
especially significant in the context of the HIV env gene because HIV is by nature
highly heterogeneous and undergoes frequent recombination in vivo (Morris et al,
1999; Hung et al, 1999). Therefore in vitro recombination has traditionally been
difficult to differentiate from natural variation and evolution in vivo. Undoubtedly
the type of sequence scrambling observed here occurred to some extent during each
of the previous attempts to characterise env sequences amplified by PCR and may
have strongly affected both genetic and phenotypic analysis. The PCR amplification
of genetically distinct template molecules has been suggested as an alternative to the
more technically demanding "DNA shuffling" (Stemmer, 1994a; Stemmer, 1994b)
approach to recombination mutagenesis (Judo et al, 1998). This approach is used
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during in vitro evolution experiments and involves the generation of chimeric
molecules for subsequent selection of those with altered biological properties from
the parental phenotypes. It may be considered somewhat paradoxical that the same
procedure utilised in some areas of biological science for generating novel chimeric
molecules is also routinely used in HIV virology for amplification of sequences that
are intended to accurately reflect virus in vivo. Methods have been outlined for the
reduction of in vitro recombination (Zylstra et al, 1998; Judo et al, 1998; Fang et al,
1998) yet these invariably advocate very low numbers of amplification cycles, a
practice that is likely to result in a significant reduction in PCR sensitivity making
the procedure unsuitable for amplifying viral sequences from all but bulk cell or
tissue DNA extractions. More importantly there has been no study describing the
complete elimination of this artefact by any method other than limiting dilution.
Restriction analysis of limiting dilution env PCR products demonstrated that
unadulterated single genotypes could be retrieved from an initial genotypic mix and
therefore the potential for env amplification from single proviral copies. This was
confirmed by comparing the env PCR sensitivity with that of a V3 PCR using both
cloned HIV-1 DNA as template (Table 4.1) and proviral DNA isolated from tissue
obtained at autopsy from the right occipital lobe of an HIV infected individual with
evidence of encephalitis (Table 4.2). These results are consistent with those of a
study using similar conditions for HIV-1 env PCR, which found that the sensitivity
achieved was such that it could be used to amplify the env gene from a single
provirus (McClure et al., 2000). The direct sequencing of PCR products amplified at
limiting dilution provides a method to prevent both single nucleotide
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misincorporations and recombination in PCR and is therefore an extremely useful
approach for accurate genetic analysis ofHIV-1 env.
Use of limiting dilution PCR has several advantages in addition to the elimination of
in vitro recombination and sequencing errors due to nucleotide misincorporation.
Firstly, preferential primer binding to certain viral genotypes present in an original
mixed population can lead to an over representation of these sequences in the end
product of a PCR reaction (Kwok et al., 1990). If only one initial sequence is present
in the mix then there is no opportunity for "swamping" of the PCR reaction by other
variants. Another common problem with traditional cloning and sequencing
techniques is that of re-sampling of clones (Liu et al, 1996), this is the process
whereby several product clones from a sample are derived from the same initial
provirus. Re-sampling can be due the presence of few proviral copies in the initial
specimen, or because of disproportionate amplification of certain templates in the
PCR reaction as described above.
To formally address the issue of resampling frequencies, the sequence diversity
obtained by direct cloning using an adequate number of template molecules was
compared with that of limiting dilution PCR on the same DNA sample. The VI/V2
region of env was amplified using over 1000 proviral molecules as template then the
resulting PCR product was cloned. Eleven isolated clones derived from this single
PCR reaction were then fully sequenced. The probability of a single resampling
event occurring with this number of input molecules was less than 5.4%. For
comparison 9 limiting dilution env PCR products were amplified from the same
DNA sample and the V1/V2 region directly sequenced. Upon phylogenetic analysis,
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cloned sequences displayed reduced diversity compared to those obtained by limiting
dilution and close inspection of the nucleotide sequences revealed that clones
contained a median of 1 mutation per sequence compared with 7 for PCR products.
The reduced diversity was largely due to at least four of the cloned sequences being
representative of only a single original proviral sequence. These results therefore
demonstrate that inputting a large number of template molecules into a PCR reaction
does not guarantee that clones derived from that reaction would not represent a
restricted number of original sequences. One way to partially circumvent this effect
is to perform several separate PCR reactions from the same stock of sample DNA,
and mix these PCR products prior to cloning thereby assuring that resulting clones
reflect at least several original template molecules. This approach is useful when
sequences appear extremely similar and resampling of clones is suspected. For
example it has been used in a study examining HIV-1 envelope sequence evolution
in the setting of potent antiviral therapy (Gunthard et al., 1999), where a large
proportion of clones obtained from the C2-V3 region of env in three patients
undergoing antiretroviral therapy appeared identical. If the clones had not been
obtained from a mixture of 4 separately amplified PCR products then resampling
error would have been strongly suspected. However, this method ofmixing separate
PCR products prior to cloning does not prevent other problems such as
recombination in PCR and the incorporation of single nucleotide misincorporations.
A recent report (Liu et al, 2000) using a very similar env PCR to that described here
almost certainly contained cloned env sequences that were the result of resampling.
The report focussed upon env sequences obtained at autopsy from bone marrow,
lymph node, lung, and four regions of brain in addition to samples of blood
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monocytes collected 5 months prior to death of the study subject. Phylogenetic
analysis demonstrated that cloned sequences obtained from the brain deep white
matter grouped more closely with bone marrow and monocyte sequences than those
in the remaining areas of brain and other tissues. The authors interpretation of this
was that HIV infected bone marrow derived monocytes had entered the parenchyma
of the deep white matter, where they either transmitted infection to this site or were
retained themselves as perivascular macrophages. This evidence was used to propose
that increased or initiated monocyte trafficking into the brain occurred during late
stage infection and is a critical step in the development ofHIV dementia, an idea that
was later expanded in a review which cited the same sequence data (Gartner, 2000).
While this underlying hypothesis is plausible, there are a number of reasons for
believing that the sequences from deep white matter (5 clones), monocytes (4
clones), and the head of the caudate (5 clones) are each only representative of a
single provirus present in the original DNA samples. Firstly, no specific efforts were
made to avoid resampling of clones and no indication of the proviral titre in each of
the samples was given, although as the brain appeared grossly normal upon
pathological examination with no multinucleated giant cells present it is probable
that the viral load was low (Bell, 1998; Gray et al, 1996). Members of each group of
cloned sequences were also extremely similar with a mean number of nucleotide
differences/clone of 1.8 for deep white matter, 1.5 for monocytes, and 1.6 for head of
caudate. These figures are very similar to the 1.57 mean nucleotide mutations/clone
described here after env PCR from cloned template DNA. Furthermore all of these
identified differences were sporadic mutations not present in other clones, a
characteristic of polymerase misincorporation during PCR. Clone F7 from head of
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caudate did contain an additional single frameshift mutation which may genuinely
separate it from other sequences in the same sample, although such frameshifts can
also result from polymerase slippage in PCR (Viguera et al., 2001) most frequently
at sites ofDNA secondary structure.
In both this and the described study the Expand High Fidelity PCR system
(Boehringer Mannheim) was used for amplification of env by PCR, therefore a
similar number of polymerase misincorporations would be expected in each.
Moreover the env gene constitutes over a quarter of the viral genome, and HIV-1
undergoes approximately 1 mutation per replication cycle (Roberts et al, 1988;
Preston et al, 1988; Ji and Loeb, 1992; Mansky and Temin, 1995). A replicating HIV
population would thus be expected to contain at least a few mutations across the
entire env gene above the background number of polymerase misincorporations that
occur during PCR, even if these mutations arose solely by genetic drift. It is possible
that expansion of an infected lymphocyte resulted in the reported identical cloned
sequences, although this is unlikely to have occurred so uniformly in several separate
anatomical sites. The isolation of identical sequences (probably all derived from a
single proviral template) in PCR reactions using 1 pg of template DNA extracted
from tissue or cells (approximately 1.5 x 105 cells) as described in the study is
consistent with contamination of samples by a small number of infected cells from
peripheral blood. If this is the case then it is probable that any observed phylogenetic
groupings reflect the stochastic nature of sampling such small sequence numbers
rather than genuine biological events. This example of resampling error is not
unique, and the presence of resampling in sequence data sets can cause erroneous
estimations of viral diversity that may result in quite misleading conclusions
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regarding the tissue specificity of HIV. Indeed, the typical tree topologies obtained
when re-sampled sequences are included in phylogenetic analysis appear
superficially as one would expect if a genetically distinct "tropic" population of virus
were present within the sample, with large genetic distances between statistically
supported clades and very little diversity within them.
Although outwith the scope of the current study it worth noting that the amplification
of heterogeneous templates by PCR can also lead to other downstream difficulties. If
heteroduplex molecules are present at the end of a reaction and the product is cloned,
then in vivo repair in E. coli may also lead to the formation of chimeric molecules,
possibly by a mechanism involving mismatch repair (Shafikhani, 2002). This
provides further evidence advocating the use of limiting dilution PCR.
The obvious potential for misinterpretation of sequence data that may have been
subject to one or more of the in vitro artefacts described above clearly must be taken
into account when obtaining sequences for genetic analysis. Therefore limiting
dilution PCR was used to amplify env sequences for further investigation into the
possible tissue specificity of HIV-1. Nine limiting dilution env sequences were
obtained by this method from the right occipital lobe of brain, 8 from the left
temporal lobe, and 8 from a lymph node of subject NA021. V3 sequences from the
different regions were relatively similar with only 3 amino acid positions varying.
Two variable sites in the env alignment were perhaps indicative of adaptation to
infect cells in the brain. One of these was at position 301, an important residue for
CD4 binding (Kwong et al, 1998). Each of the brain sequences contained an
asparagine at this position as opposed to a valine or alanine in lymph node-derived
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sequences. Segregating mutations between brain and lymph node-derived HIV
sequences such as this (in CD4 or CCR5 binding domains of gpl20) may be
expected if adaptation to infect cells in the brain expressing lower levels ofCD4 and
CCR5 had occurred. Another possibly significant site where all but three of the
brain-derived sequences were distinct from lymphoid variants was position 215 in
the VIA/2 stem. Brain isolates had lost an N-linked glycosylation site in this position
(in a relative asparagine to aspartic acid change). The loss of this site had only been
documented in 7 of 208 subtype B env sequences in the Los Alamos National
Laboratory HIV Database and was therefore highly unusual. Loss of the same
glycosylation site was found to alter the position of the VI/V2 variable loops in HIV-
1 ADA Env, exposing the CCR5 binding site in gpl20 and facilitating CD4-
independent infection (Kolchinsky et al, 1999; Kolchinsky et al., 2001b). Gorry and
colleagues also used brain tissue from subject NA021, the same individual described
here (Gorry et al, 2002a; Gorry et al, 2001) (designated UKl-br in their studies), for
amplification of env sequences that were subsequently cloned and used in functional
analysis. The lacking N-linked glycosylation site at position 215 (corresponding to
position 197 in HXB2) described here was also identified in the 3 clones from the
brain of NA021 in their study. To investigate whether it contributed to increased
CCR5 affinity and/or CD4-independent CCR5 binding they restored this asparagine
in one of their clones by site-directed mutagenesis (Gorry et al, 2002a). However,
this restoration had no effect on the level ofCCR5 binding in the presence or absence
of soluble CD4, suggesting that loss of the glycosylation site at this position led to a
CD4-independent phenotype only in a strain specific manner and was not applicable
to the UKlbr-15 clone from NA021. Loss of a glycosylation site at position 215 may
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alone not be sufficient to confer increased CCR5 affinity. Yet the presence of an
asparagine at this site in all lymph node variants isolated from the same individual
provides some evidence for its potential importance in the context of this infection.
Given that the glycosylation site was present in virus elsewhere in the infected
individual and appeared to be specifically lost during viral replication in the brain,
this mutation is suggestive of specific adaptation. The same report comprehensively
characterised the brain-derived Envs and found that they induced both high levels of
fusion in monocyte-derived macrophages and neuronal apoptosis. In addition these
Envs also bound to CCR5 in the absence of soluble CD4 and required only low
levels of CD4 and CCR5 expression to mediate membrane binding and fusion in cell-
to-cell fusion and single round infection assays, although they could not mediate
CD4-independent infection. Virus in the brain of this infected individual therefore
appeared to represents a well-adapted, "neurotropic" HIV population. When coupled
with previous results (Chapter 3) implying that recombination had occurred between
pl7gag and V3 in this virus subpopulation, HIV variants from this study subject
appeared suitable for further investigation into the potential role of recombination in
the evolution ofHIV during viral expansion into new anatomical sites.
Obtaining entire env sequences at limiting dilution allows direct comparisons
between the evolutionary histories of different subgenomic regions to be made, as
opposed to these relationships being indirectly inferred using different small sections
of sequence obtained individually from the major viral variants present in each
anatomical site. Unfortunately, in most areas of evolutionary biology recombination
is notoriously difficult to identify unequivocally. One complication is that the
original ancestral strains may no longer be extant, and their contribution to
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contemporary organisms may be only small sections of sequence. Another is the
problem of defining which organisms represent ancestral genotypes and which are
recombinants. Taking the example ofHIV-1 group M subtypes, strains grouping with
the circulating recombinant form CRF_cpx (CY032) (previously designated subtype
I) are complex mixtures of subtypes A, G, K, and other unclassifiable areas. Yet if
the subtype I mosaic sequence had been isolated before subtypes A, G, and K then
this would have been defined as a subtype and A, G, and K termed complex
recombinants because they each contain regions of sequence similar to subtype I.
Defining a subtype in terms of its relative abundance is also unsuitable because
issues such as founder effects can lead to a recombinant becoming the most common
genotype in a population, for example the widespread presence of an A/E
recombinant now designated CRF01AE (CM240) (Robertson et al, 2000) in South
East Asia (Gao et al, 1996b). Thus "recombinant" must always be used as a relative
term unless the genotype of ancestral sequences is known. These difficulties are
compounded in the context of variants that have diverged within a single infection
where genetic distances are much smaller than found between subtypes and ancestral
sequences may be present in their original form as (probably defective) proviruses.
However, it is possible to assess the evolutionary relationships of different sections
from a single sequence with others isolated from several anatomical sites. If these
relationships differ across the sequence then the occurrence of recombination
between variants can be inferred. Methods for identifying intersubtype
recombination such as bootscanning (Salminen et al, 1995) were originally designed
for the classification of recombinant genomes with larger genetic distances between
original variants than generally found within single infected individuals. Issues such
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as the specific position of an outgroup become more important when similar
sequences are compared, therefore a new method based upon branching patterns of
unrooted trees coupled with a sliding window across the alignment was developed
for analysis of the env sequences isolated in this study.
Several env sequences were identified in this analysis where different sequence
sections had distinct evolutionary histories (Fig. 4.10 to 4.12), most likely as a result
of recombination. Thus providing further evidence for the frequent occurrence of this
mutational mechanism during HIV replication in the brain. These recombination
events did not necessarily occur directly between variants in the right occipital, left
temporal, or lymph node but possibly between HIV sequences closely related to
those present in two or more of these separate sites. All sequences were predicted to
use CCR5 on the basis of negatively charged or uncharged residues at positions 11
and 25 of the V3 loop, and this was confirmed with several RO Envs by construction
of pseudotype virus (see below). More subtle Env determinants of tropism may be
both complex and strain dependent, and are incompletely understood. Therefore the
question of whether the specific recombination events described here have any
functional significance is open to conjecture. None of the recombinant envs from
brain had lymphoid-like portions of sequence in V1/V2 or V3. It may be speculated
that progeny virus of such recombination events would be selected against, because
if viral adaptation occurs during infection of the brain then these subgenomic regions
are likely to contain at least some of the determinants of such tropism. The presence
of two right occipital like segments in sequences LT1 and LT2, including the V1/V2
region, and a left temporal like V3 region in R04, perhaps reflects the
interchangeability of these portions of sequence within brain adapted virus. This,
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along with other close associations and potential recombination events between the
RO and LT sequences suggests both the trafficking of virus between these two
regions of brain and the presence of similar selection pressures on viral Env
sequences in both of these sites. Such close relationships between virus present in
different brain regions also suggest that multiple re-seeding events from the
lymphoid system are not solely responsible for the origin and continued presence of
virus in different regions of brain.
A number of env sequences obtained from brain (R08, R09, LT1, and LT2)
contained segments that grouped more with those from lymph node than with other
brain sequences. The most obvious explanation for this is that lymphoid HIV variants
had entered the brain of this individual at some point and recombined with the HIV
population already in situ. Possible implications of such an event have been
discussed (Chapter 3). However it is worth restating that this provides strong
evidence against anatomical segregation between virus in the brain and lymphoid
system as an explanation of the frequently observed genetic differences between HIV
variants in these two sites. If temporal or spatial separation of variants at different
anatomical sites were significant factors in generating the observed genetic
segregation then other regions of the env gene would not be so easily interchanged as
described here. Also, recombination of this type provides a powerful mechanism for
HIV in the brain to selectively exchange advantageous characteristics such as
antiviral resistance or immune escape mutations with variants present in the
peripheral blood while maintaining their neuroadapted phenotype. All but one lymph
node sequence grouped strongly with others from lymph node, and this intra group
association was much more defined than within either of the brain sequence sets.
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One possible explanation is that infiltration of infected cells into the brain is
relatively common and there are greater opportunities for (the more abundant)
lymphoid virus to affect brain populations than the reverse. LN26 contrasted strongly
with the other lymph node-derived sequences by containing sections of brain-like
sequence. This sequence may represent a lymphoid variant that entered the brain and
recombined with virus already at this site, followed by the return of progeny virus
derived from this recombination event into the lymphoid system at a later time.
Alternatively recombination between a lymphoid variant with a brain-like and
probably macrophage tropic variant elsewhere in the body (such as the colon) may
have resulted in the observed genetic reshuffling. If the former is true then it lends
support to the possibility ofHIV from the brain of re-seeding of the lymphoid system
in patients upon cessation of antiviral therapy.
These results are derived from a single patient and while they are consistent with
those obtained in a similar but less comprehensive analysis of HIV subgenomic
regions in several other infected individuals (chapter 1) (Morris et al, 1999), and a
large number of other observations regarding recombination in HIV-1 (Jetzt et al,
2000; Sabino et al., 1994; Robertson et al, 1995; Gao et al, 1996b; Jung et al, 2002)
their generality has not been fully assessed. Also, the assumption made here is that
these recombination events occurred in the brain. However, none of these results
preclude the possibility that apparently brain specific sequences and recombinants
were originally generated in another anatomical site or cell subset followed by
multiple seedings of the brain by virus this site. Therefore the hypothesis of a
genetically distinct HIV population in the bone marrow being responsible for
multiple seeding of the brain during late-stage HIV infection, facilitated by increased
239
entry of blood monocytes into the brain parenchyma (Liu et al, 2000; Gartner, 2000)
cannot be discounted on the basis of this data. Yet the incompletely defined specific
anatomical sites in which the recombination events documented here occurred does
not detract from their potential biological significance in the evolution of viral
variants during a single infection. Importantly, had these env genes been obtained by
standard PCR and cloning procedures rather than by limiting dilution PCR then
recombination during PCR would have rendered any meaningful analysis of genuine
in vivo recombination events impossible. Likewise if these in vivo recombination
events had brought together new combinations of sequences leading to altered Env
phenotypes then these too would probably have been lost during PCR amplification
ofmixed proviral templates.
In order to circumvent each of the potential artefacts associated with PCR and
cloning of env genes described above, and to generate unadulterated env clones
suitable for subsequent phenotypic analysis a novel approach was undertaken. Using
standard cloning procedures the majority of env product clones are likely to contain
polymerase errors, even when a mixture of enzymes resulting in fairly high fidelity is
used such as described here. However, if ten clones are taken from the product of a
limiting dilution PCR reaction then there is a high probability that some will contain
no errors. In addition those errors that are present most likely will have occurred at
different nucleotide positions, because even if an error occurred in the first round of a
then PCR it will only be present in a quarter of the product clones. Moreover only
around 75% of the random nucleotide misincorporations will result in amino acid
changes in encoded proteins. Therefore the overall sequence of this consensus clone
will be identical to the one that was present in vivo and consequently if the consensus
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clones are used for translation then a significant proportion of the expressed protein
will be phenotypically identical to that present in vivo. The validity of this approach
was assessed by the generation of pseudotype HIV virus. Co-transfection of several
env consensus clones with an env defective proviral clone (pNL4.3Ae«vGFP) into
293T cells produced virus that could be used in a single round infection assay.
Pseudotype virus generated in this way was viable and used CCR5 in conjunction
with CD4 to enter cells (Table 4.3).
In summary the focus here on generating env sequences for analysis that are identical
to those present in vivo is particularly relevant at the present time where interest in
the field has shifted from simply identifying the receptors used by isolates to enter
different cell types to more subtle considerations. Identification of different
molecules that can be used as receptors by HIV-1 primary isolates (both known and
as yet undiscovered) is still an area of research that may yield interesting results. Yet
observations that the majority of primary viral isolates use either CCR5 or CXCR4
has led to a renewed interest in other factors that may mediate the perceived
differential cellular tropism ofHIV. For example by identifying not only the type of
receptor used but also the density of and conformation of these molecules required
by different primary viral isolates to adsorb and fuse with the host cell membrane.
The binding affinity of Envs to CD4 or coreceptors and the specific regions of the
coreceptor molecules used by distinct primary virus Envs is also under close
scrutiny. This type of analysis when used in conjunction with the careful profiling of
HIV-1 receptor expression patterns in different primary cell types, and in vitro
infection experiments using chimeric or pseudotype viruses, will provide a more
thorough understand of the in vivo tropism of HIV-1. A crucial consideration when
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performing these technically elegant investigations is to ensure that the viral
sequences used for analysis are a true representation of the original in vivo virus and
not the product of in vitro artefacts. Several of such artefacts were highlighted and
quantified here and means of eliminating them provided. HIV-1 envelope sequences
amplified at limiting dilution from the brain and lymphoid tissue were, overall,
genetically distinct, implying the presence of an adapted viral population in the brain.
The identification of segregation between brain and lymphoid isolates at two
positions in the env gene with potentially important roles in receptor binding
supports this assessment. However, such segregation is not evident across the env
gene and the evolutionary relationships between variants present in the right occipital
lobe, left temporal lobe and lymph node of this individual varied depending upon the
specific region of env analysed. Such complex interrelationships imply that
recombination is a frequent event during the evolution of HIV in the brain and that
anatomical separation of variants in the brain and the lymphoid system is far from
complete. Therefore genetic differences between HIV in the brain and the lymphoid
system are likely to represent adaptive viral evolution.
Finally, a severe instability of clones containing the env open reading frame was also
identified during the course of this study (Fig. 4.15), both during initial cloning
procedures and after the re-growth of clones from glycerol stocks containing
previously verified complete env inserts. This observation is consistent with several
previous studies indicating that lentiviral env gene clones are unstable when
propagated in E. coli (Peden, 1992; Cunningham et al, 1993; Wang and Mullins,
1995), possibly as a result of uninduced expression of the toxic env gene product in
bacterial cells (Cunningham et al, 1993). Instability may be manifest as point
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mutations, insertions, deletions, and sequence rearrangements (Cunningham et al,
1993). It is entirely possible that these issues may lead to the generation or
preferential isolation of env clones with stop codons or frameshifts. Such changes
were perhaps present in previous studies and could have direct implications in for
example the estimation of frequencies of defective provirus and their significance in
HIV infection. In extreme cases envs with strong cryptic E. coli promoter activities
or particularly toxic gene products may be completely refractory to isolation by
standard cloning procedures. Given the focus here on obtaining genuine in vivo
sequences the unpredictable alteration of env sequences in E. coli is far from ideal. A
more suitable approach in cases like this would be to dispose of all steps involving E.
coli in the production of open reading frames suitable for expression in eukaryotic
cells. This is the subject of Chapter 5.
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Chapter 5: Results (iii)
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5.1 Introduction
Efficient expression of recombinant proteins in eukaryotic cells requires the use of
DNA for transfection that contains an upstream promoter and a downstream
polyadenylation (poly [A]) signal flanking the gene of interest. These sequences
allow transcription and translation of the open reading frame when large amounts of
DNA (typically >1 pg) are transfected into eukaryotic cells. In general, to produce
this DNA a gene is first cloned into an expression plasmid then expanded in E. coli,
yeast, or other host cell before re-purification. The genetic instability in clones
containing the HIV-1 env gene during propagation in E. coli described in Results
chapter 4 strongly suggested that this method was not ideal as a means of generating
DNA for subsequent phenotypic analysis of primary HIV-1 Envs. This identification
of deletions or rearrangements in E. coli of plasmids containing specific inserts is far
from unique.
One of the difficulties in cloning the cystic fibrosis transmembrane conductance
regulator (CFTR) was the presence of a cryptic bacterial promoter within the CFTR
gene sequence. The result was unintended expression of the toxic gene product in E.
coli and exclusive isolation of extensively rearranged clones. A stable plasmid
containing the complete gene was only obtained by the construction of a
complementary DNA in a low-copy-number vector (Gregory et al., 1990). Similarly
the presence of a cryptic bacterial promoter in the hepatitis C virus (HCV) genome
led to the preferential cloning of defective viral sequences, with stop codons or
prematurely truncated inserts present in the vast majority of isolated clones (Forns et
ah, 1997). Insertion of extra nucleotides upstream of the start codon of the HCV
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insert led to a significant increase in the number of fully functional clones.
Nonrandom selection of clones from an initially diverse population such as in this
case can lead to false interpretations of virus diversity and an erroneous estimation of
the frequency of defective viral genomes in vivo. In the context of lentiviruses a
number of previous reports have demonstrated that both full-length proviral clones
and individual env gene clones are unstable in E. coli. One report identified a large
number of deletions when amplifying HIV proviral clones in high copy number
plasmids, and suggested the use of medium-copy-number plasmids to circumvent
this difficulty (Peden, 1992). A subsequent report demonstrated that meduim-copy-
number vectors were also unsuitable to maintain the integrity of the simian
immunodeficiency virus (SIV) and equine infectious anemia virus (EIAV) env clones
and advocated the use of low-copy-number plasmids instead, although this greatly
reduces plasmid yield (Cunningham et al, 1993). The same report also identified a
cryptic bacterial promoter sequence present at the beginning of lentiviral env genes,
leading to the unintended expression of these toxic gene products. The toxicity of
membrane protein genes including fragments ofHIV-1 env cloned in E. coli has been
well documented (Rose and Shafferman, 1981; Samuel et al., 1988). It is therefore
unsurprising that if basal levels of lentiviral Envs are unintentionally expressed in E.
coli then they would have a toxic effect leading to the preferential isolation of altered
plasmids or defective inserts. Thus it is entirely possible that cloning and propagation
in E. coli ofHIV-1 env genes leads to the preferential isolation or de novo generation
of coding sequences with stop codons, deletions, ffameshifts, and other functionally
deleterious mutations. This issue may have been a factor in the large number of
apparently non-functional env open reading frames identified in previous studies
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based upon cloning of full-length H1V-1 env genes (Gorry et al, 2001; Liu et al,
2000).
In addition to the unintended expression of toxic gene products, a number of other
factors may make initial cloning procedures difficult and time consuming. For
example unusual G+C content or the presence of internal repeats (Yamada et al.,
1995) may also make the introduced gene unstable or prone to deletion or
rearrangement. The sequence to be expressed may lack suitable restriction sites, start,
or stop codons to allow the intended gene to be inserted appropriately into an
expression cassette. Apart from the potential adulteration of cloned sequences, the
cloning procedure itself can take several days and requires an array of specialist
equipment and several lengthy stages of skilled worker input. Because of these
limitations, accurate phenotypic analysis of variable gene products may take
extended periods of time.
These difficulties are especially significant when analysing the cellular tropism
conferred by different HIV-1 Envs derived from primary virus for several reasons.
Firstly, the identification of a certain number of non-functional sequences derived
from defective virus present in vivo would be expected, given the error prone
replication ofHIV, making deleterious mutations introduced during cloning difficult
to separate from genuine in vivo sequences. Secondly env gene sequences may vary
extensively within single infected individuals and the sequence signatures and
consequent molecular contortions within Envs leading to differential cellular tropism
are incompletely understood. Therefore if important residues were lost or altered
during the amplification process it may go unnoticed upon inspection of nucleotide
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or amino acid sequence data obtained from clones. Thirdly Env expression is toxic in
many eukaryotic cell types and if genes are not fully sequenced prior to phenotypic
analysis then apparent failure to express artefactually truncated or otherwise
adulterated sequences derived from passage through bacteria may be mistaken for
toxicity of env gene products in these eukaryotic cells. Use of limiting dilution PCR
for amplification of env sequences from biological samples avoids many of the
artefacts associated with PCR and cloning procedures such as recombination and re¬
sampling (Chapter 4). However, developing strategies to negate the effects of
polymerase induced single nucleotide misincorporations present in clones derived
from PCR products is also important for thorough analysis.
Given the limitations of standard cloning techniques outlined above a rapid method
for attaching promoter and poly (A) sequences to PCR products that does not require
propagation in E, coli or other cells before transfection into eukaryotic cells would be
extremely useful. One report describes such a procedure (Sykes and Johnston,
1999), whereby a gene, a promoter, and a polyadenylation signal, were separately
PCR amplified with primers containing a 12bp to 15bp complementary stretch in
which deoxyuridines were incorporated every third position. The PCR products were
then treated with uracil-DNA glycosylase to excise uracil residues, therefore
providing complementary overhangs suitable for linking the separate PCR products.
Resultant DNA was found to be suitable for transfection directly into both mice and
cells in culture and resulted in expression of the introduced gene. This approach,
while novel, provided fairly poor purity of the final product DNA. We therefore
proposed to develop an alternative method for generating this promoter-gene-poly
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(A) DNA and tested its efficacy in expression of a variety of genes including HIV-1
env.
5.2 Aims
1) To develop a rapid method for the generation of large amounts of coding DNA
with the appropriate promoter and poly (A) sequences attached for expression in
eukaryotic cells without the use of cloning and plasmid expansion in E. coli.
2) Assess the functionality of standard reporter genes when modified in this way by
direct transfection into eukaryotic cells followed by analysis of gene expression.
3) To assess and improve the general robustness of this method by using open
reading frames of different sizes, and requiring more complex post translational
modifications, including HIV-1 env amplified at limiting dilution by nested PCR
from small samples of biological tissue.
5.3 Materials and methods
As described in chapter 2.
5.4 Results
5.4.1 Assessment of linear PCR product DNA for transient
gene expression
The proposed strategy involved the use of PCR and overlap extension reactions to
create the appropriate DNA for direct transfection (see below). It has been previously
noted that in eukaryotic gene expression experiments supercoiled plasmid DNA is
more efficient at inducing transient gene expression, perhaps because DNA in this
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conformation interacts with chromatin and is expressed in a similar manner to a
cellular gene. In contrast linear DNA may be more recombinogenic and so more
suitable for stable gene expression after integration into the host cell genome
(Cepko, 2001). In order to assess the efficiency of linear, PCR generated DNA in
producing transient gene expression in eukaryotic cells the entire promoter-EGFP-
poly (A) segment of pEGFP-Cl was amplified by PCR (Fig 5.1). The resultant 1600
bp amplicon therefore contained the cytomegalovirus immediate early (CMV IE)
promoter attached to an enhanced green fluorescent protein (EGFP) open reading
frame (ORE) followed by an SV40 poly (A) sequence. This PCR product was
purified using a spin column and 1 pg of the resultant DNA electroporated into 293
T cells. Two days after electroporation the cells were observed under a fluorescent
microscope and high levels of gene expression was observed. Negative control
electroporation reactions containing either no DNA or dilutions of pEGFP clone
equivalent to those that would be present at the end of a PCR reaction were also
performed and resulted in no fluorescence (data not shown). This verified that
positive results were due to PCR product expression and not expression of small
amounts of original template clone carried through the PCR reaction.
5.4.2 Development of PCR expression constructs
Given the efficient gene expression of linear PCR products, a strategy for producing
PCR expression constructs was undertaken and tested for various ORFs. The process
of ligating a PCR product into a vector is seldom 100% efficient and a certain
amount of vector self-ligation occurs even when the 5' phosphate in the reaction is
contributed by the PCR product to ensure correct orientation of insert as described
here (refer to section 2.8).
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I PCR Amplfied Promoter-EGFP-poly (A)
100 bp 1Kb
Product Marker Marker
1.6 Kb PCR product 1500 bp
Electroporated into 293T cells
Figure 5.1. Expression of PCR product in 293T cells. The 1600
bp Promoter-EGFP-Poly (A) portion of pEGFP-Cl was amplified by
PCR then transfected into 293T cells by electroporation. EGFP protein
expression was assessed after 2 days by visualisation of cells under a
fluorescent microscope (original magnification: x 40).
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Hence if a ligation reaction product is used directly as template in a PCR reaction
from the start of the promoter to the end of the Poly (A) signal, spanning the multiple
cloning site, the vast majority of resulting PCR product is derived from self-ligated
vector. This is due to the amplification process being more efficient in the shorter,
self-ligated vector, than in ligation products containing appropriate inserts. The effect
becomes more apparent as longer inserts are amplified, and with inserts over
approximately 1 Kb no visible product corresponding to the promoter-insert-poly (A)
sequence is present (data not shown). Therefore an alternative approach was
employed. A schematic diagram of all amplification steps in the process is provided
(Fig. 5.2). The validity of this approach was then tested by generating PCR
expression constructs using several different genes. Open reading frames were
amplified then ligated into pCR3.1 unidirectional vector, an expression vector with
the multiple cloning site flanked by the immediate early promoter of CMV and the
bovine growth hormone (BGH) poly (A).
These sequences allow the transcription and translation of a cloned gene when large
amounts of plasmid DNA are introduced into eukaryotic cells. Generally, in order to
generate enough DNA for transfection the plasmid must first be transformed into and
amplified in E. coli before re-purification. Here the ligated insert was diluted and
then two overlapping fragments amplified by PCR. Fragment A consisted of the
promoter and start of the gene of interest, and fragment B incorporated the end of the
gene along with the poly (A) signal. PCR products A and B were mixed with a DNA
polymerase and dNTPs then subjected to thermal cycles allowing extension of the
mixed fragments resulting in the production of a single promoter-Gene-poly (A)
product.
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Figure 5.2. Schematic representation of amplification
steps used in production of PCR expression constructs.
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This template was amplified with primers at the ends and the resultant product then
purified and concentrated by standard spin column purification to remove unwanted
reagents in the PCR mixture such as primers and detergent. The final products
therefore consisted of the gene of interest with the appropriate sequence information
attached for expression in eukaryotic cells.
EGFP
The EGFP gene was amplified by single round PCR using the plasmid pEGFP-Cl as
template. The antisense PCR primer was modified from vector sequence to
incorporate an amber (TAG) stop codon. A PCR expression construct was generated
as shown (Fig. 5.3.A) with the same sense and antisense primers used for initial
amplification also used in production of PCR products B and A respectively. The
final product generated was not ideal (Fig. 5.3.B), with several non-specific bands
also present at concentrations nearly equivalent to that of the desired product.
However, the purity of this construct was broadly equivalent to that achieved in a
report describing a similar approach (Sykes and Johnston, 1999). This construct was
then electroporated into 293T cells in parallel with appropriate controls and cells
were assessed for EGFP protein production after 48 hours. Half the amount (0.5 pg)
of EGFP linear expression construct was used in transfection compared to the
pEGFP-Cl positive control to compensate for additional non-coding sequences
present in the vector but not in the PCR construct. EGFP expression was observed in
both cells electroporated with pEGFP-Cl control plasmid and with the PCR





























Figure 5.3. EGFP PCR expression construct. A) Schematic representation
of primer binding sites and amplification steps, primers are underlined. B)
Final EGFP PCR expression construct used for transfection. Lane 1: 1 Kb
DNA marker, Lane 2: 100 bp DNA marker, Lane 3: PCR expression construct.
C) 293T cells 48 hours after electroporation with EGFP PCR expression
construct (PCR product), pEGFP-Cl clone (positive control), or water
(negative control). Original magnification: x 10.
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Luciferase
The Firefly luciferase (luc+) gene was amplified by single round PCR using the
pGL3-control (Promega) plasmid as template. To improve the specificity of the
amplification process compared with EGFP and to avoid preferential amplification of
truncated, ligated PCR products the luciferase PCRs A and B were performed using
primers binding 10 bp in from the ends of the insert along with the relevant vector
primers (Fig. 5.4.A). The products ofPCR A, PCR B, the extension reaction, and the
final PCR expression construct are shown (Fig. 5.4.B). The purity of the final
product was therefore enhanced by the altered primer positions. This construct was
transfected into 293T cells and these cells assayed after 48 hours for luciferase
activity. Again half the amount of PCR construct (1 pg) was added compared to
positive (pGL3-control) and negative (pGL3-basic) control vectors. The entire
process was repeated in three independent experiments. Results of the luciferase
assay are shown (Fig. 5.4.C).
For each DNA dilution luciferase activity in cells electroporated with the luc+ PCR
generated expression construct was approximately 100 fold that found in cells
electroporated with positive control plasmid.
HIV-1 nef
The HIV-1 nef gene was amplified by nested PCR from brain tissue obtained at
autopsy from the right occipital lobe of an HIV infected individual displaying giant
cell encephalitis (NA021). Approximately 600 proviral templates were present in this
reaction as determined by PCR using V3 primers.
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Figure 5.4. Luciferase PCR expression construct. A) Schematic representation
of primer binding sites and amplification steps, primers are underlined. B) PCR
products Lane 1: 1 Kb DNA marker, Lane 2: PCR A, Lane 3: PCR B, Lane 4:
extension reaction product, Lane 5: final construct, Lane 6: 100 bp DNA marker. C)
Luciferase assay result. 293T cells were analysed for luciferase activity 2 days after
electroporation with different amounts of positive control clone (pGL3-control),
negative control clone containing no promoter or poly (A) signal sequences (pGL3-
basic), or luc PCR expression construct. Error bars represent the standard error of
three independent experiments where control clones were re-isolated from fresh
stocks and PCR expression constructs were generated using the newly isolated
positive control vector pGL3-control as template.
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In order to determine the robustness of the extension step the nef gene insert was
amplified using one primer binding 5bp into the gene for PCR A, and one binding
near the centre for PCR B, along with the appropriate primers in the vector, thus
providing the smaller 400 bp overlap for subsequent extension (Fig. 5.5.A). Nef
protein production was assessed using a Nef specific monoclonal antibody for
immunocytochemical staining. Staining was evident on 293T cells transfected with 1
pg of the nef PCR product but not on negative control cells two days after
electroporation (Fig. 5.5.B).
HIV-1 env
HIV-l env was amplified by limiting dilution nested PCR using the same DNA
sample as for the nefgene above. The original env PCR product was approximately 3
Kb in size and in order to circumvent potential problems with amplifying a gene of
this size along with promoter or poly (A) sequences the PCRs A and B for this gene
were each designed to be less than 3 Kb in length but allow a 400bp overlap for
extension reaction (Fig. 5.6.A).
The final reaction product consisted of a discrete band at approximately 4 Kb (Fig.
5.6.B). Determining whether a fully functional HIV-1 envelope protein had been
produced after transfection into eukaryotic cells required a more complex assay
system. This protein undergoes a number of post-translational modifications
including cleavage of gpl60 into gpl20 and gp41 and extensive glycosylation,
resulting in the presence of fully functional proteins on the surface of progeny
virions. A viral pseudotype assay as described in chapter 4 was therefore undertaken
allowing assessment of Env protein functionality when DNA for transfection was
generated by production of PCR expression constructs.
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Figure 5.5. Nef expression. A) Schematic representation of primer binding
sites and amplification steps, primers are underlined. B) 293T cells were
electroporated with water or a nef PCR expression construct and stained 48
hours later by immunocytochemistry using Nef specific monoclonal antibodies.
Original magnification: x 40.
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Figure 5.6. Env expression.
A) Schematic representation of primer binding sites and amplification steps. Primers
are underlined.
B) Gel picture of amplification products. Lane 1: 1 Kb DNA marker, Lane 2: PCR
A, Lane 3: PCR B, Lane 4: extension reaction product, Lane 5: final construct,
Lane 6: 100 bp DNA marker.
C) Infected CD4 and CCR5 expressing NP2 cell viewed under a fluorescent
microscope 48 hours after addition of pseudotype virus created with an env PCR
expression construct. GFP in place of nef in the env defective proviral backbone is
expressed upon infection of a new cell.
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Pseudotype virus was produced using envelopes generated with PCR expression
constructs and this virus was used for infection of standard indicator cell lines (NP2)
expressing the HIV receptors CD4 and CCR5. Pseudotype virus generated with PCR
expression constructs was viable, and an example of an NP2 cell expressing CD4 and
CCR5, and infected with virus produced in this way is shown (Fig. 5.6.C). A
comparison of single round infection assay results using PCR expression construct
generated env pseudotype virus with that constructed using consensus-cloning
procedures (chapter 4) on the same sequences is provided (Table 5.1). It should be
noted that these two experiments were performed at different times, and a
standardised amount of harvested pseudotype virus was not added to target cells.
Therefore the comparison serves only to show that infectious pseudotype virus can
be created from identical sequences using both techniques, and does not provide any
information on the relative infectivity of virus produced with the different env
sequences or using the different techniques. Positive control YU2 envelope
expressing virus produced approximately 100 to 1000-fold more foci of infection
than that generated with patient derived Envs.
This disparity may reflect improved HIV gene expression when driven by the
truncated HIV LTR promoter in the pSVIII vector as compared with the CMV IE
promoter in pCR3.1.
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Sample* Clone PCR Expression construct
ROl 2.1 x 103 1.2 x 103
R03 1.75 x 103 6.5 x 102
R06 4.1 x 102 2.8 x 102




Table 5.1. Infectious titre of pseudotype virus on NP2 cells
expressing CD4 and CCR5. Comparison of virus generated with env
consensus clones (chapter 4) and PCR generated expression constructs
made from the same sequences. Numbers correspond to focal forming
units/ml. * RO: limiting dilution env PCR products as described in chapter
4, YU2: control clone from CCR5-using HIV-1 isolate.
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5.5 Discussion
The procedures described here present a rapid, simple, method for the generation of
large amounts of an open reading frame (ORF) flanked by the promoter and poly (A)
sequences necessary for expression in eukaryotic cells without the need for prior
amplification in bacterial cells. Initial transfection experiments using a promoter-
EGFP-poly (A) fragment amplified as a single PCR product from a control plasmid
demonstrated that PCR generated, linear DNA was suitable for gene expression in
eukaryotic cells (Fig. 5.1). Consequently we designed a technique for generation of
such an expression construct directly from ligation reaction products by PCR and
overlap extension procedures (Fig. 5.2). An EGFP PCR expression construct was
then generated by this method (Fig. 5.3) and green fluorescent protein expression
after electroporation into 293 T cells compared with that of the positive control clone
pEGFP-Cl (Fig. 5.3.C). This illustrated that sequences modified and amplified in
this way were suitable for producing gene expression in eukaryotic cells at similar
levels to the parental positive control clone. Amplification of luc+ PCRs A and B
using primers that bind 10 bp inside the original PCR product improved the
specificity of the amplification process and therefore the purity of the final product
(Fig. 5.4). Luciferase results provided quantitative data on gene expression, with
100-fold activity detected in cells transfected with luc+ PCR expression construct
when compared with cells transfected with the pGL3-control positive control clone.
This large difference in expression levels was consistent in three completely
independent experiments and is likely to reflect improved activity of the CMV IE
promoter in 293T cells when compared with the SV40 promoter present in the pGL3-
control plasmid. Possibly the altered DNA conformation (linear PCR product DNA
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compared with covalently closed circular supercoiled plasmid DNA) was also a
factor in the differing level of gene expression. In any case large amounts of
luciferase activity were detected, demonstrating high levels of protein production in
transfected cells. These results also demonstrated that this approach could be used for
expression of the 1649 bp luc+ gene as well as the shorter 723 bp EGFP gene.
To assess the efficacy of using this procedure for analysis of HIV-1 gene products
the HIV-1 nef and env genes were amplified and tested using a similar process.
Amplification of the HIV-1 nef gene by nested PCR using template DNA extracted
from autopsy tissue followed by production of an expression construct established
that the procedure was indeed suitable for use with genes amplified from small
amounts of biological tissue. Generation of this construct was undertaken using a
primer for PCR A that binds near the centre of the gene, indicating that a relatively
small overlap of 400 bp between PCRs A and B is sufficient for an efficient
subsequent extension reaction. Clearly the use of DNA containing several hundred
original templates may make this reaction subject to recombination during PCR.
However, this would not be significant if the process were to be used on non-variable
genes. Also, in some cases an average phenotype from a population of sequences
may be all that is required, or a quick screen of a large selection of variable genes to
identify the presence of some with a desired property. Nef protein expression was
observed by immunocytochemistry using a Nef specific monoclonal antibody in cells
electroporated with a nefPCR expression construct but not in negative control cells
electroporated in the absence of DNA (Fig. 5.5). Finally, production of functional
pseudotype virus using an env PCR expression construct demonstrated that the
system could be used to produce a fully functional viral envelope protein requiring
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complex post translational modifications using DNA amplified from biological
samples. Therefore the procedure is suitable for use in phenotypic analysis of HIV-1
Env proteins without the possibility of alterations in E. coli. Moreover when used in
conjunction with original PCR amplification at limiting dilution then any deleterious
effects of polymerase misincorporation during PCR are negated (the rational for this
is as for generation of consensus clones in chapter 4). One possibly important issue
in the method described for amplification of nef and env PCR expression constructs
is that some of the primers used were specific for areas in the centre of the original
PCR amplicon. Primers placed in this way may lead to the formation of chimeric
molecules if genetically distinct sequences are present at the end of a PCR reaction,
such as probably would be the case in the nefPCR reaction described. Also, even if
the original PCR is amplified at limiting dilution as for the env gene here then the
central primer sequences used for amplification of PCRs A and B would be
incorporated into the final construct. The primers used here were designed to
correspond to fairly conserved regions of env, and these experiments intended only
as proof of principal. Nevertheless in future a more rigorous approach would be to
use primers for PCR A and B that are only 5 or 10 bp from the ends of the original
amplicon as described for «e/PCR A the luc+ gene.
In addition to providing a means for expressing genes in eukaryotic cells that are
toxic in E. coli and thus may be refractory to standard cloning procedures, the
method described here has a number of other advantages over more established
techniques. DNA suitable for transfection can be produced in a single working day.
Also, the specialist worker knowledge and array of equipment needed for bacterial
cloning procedures are not required. If variants of the same gene are to be
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phenotypically analysed then a single promoter and poly (A) pair, designed with
appropriate extensions corresponding to the ends of the gene could be used for
generation of expression constructs for all variants of that gene, thereby negating the
need for ligation into a vector and amplification of overlapping fragments before
overlap extension. One obvious potential application of this technique is in the
phenotypic analysis of resistance to antiviral agents.
HIV-1 entry inhibitors including those that specifically target HIV-1 Env are
currently under development, and should soon be available for treatment of infected
individuals (D'Souza et al., 2000). In clinical trials, use of the fusion inhibitor T20
effectively reduced plasma HIV RNA in infected individuals (Kilby et al., 1998).
However, an escape mutant to a fusion inhibitor has been identified in tissue culture
(Rimsky et al., 1998), and it would be expected for similar resistance mutations to
arise in virus within treated patients. As more elaborate cocktails of antiviral agents
are targeted towards Env, it is probable that mutations in env that confer drug
resistance will become increasingly complex, as has been the case with other HIV-1
protein targets for antiviral therapy (Jacobsen et al, 1995; Winters et al, 1998; Larder
and Kemp, 1989; Richman et al, 1994). It may therefore be expected for phenotypic
assays to be required for the complete characterisation of drug resistant viral
phenotypes. The rapid generation of envelope sequences suitable for phenotypic
analysis without the requirement for cloning as described here may prove useful in
the context of these future applications.
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Chapter 6: Final discussion
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The genotypic and phenotypic characteristics of HIV-1 within the brain remain
incompletely defined. Many factors could lead to the apparent tissue specific
compartmentalisation often observed in individuals with AIDS and HIVE (Epstein et
al, 1991b; Epstein et al, 1991a; Haggerty and Stevenson, 1991; Korber et al, 1994a;
Pang et al, 1991; Chang et al, 1998; Donaldson et al, 1994a; Gartner et al, 1997;
Gorry et al, 2001; Hughes et al, 1997a; Shapshak et al, 1999). Similarly, evidence for
the role of recombination between strains that have diverged within a single infected
individual is currently confined to a limited number of studies (Jung et al, 2002;
Dykes et al, 2000). One aim of this project was to search for evidence of
recombination between the apparent tissue-specific variants in the brain and
contemporary HIV-1 sequences present in the lymphoid system of the same
individuals, thus providing information on both of these important issues.
Factors that could in principal lead to the development of a separate virus population
in the brain include physical isolation of the two populations and differences in virus
turnover rates in the two compartments. Alternatively, the genetic segregation may
be a result of adaptation to the particular microenvironment and available host cells
within the brain. If this is the case then lymphoid variants may enter the brain with
relative ease, but be poorly equipped for prolonged survival in the unique
environment of the CNS. These newly infiltrating lymphoid variants could
circumvent such a restriction by recombining with virus already in situ, and
acquiring the necessary sequences for neuroadaptation while retaining "lymphoid-
like" sequence segments elsewhere in their genomes.
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To address these possibilities, and obtain a broad overview of the sequence
relationships manifest in different areas of the viral genome in brain and lymphoid
tissue, consensus sequences (and in one study subject representative clones) were
obtained corresponding to the pl7gag and V3 HIV-1 subgenomic regions. These
sequences were recovered from several different areas of brain and the lymphoid
compartment of four study subjects with evidence of HIVE upon autopsy.
Synonymous mutations in the pl7gag region had previously been demonstrated to
accumulate at a relatively fixed rate over time, and could therefore be used as a
molecular clock (Hughes et al, 1997b; Wang et al, 2001; Holmes et al, 1993; Kasper
et al, 1995). In two study subjects the lineage in pl7gag that contained lymphoid
sequences was separate from most brain-derived pl7gag sequences, allowing mean
synonymous pairwise J-C distances to be calculated, and the approximate divergence
time of the two populations to be estimated. In two individuals this divergence time
preceded the onset ofAIDS, perhaps suggesting a pre-AIDS entry of HIV-1 into the
CNS of these study subjects.
Further information was obtained from the observed phylogenetic relationships
between viral variants present in different anatomical sites. In an asexually
reproducing population where recombination has not occurred, one would expect for
the sequence relationships between different isolates to be the same regardless of the
genomic region analysed. This assumption is of course subject to the requirement
that the genomic regions in question must contain a sufficient number of nucleotide
differences to be phylogenetically informative. In each study subject, the
relationships between proviral sequences from different anatomical sites differed
depending upon whether V3 or pl7gag sequences were being compared. The most
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obvious explanation for these discordant phylogenetic relationships is the occurrence
of recombination at a point in the viral genome between the pl7gag and V3 regions.
An association was also noted between the sequence divergence in V3 both within
brain and between brain and lymphoid virus, and the severity of HIVE. This may
reflect increased genetic drift in V3 sequences within the brain, permitted by a
weaker anti-HIV humoral immune response in the CNS.
In order to further characterise the role of recombination during HIV-1 infection of
the brain it was necessary to obtain longer sequences from single proviruses present
in different anatomical sites. The env gene was chosen for this application, as it was
most likely to contain the determinants of differential HIV-1 cellular tropism, and
was of sufficient length to potentially contain both "brain-like" and "lymphoid-like"
segments of sequence. The standard method for obtaining sequences such as this is
by PCR amplification of a large number of template molecules in a single reaction,
followed by molecular cloning of the PCR products. A number of experiments
designed to assess the validity of these techniques demonstrated that they were
unsuitable for the purpose of obtaining sequences to study in vivo recombination. For
example recombination during PCR amplification of an approximately 3 Kb genomic
region encompassing the env gene was found to occur at a very high level, and would
make the task of identifying natural recombinants impossible. Hence, env genes for
the detection of recombinants were all amplified by limiting dilution PCR.
Sequences were obtained from lymph node 2, and both the right occipital and left
temporal brain regions of study subject NA021. While it is difficult to unequivocally
identify recombinants unless the genotype of the parental sequences is known, the
complete sequences used in this study did cluster broadly into phylogenetically
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distinct groups. It was therefore possible to use a sliding window approach to
compare the phylogenetic affinity of 500 bp segments along the length of a single
sequence with all the remaining sequences in the three groups. If the phylogenetic
affinity switched from one group to another, then that sequence was deemed likely to
be a recombinant. In this way several env recombinants were identified, where in one
area of the env gene they were almost indistinguishable from lymphoid variants, and
in another they were closely related to variants in one of the regions of brain.
Interestingly, no sequence from brain grouped with lymphoid sequences in the VI-
V3 region of env, perhaps reflecting the importance of this subgenomic region as a
determinant of HIV-1 cellular/tissue tropism (Chesebro et al, 1991; Hwang et al,
1991; Fouchier et al, 1992; Speck et al, 1997; Carrillo and Ratner, 1996; Shioda et al,
1991; Martin et al, 2001). In several cases, switches in phylogenetic affinity from
members of one brain region to members of the second brain region was also evident
in different segments of the same sequence, suggesting recombination between viral
variants present in anatomically distinct areas of brain. Again, if viral variants from
different sites can recombine with one another, then they must have at some point
infected the same cell. Therefore these results suggest some spreading or movement
ofHIV within the brain, allowing variants that had diverged previously to come into
close proximity and recombine.
Together these results have several implications. Firstly, it appears that
recombination between variants that have diverged within a single infection is a
common event. This high level of recombination is perhaps to be expected, given the
global prevalence of recombinant HIV genomes (Liitsola et al, 1998; Gao et al, 1998;
Liitsola et al, 2000; Montavon et al, 1999). However only a limited number of
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studies have attempted to identify recombinants between closely related variants as
described here (Brown and Cleland, 1996; Jung et al, 2002). Recombination such as
this may bring together separate constellations of mutations associated with drug
resistance, allowing the outgrowth of resistant virus much more rapidly than if each
had to be acquired by the step-by-step accumulation of single mutations. In the
context of HIV-1 and the brain, the identification of brain/lymphoid recombinants
suggests that the two compartments may not be as physically separated as previously
supposed. If lymphoid variants are able to access the brain and recombine with virus
already present, then it appears unlikely that the genetic compartmentalisation often
seen between brain and lymphoid variants could be due to physical isolation or
differences in viral turnover rates in the two compartments. Therefore regions of the
viral genome that do demonstrate tissue specific groupings (generally the VI-V3
regions of env) are likely to be genetically distinct for a reason. If there were no
selective advantage associated with these sequences in the brain then it would be
expected for them to be replaced by, or mixed with, the lymphoid variants that
appear to be able to enter and exchange other subgenomic regions by recombination.
Recombination between the two populations could also allow virus in the brain to
acquire advantageous mutations such as cytotoxic T lymphocyte escape mutations, or
antiviral resistance mutations, while still retaining their neuroadapted phenotype. The
reverse could also be true, with the poor penetration of many antiretroviral agents
into the CNS potentially providing an optimal environment for the generation HIV-1
variants with resistance to antiviral drugs (Lewis et al, 1996; Yarchoan et al, 1988). It
has been suggested that a neuroadapted HIV-1 env phenotype may involve an
increase in coreceptor affinity at the expense of a higher susceptibility to antibody
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neutralisation (Gorry et al, 2002a; Martin et al, 2001). Thus a neuroadapted viral
phenotype may be poorly adapted for replication in the lymphoid system. In this case
drug resistance mutations that have evolved in the brain could potentially be acquired
by lymphoid variants via recombination and carried back to the lymphoid system.
Mutations in env that affect receptor interactions, cellular tropism, and potentially
tissue tropism are often highly complex and strain dependent. Apart from the
frequent, but not complete, association between particular amino acid residues in V3
and CXCR4 usage (Speck et al, 1997) it is not possible to predict the phenotype of a
particular Env from the primary nucleotide or amino acid sequence. This is
especially significant in the context of HIV-1 in the brain, where potential
neuroadaptation and neurovirulence does not appear to be due to a change in
coreceptor usage. The limited numbers of comprehensive studies into interactions
between brain-derived Envs with HIV-1 cellular receptors suggest that determinants
of neurotropism may be subtle. For example they may include increases in receptor
affinity and alterations in the specific manner that coreceptors are used, which are
conferred by mutations in a complex and strain specific manner (Gorry et al, 2002a;
Martin et al, 2001). These caveats make it of paramount importance that HIV-1 env
sequences analysed for particular phenotypic properties accurately represent those
present in vivo. A related issue is that technological advances have led to increasing
numbers and lengths of nucleotide sequences being obtained from viral variants in
HIV-1 infected individuals. Sequence analysis of HIV-1 variants in the context of a
single infection can provide many insights into HIV biology. However, it is
important that sequences obtained are free from in vitro artefacts.
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A number of potential in vitro artefacts are associated with common PCR and
cloning methods for obtaining sequences from heterogeneous viral populations.
These include the incorporation of single nucleotide polymorphisms during PCR,
recombination during PCR, resampling of clones, and alterations of sequences during
plasmid expansion in bacteria. The relative importance of each of these artefacts was
assessed in the context of the env gene. Results showed that all of these in vitro
artifacts had a significant impact upon the final sequences obtained. It may therefore
be expected (if there were no specific attempts to avoid such artefacts) that this type
of sequence adulteration or misrepresentation of sequence diversity would be present
in other studies that used similar techniques. Of particular interest was the observed
resampling of clones, despite the presence of sufficient amplifiable template
molecules. Recombination during PCR was also found to occur at a high level, even
when only a small number of templates copies from each original genotype were
present. Consequently, the fairly common procedure of reducing template copy
number to reduce recombination during PCR may not be sufficient in many cases.
Thus when the same primer pairs are used amplify mixtures of different template
molecules, the level of in vitro recombination should be empirically determined for
each individual PCR. Inclusion of point mutations during PCR amplification could
also alter phenotypic properties of amplified sequences, and may partially obscure
clone resampling when it has occurred by artificially increasing the observed
nucleotide differences between individual clones. Together these results imply that in
order to ensure that amplified sequences correspond to those present in vivo, limiting
dilution PCR should be used.
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The issues described above, together with the toxic effect of lentiviral env sequences
within E. coli observed in this and other studies (Cunningham et al, 1993; Peden,
1992; Wang and Mullins, 1995), suggested that env sequences to be used for
phenotypic analysis should ideally be obtained by limiting dilution PCR, and not be
subjected to passage through bacteria during cloning. To this end a PCR and overlap
extension method was developed, where promoter and poly (A) sequences could be
attached to an open reading frame without the need for standard cloning and passage
through bacteria. This method was found to be effective for expression of the EGFP
and luc+ reporter genes. Further assessment of this method using the HIV-1 genes nef
and env derived from an infected individual also led to efficient expression. The
expression of env open reading frames was also performed using PCR products
obtained at limiting dilution, and therefore conformed to all the ideal criteria for
maintenance of in vivo sequence characteristics. This method may therefore prove
useful for analysis of the subtle determinants in Env that confer differential cell and
potentially tissue tropism. Moreover antiviral therapies targeted towards HIV-1 Env
should become widely available in the near future (D'Souza et al, 2000; Chan et al.,
1998; Kilby et al, 1998). Viral escape mutants to one of these agents: DP178 (Wild et
al., 1994), have been identified in tissue culture experiments (Rimsky et al, 1998).
Given the complex collections of mutations that correlate with HIV resistance to
currently available therapies (Jacobsen et al, 1995; Winters et al, 1998; Larder and
Kemp, 1989; Richman et al, 1994), it may be expected that mutations conferring
resistance to antiviral agents targeted against Env proteins will be similarly difficult
to interpret at a genotypic level. Hence phenotypic assays will likely be required,
designed for testing the susceptibility of patient-derived Envs to different antiviral
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agents. The rapid and cloning-free method described here for producing env genes
suitable for expression in mammalian cells may therefore also prove useful in the
context of these potential future applications.
In summary, the results of this investigation suggest that recombination between
HIV-1 variants that have diverged during the course of a single infection is a
common event. This recombination was readily evident between brain and lymphoid
derived HIV-1 variants in several infected individuals with HIVE. Therefore it
appears that variants from outwith the brain interact with those present in the CNS
with some regularity. Consequently it may be inferred that the regions of the viral
genome that do show tissue specific segregation probably confer some level of
selective advantage for replication in the CNS. The results of investigations into in
vitro artefacts incorporated during PCR and cloning strongly suggest that limiting
dilution PCR should be used for obtaining sequences from heterogeneous viral
populations. A method for avoiding each of these artefacts was also presented and
may prove useful in future investigations.
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Future work
The results of in vivo recombination within the env gene between HIV-1 variants
present in the brain and lymphoid system, while interesting, are based upon virus
present in one infected individual. Clearly it is not possible to draw broad
conclusions from results derived from a single study subject. Consequently Takumi
Shirafuji, a colleague in the laboratory, is currently obtaining viral sequences from a
second study subject for use in the same type of analysis. Preliminary results of this
analysis are consistent with those presented herein. Kirsty Newman, another
coworker in the laboratory, is using a modified version of the overlap extension
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In addition to immunodeficiency, human immunodeficiency virus type 1 (HIV-1) can cause cognitive im¬
pairment and dementia through direct infection of the brain. To investigate the adaptive process and timing
of HIV-1 entry into the central nervous system, we carried out an extensive genetic characterization of variants
amplified from different regions of the brain and determined their relatedness to those in lymphoid tissue.
HIV-1 genomes infecting different regions of the brain of one study subject with HIV encephalitis (HIVE) had
a mosaic structure, being assembled from different combinations of evolutionarily distinct lineages in pl7s"s,
pol, individual hypervariable regions of gpl20 (V1/V2, V3, V4, and V5), and gp41/ne/. Similar discordant
phylogenetic relationships were observed between p 1 lg"K and V3 sequences of brain and lymphoid tissue from
three other individuals with HIVE. The observation that different parts of the genome of HIV infecting a
particular tissue can have different evolutionary histories necessarily limits the conclusions that can be drawn
from previous studies of the compartmentalization of distinct HIV populations in different tissues, as these
have been generally restricted to sequence comparisons of single subgenomic regions. The complexity of viral
populations in the brain produced by recombination could provide a powerful adaptive mechanism for the
spread of virus with new phenotypes, such as antiviral resistance or escape from cytotoxic T-cell recognition
into existing tissue-adapted virus populations.
Isolates of human immunodeficiency virus (HIV) show great
heterogeneity in their kinetics of replication, coreceptor usage,
cellular tropism, and cytopathic effects. Differences in these
properties have been hypothesized to underlie in vivo differ¬
ences in pathogenicity, which in turn may influence the rate of
disease progression in HIV-infected individuals (1, 2, 5, 9, 11,
16, 19, 20, 28, 40, 44). Differences in phenotype may also
underlie differences in in vivo cellular tropism, which would
substantiate the hypothesis that the different populations of
HIV infecting lymphoid tissue, brain, and other tissues may
have originated through an adaptive process following primary
infection. Difficulties in recovering HIV from nonlymphoid
tissues have to date prevented extensive analysis of their bio¬
logical properties, although the existence of consistent se¬
quence differences in the envelope gene from those recovered
from lymphoid tissues provides indirect evidence for specific
cellular tropisms (3, 13, 14, 17, 22, 26, 27, 30, 31, 34-36, 42).
However, an alternative hypothesis proposes that differences
in the rate of virus turnover in different cell types may lead to
the observed population differences, given the rapid temporal
change in HIV populations over time in peripheral blood
mononuclear cells, in lymph nodes (LN), and among HIV
variants recovered from the gastrointestinal tract (27, 45, 46).
To investigate whether differences in V3 and elsewhere in
the HIV genome reflect tissue adaptation, or whether they
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Microbiology, University of Edinburgh, Teviot Ptace, Edinburgh EH8
9AG, United Kingdom. Phone: 44 131 650 3138. Fax: 44 131 650 6531.
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arise simply though limited spatial or temporal sampling, we
have compared nucleotide sequences in different regions of the
HIV type 1 (HIV-1) genome from lymphoid tissue with au¬
topsy samples from anatomically separated parts of the brains
of four study subjects with HIV encephalitis (HIVE). We also
determined whether sequences in p\lgag, pol, and different
regions of the env gene (V1/V2, V3, V4, V5, and gp41/nef)
between different brain samples and those from lymphoid tis¬
sue provided equivalent evidence for tissue-specific compart¬
mentalization of HIV-1.
MATERIALS AND METHODS
Study subjects. Frozen samples of LN or spleen and from several anatomically
distinct regions of the brain from four individuals with HIV giant cell encepha¬
litis were stored at autopsy (risk group, CD4 counts, and brain pathology are
summarized in Table 1). Subject NA129 had received zidovudine monotherapy
for 17 months up to approximately 1 year before death; ddC was used for 1
month, finishing 3 months before death. The other study subjects had received
minimal antiviral treatment: for NA234, a single course of zidovudine for a
duration of 1 month at 1 year before death; for NA021, zidovudine intermittently
over 1 year at 5 years before death and zidovudine-ddC for 1 month at 1 year
before death; for NA173, zidovudine for 4 months at 2 years before death and
then for 1 month at 1 year before death. None of the study subjects showed
evidence for genotypic resistance to zidovudine or other antiviral agents (42a).
Pathology examination. The brains were examined pathologically as previously
described (4). Assessment of pathology findings was undertaken blind to the
PCR analysis and validated by three independent observers.
DNA extraction and amplification. DNA was extracted from the brain, LN,
and spleen and quantified as previously described (15). Total DNA was quanti¬
fied spectroscopically, while HIV proviral DNA was semiquantitated by ampli¬
fication, using the plT8"* primers, of serial 10-fold dilutions of DNA, with the last
positive dilution used to indicate the minimum proviral load in the sample.
Samples were used for sequence comparison only if proviral frequencies were
>100 copies/106 cells, and this excluded analysis of left parietal (LP) and both
cerebellum samples from NA234. Low levels were detected in two atrophied LN
8720
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TABLE 1. Clinical background and pathology appearance of study subjects
CD4/|xl HIV-related pathology''
Study Age Risk Other




PV WM GM BG BS Cere pathology
NA173 34 MH 1 0 + + +/- +/- +/- +/- - Toxoplasma
NA021 49 IVDU 300 87 + + + + + +/- +/-
NA128 48 MH 12 4 +/- + + + + + + + + + - Toxoplasma
NA234 28 IVDU 90 30 + + + + + + + + + Lymphoma
a MH, male homosexual; IVDU, intravenous drug user.
h Scored as - (negative), +/— (sparse pathology) +, (slight pathology), or + + + (severe pathology in different brain compartments). PV, perivascular; WM, white
matter; GM, grey matter; BG, basal ganglia; BS, brain stem; Cere, cerebellum.
samples from NA128, and lymphoid sequences were therefore obtained from the
spleen. For nucleotide sequencing, 1-p.g aliquots of extracted DNA were ampli¬
fied as previously described (39) or amplified after dilution to an endpoint (see
below).
Amplified DNA was either sequenced directly by cycle sequencing (Amer-
sham) or cloned into pGEM, using poly(T) overhangs (pGEM-T Vector system;
Promega). Miniprepped DNA from clones was sequenced by using a Sequenase
version 2.0 kit (U.S. Biochemical) according to the manufacturer's protocol.
Nucleotide sequencing. For samples with evidence of sequence heterogeneity,
amplified DNA was cloned and approximately 10 clones were sequenced. Se¬
quences from other samples without evidence for heterogeneity (no detectable
multiple bands at any position on a sequencing gel lane) or length polymorphism
analysis (23) were directly sequenced. The sequence data set for the \)\lgag
region of NA234 was assembled from cloned sequences from each of the brain
regions and extended from positions 405 to 795 in the HIVLAI genomic sequence
(GenBank accession no. K02013). Sequences in the pol region of NA234 were
directly sequenced from amplified DNA and compared between bases 2189 and
2842, using the PCR primers used for detection of antiviral resistance mutations
(43); there was no evidence for intrasample sequence heterogeneity. Sequences
in the V1/V2 region from NA234 were amplified by using primers as previously
described (23). Amplified DNA was homogeneous by length polymorphism anal¬
ysis, and nucleotide sequences from regions other than LN, left frontal (LF), and
right frontal (RF) were obtained by direct sequencing of amplified DNA. Se¬
quences in V3 and V4/V5 were amplified by using primers as previously de¬
scribed (38). Length polymorphisms in the V4/V5 region in some brain samples
from NA234 necessitated multiple clones to be sequenced. Sequences from each
tissue were amplified in the gp41/rce/ region by using outer primers 5'-AGGGC
TGCTATTAACAAGAGATGG-3' and 5'-GTAGCTGCTGTATTGCTACTT
GTG-3' and inner primers 5'-AGGTCTTCAGACCTGGAGGAGG-3' and 5'-
TATTGCTACTTGTGATTGCTCCATG-3' (5' base positions 7166, 8541, 7215,
and 8531, respectively). Direct sequencing was carried out on the amplified DNA
from the 3' end by using the antisense inner primer, while an internal primer
(5' -TGAGGGGACAGATAGGGTTATAGA-3', position of 5' base 8287 in
HIVlai genome) was used to sequence the 5' end.
Sequences were aligned and distances were estimated with the Simmonic 2000
Sequence Editor package. Synonymous and nonsynonymous distances and stan¬
dard errors were estimated by the method of Nei and Gojobori (33). Phyloge-
netic analysis was carried out with the MEGA program (29). The nucleotide
sequences from p\lgag and V3 amplified from each of the study subjects were
compared with each other and with a range of standard HIV-1 variants. Each set
of sequences from the four study subjects was monophyletic in both genomic
regions and distinct from those of the published sequences of subtype B: HIVSF2
(K02007), HIVRF (M17451), HIVOYI (M26727), HIVLAI (K02013),
HIVJRFL (M74978), HIVYU2 (M93258), HIVCAM1 (D10112), HIVNY5CG
(M38431), HIVHAN (U43131), HIVWMJ22 (M12507), and HIVSFAAA
(M65024). This comparison provided no evidence for coinfection with more than
one epidemiologically unrelated HIV strains or for intersample or exogenous
laboratory contamination.
Nucleotide sequence accession numbers. Nucleotide sequences obtained in
this study have been submitted to GenBank and assigned accession no.
AF174692 through AF175123.
RESULTS
Sequence relationships in different regions of the HIV-1
genome. Autopsy samples were obtained from multiple regions
of the brain and from LN of an individual (NA234) with au¬
topsy evidence of HIVE. The pl7gaff region was amplified by
nested PCR and cloned from samples with virus loads of
greater than 100 proviral copies/10 cells. These nucleotide
sequences formed two distinct evolutionary lineages, each with
bootstrap support of §80%. Sequences from LN, brain stem,
right parietal (RP) and LF regions (lineage A) showed a closer
sequence relationship to each other than to variants obtained
from elsewhere in the brain (lineage B) (Fig. 1). At synony¬
mous sites, the mean pairwise Jukes-Cantor (J-C) distances
were 0.057 (mean standard error ±0.026) among members of
lineage A and 0.055 (±0.024) for lineage B, almost nonover-
lapping with the range of pairwise distances observed between
the two lineages (mean synonymous distance 0.109 ± 0.038).
On the basis of the previously established mean rate of se¬
quence change in this region of gag (0.6 to 0.7% per site per
year [24, 25]), these distances suggest a time of divergence
between lineages A and B of around 8.4 ± 2.9 years, compared
with a likely duration of HIV infection of around 10 years in
this study subject.
In contrast to LN sequences, those from other regions of the
brain were relatively homogeneous, apart from those from the
RP region, which formed at least three separate clusters within
lineage A, and a single sequence from the LF region, which
grouped in lineage B instead of lineage A. Sequences in lin¬
eage B, comprising exclusively brain-derived variants, clustered
by tissue origin, with a tendency for variants recovered from
adjacent tissues to be more similar to each other (e.g., left
occipital |LO) and right occipital [RO] regions) than to vari¬
ants from virus with greater physical separation (e.g., occipital
region to RF region). Most regional variants in lineage B had
common ancestors distinct from any variants found in lym¬
phoid tissue, and more recent times of divergence than that
between lineages A and B can be inferred. Variants within
lineage B may therefore have originated from the spread of
HIV within the brain rather than from multiple seeding from
the peripheral circulation and thus differ in origin from brain-
derived variants in lineage A (LF and RP). To confirm the
separate groupings of LF and RF sequences, DNAs extracted
from these tissues and from LN were separately analyzed by
limiting dilution as previously described (39). Sequences ob¬
tained were similar or identical to those obtained by cloning of
PCR products (data not shown).
In marked contrast to the relationships observed in pl7s"s,
LF and RF sequences from both V1/V2 and V3 regions in
gpl20 grouped together in a distinct lineage from those of LN
sequences (bootstrap support §80%) (Fig. 2A and B), dem¬
onstrating that variants from LF and RF regions shared a
common ancestor distinct from that of variants in the LN
region. The probability of this discordant phylogeny arising
through sampling was <0.0001 (Fisher's exact test). To inves¬
tigate the robustness of the difference in branching order in
p17s"* and V3, a user-defined tree of p I 7gag sequences with the
branching order of V3 was created by using RETREE in the
PHYLIP package (18). With the Hasegawa-Kishino-Yano test,
a p\lgas tree with the V3 branching order was significantly less
FIG. 1. Phylogenetic analysis of the pl7gag region amplified from different regions of the brain and from lymphoid tissue of NA234. Divergence between nucleotide
sequences was estimated from J-C distances (scale indicated below tree), and the tree was constructed from the distance matrix by the neighbor-joining method. The
robustness of groupings was indicated by bootstrap resampling of 100 data sets, with values of ^75% indicated on branches; lineages are indicated by single letters.































FIG. 2. Comparison of sequences from LF and RF regions of the brain of NA234 with those of the LN region in V1/V2 (A), V3 (B), V4 (C), and V5 (D)
hypervariable regions (outgroup, symbols, and bootstrap method as for Fig. 1).
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A)
Tissue origin Pl7 pol V1/V2 V3 V4 V5 gp41
Lymph node a a a a C b c|a|b B A A
Choroid plexus b a a C D c B B C A
Right parietal a a D D c B b
Brain stem a a D D c F b C
Left occipital b a D D E D C
1 Right occipital b a d D E D C
Left frontal a a c d C D C b B
Right frontal b a c d D C b
Right temporal b a b d C b b



















Lymph node Choroid plexus Left frontal
FIG. 3. (A) Distribution of phylogenetic groupings in different regions of the genome of 11IV-1 variants infecting NA234. Letters refer to bootstrap-supported
groupings identified by phylogenetic analysis (Fig. 1, 2, and 3); vertical bars indicate discontinuities in groupings that require the minimum number of recombination
events. The sequence conservation and monophylogeny of thepol region originated either through recombination or from a lower rate of sequence change compared
with the rest of the genome; sequence relationships are indicated with an interrupted line to indicate this uncertainty. Three samples contained sequences distributed
in more than one clade in V4 and V5, in the combinations tabulated in LN (B), CP (C), and LF (D) regions of the brain.
likely than the most likely tree calculated by using maximum
likelihood (DNAML; P = 0.018).
In the V4/V5 region, sequence relationships were more com¬
plex and also discordant from those observed both for pl7gag
and for V1/V2 or V3 (Fig. 2C, 2D, 3C, and 3D). Variants from
the LN region formed three lineages (A, B, and C), with a
fourth lineage comprising variants from the LF and RF regions
(lineage D). However, approximately half of the LF variants
grouped with lineage C. Similar sequence relationships were
observed for the V5 region, with three main lineages compris¬
ing LN (A), LN and LF (B), and LF and RF (C). Because V4
and V5 sequences were amplified in the same PCR fragment,
it was also possible to observe different combinations of lin¬
eages between the two regions (Fig. 3D). For example, V4
sequences of 12 LF clones were in lineage C in V4 and in
lineage B in V5 (i.e., CB), while 9 clones were DC and 7 were
CC. Similar reassortments were observed in LN sequences
(one AA, two AB, one BB, and three BC).
To investigate further the tissue distribution of variants in
different genomic regions, we obtained sequences from thepol,
V1/V2, V3, and gp41/«e/ regions of variants recovered from
other parts of the brain (Fig. 4). The most conserved region
was the pol region, in which sequences from different regions
of the brain did not display any significant phylogenetic group¬
ings. The mean pairwise distance between pol sequences from
different samples was 0.013 (0.048 at synonymous sites), lower
than observed between variants within either lineage A or
lineage B in the pi7gag region. Either there was a lower rate of
sequence change at synonymous sites in this part of the ge¬
nome or the pol region of the genome originated after the
diversification of pl7gag, implying the existence of recombina¬
tion between the pol region and more variable regions of the
genome.
In V1/V2, we observed four bootstrap-supported lineages,
differing from each other by distances of 0.022 to 0.076, com¬
pared with distances of 0 to 0.008 within lineages. The distri¬
bution of sequences from different regions of brain did not
match the distribution of sequences into the two lineages in
pYP"g (Fig. 3 and 4). For example, sequences from LN (A in
pl7gag) and choroid plexus (CP) (B in p!7gag) regions were
found in the same lineage in V1/V2, while sequences from LF
and RP regions, which grouped with the LN sequence in
pl7gag, were on three separate lineages in V1/V2 (A, C, and
D).
Similar complexity was observed among sequences from V3,
V4, V5, and gp41/ne/, with variants from the CP showing the
greatest diversity in V3, V4, and V5. A subpopulation of CP
variants grouped with those found in lymphoid tissue (e.g.,
lineages C in V3, B in V4 and V5, and A in gp41), but as
described above for LN and LF, there were inconsistent rela¬
tionships in the V4 and V5 regions (Fig. 3C), with all four
combinations of lineages B and C in V4 and A and B in V5
being observed. Overall, no consistent relationship between
lineages was observed among the other samples collected from
the brain (Fig. 3), and apart from LO and RO regions, each
region of the brain contained a different combination of phy-
logenetically distinct subgenomic fragments.
Tissue-specific grouping. Variants from different regions of
the brain of NA234 consistently grouped separately from those
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FIG. 4. Comparison of inferred amino acid sequences of variants from different regions of the brain of NA234 in V1/V2 (A), V3 (B), V4 (C), V5 (D), and gp41
(E) /nef, using LN variants as reference sequences. Horizontal lines divide primary bootstrap-supported (^75% of data sets) phylogenetic groupings of nucleotide
sequences. Each number in the third column indicates the number of clones used to create the indicated consensus sequence, c, consensus sequence obtained by direct
sequencing of PCR product. Symbols: % sequence identity with LN sequence; gap introduced to presence sequence alignment; *, termination codon. Sequences are
numbered by their positions in the HIV^, gp!20 (A to D) or nef (E) sequence. BS, brain stem.
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Mean Error Rank'' Mean Error Rank
Within brain NA021 0.034 0.009 3 0.015 0.008 4
NA173 0.035 0.010 2 0.017 0.008 3
NA128 0.012 0.006 4 0.035 0.011 1
NA234 0.042 0.011 1 0.028 0.010 2
Brain-lymphoid tissue NA021 0.040 0.009 3 0.043 0.014 3
NA173 0.040 0.011 2 0.031 0.011 4
NA128 0.023 0.008 4 0.080 0.018 1
NA234 0.057 0.013 1 0.072 0.018 2
° Mean J-C distance between variants within brain or between brain and LN or spleen (excluding CP).
b Rank of variability (1 = most variable).
genomic regions. To investigate further the diiferentiation be¬
tween lymphoid and brain-derived variants, sequences from
the pl7g"g and V3 regions were obtained from 8 to 12 brain
regions from three other individuals (NA021, NA173, and
NA128) and compared with those amplified from the corre¬
sponding LN or spleen samples (Table 2; Fig. 5 and 6). Se¬
quences from each individual were monophyletic in both
pl7gag and V3 upon comparison with each other and with
epidemiologically unlinked subtype B sequences (listed in Ma¬
terials and Methods).
In each of the three study subjects, pl7gog sequences of





















RT N. K. .K. ...........
LP N p.. K. .K
LO
C) NA128
FIG. 5. Comparison of inferred amino acid sequences of variants from the V3 region of NA173 (A), NA021 (B), and NA128 (C), using the LN or spleen (SPL)
sequences as a reference. Horizontal lines divide bootstrap-supported (^75% of data sets) phylogenetic groupings of nucleotide sequences (symbols and sequence















































































FIG. 6. Phylogenetic analysis of p\78°s (column 1) and V3 sequences (column 2) of the four study subjects (A through D). Sequences from each of the four subjects
were monophyletic in both genomic regions upon comparison with each other and the sequences available from GenBank listed in Materials and Methods and were
used to root each clade. pll8"8 and V3 trees from different study subjects were plotted by using the indicated scale of J-C distances. Sequences were derived from brain
(•), from lymphoid tissue (LN or spleen [SPL]) (O), or from CP (□). All bootstrap values of ^75% are indicated on branches. Sequences from NA234 were obtained
from individual clones of amplified DNA instead of by direct sequencing; single representative clones from each sample or multiple clones for those containing
sequences in more than one lineage (i.e., LN and CP) have therefore been included. BS, brain stem; BG, basal ganglia.
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tissue showed interrelationships different from those observed
in V3. First, there was no correlation between sequence diver¬
sity between the two genomic regions (Table 2). For example,
p 11K"K sequences from NA173 showed two- to threefold-
greater variability between brain regions (mean J-C distance of
0.035 ± 0.010) and between brain and lymphoid tissue (mean
J-C distance of 0.04 ± 0.011) than the corresponding se¬
quences from NA128 (distances of 0.012 ± 0.006 and 0.023 ±
0.008). In contrast, sequences from NA128 in the V3 region
were more variable than those from NA173 (0.035 ± 0.011 and
0.080 ± 0.018, compared with mean distances of 0.017 ± 0.008
and 0.031 ± 0.011 for NA173).
Second, phylogenetic analysis of the pi7^ and V3 se¬
quences produced different groupings of variants (Fig. 6). For
example, LN sequences from NA021 clustered separately from
brain-derived variants in the V3 region but grouped with brain
variants in pYlgag. Conversely, LN sequences from NA173 were
distinct from all but one of the variants in pi7^ but were
undifferentiated from brain variants in V3. In each of the four
study subjects, tissue specificity depended on the region being
compared. A specific instance of incompatible phylogeny com¬
parable to that observed for NA234 (see above) was observed
in NA021, where LN sequences formed a bootstrap supported
lineage in V3 distinct from the brain variants, while the pri¬
mary branching order in pi7^ divided sequences from the RT
and RO brain regions from the rest of the sequences.
Sequence divergence and pathology appearance. The sever¬
ity of HIVE varied between the study subjects (Table 1), rang¬
ing from infrequent giant cells confined to perivascular regions
(NA173) to widespread pathology affecting both white and
grey matter (NA128; Fig. 7). The extent and type of HIV-
induced pathology correlated with the degree of V3 but not
plTg"g sequence diversity between different brain regions and
in the extent to which V3 sequences from the brain differed
from those in lymphoid tissue. V3 sequences from NA173
(who showed minimal HIV-related pathology) were largely
undifferentiated from those detected in LN, with only an ala-
nine-arginine change segregating by tissue (mean J-C distances
listed in Table 2). At the other extreme, the spleen-derived
sequence from NA128 had a predicted syncytium-inducing
phenotype and differed at multiple sites from the nonsyncy-
tium-inducing variants in the brain. In the p\lgag region, how¬
ever, sequences from NA173 were the most variable, and those
from NA128 were the least variable.
DISCUSSION
This study documents the extraordinary complexity of HIV
populations in vivo, findings which have several implications in
understanding mechanisms of tissue adaptation and the timing
of entry of HIV into the central nervous system (CNS). The
marked sequence diversity of the p\lgag region and the readily
identifiable clusters of sequences in the hypervariable regions
of env (V1/V2, V3, V4, and V5) of NA234 and other study
subjects provided evidence for recombination between differ¬
ent regions of the genome. For example, variants infecting
separate regions of the brain of NA234 were assembled from
two different p\lgag lineages and a limited number of distinct
hypervariable region lineages, often with different combina¬
tions within same autopsy sample (e.g., the V4 and V5 se¬
quences in the LN, CP, and LF sequences [Fig. 3 to D]). In the
other three study subjects, the different degrees of variability
and the discordant phylogenetic groupings between pYlgag and
V3 regions indicate a lack of genetic linkage between these two
subgenomic regions and further support the hypothesis of fre¬
quent recombination in vivo.
To date, recombination has been most easily identified be¬
tween different subtypes of HIV-1; for example, variants of
HIV-1 from Thailand contain gag sequences resembling those
of subtype A but distinct from subtype A in the env gene (7),
while other viruses appear to have been generated by multiple
recombination events (e.g., HIV-1MAL [10, 37] and subtype I
[21]). Recombination has also been observed upon infection
with different strains of HIV-1, either experimentally in a
chimpanzee exposed to the laboratory isolates HIVLAI and
HIV-1SF2 (47) or possibly through multiple exposure to two or
more sources of HIV infection in a blood recipient and an
injecting drug user (12, 49). We have now demonstrated that
recombination also occurs within an infected individual be¬
tween variants descended in each case from the original infect¬
ing strain. The finding that different parts of the HIV genome
can have different evolutionary histories severely limits the
concept of tissue specificity of variants of HIV in vivo, partic¬
ularly if these conclusions are based on a single subgenomic
region. For example, the brain-specific and frequently mono-
phyletic nature ofHIV sequences in the pol region (virodemes)
of variants infecting antiviral agent-treated individuals (48)
may not be reflected elsewhere in the genome. Indeed, se¬
quence relationships in the env gene may differ substantially
from pol, as variation in the former region is more likely to
confer phenotypic differences in cellular tropism. The exis¬
tence of recombination provides an explanation for discordant
phylogenies between pllgag, V1/V2, and V3 that we observed
between brain (in the LF region) and LN sequences in three
previous subjects (14, 23, 24). While sequences in V3 were
tissue specific, sequences in the pilgag and VI/V2 regions were
diverse, and some evolutionary lineages were common to vari¬
ants recovered from brain, lung, and LN. Our observations
support the hypothesis that recombination may accompany the
acquisition of antiviral resistance, as exemplified by the ap¬
pearance of zidovudine-resistant mutants in the peripheral cir¬
culation which occurred without evidence for a comparable
bottlenecking in env (6); V3 sequences showed no reduction in
diversity during the process of population replacement in pol
region.
The diversity of V3 sequences in different brain regions of
the four study subjects was similar to a previous comparison of
variants infecting different brain regions (mean pairwise dis¬
tance between brain regions, 0.021 [8], excluding sequences
from the LF region that were highly divergent in sequence and
failed to group phylogenetically with sequences derived from
other regions of the brain). The LF sequences may have orig¬
inated from exogenous contamination of the PCR, or corre¬
sponded to an epidemiologically unlinked isolate in a case of
mixed infection. In either case, the observed degree of se¬
quence divergence was unlikely to have originated from se¬
quence change over the course of infection within the study
subject.
Greater degrees of sequence complexity may also originate
from the presence of different infected cell types in a tissue
sample. HIV sequences amplified from the choroid plexus of
NA234 showed the greatest diversity in the env region, con¬
taining variants corresponding to those from lymphoid tissue
and brain, consistent with the presence of virus from blood-
derived cells and brain parenchyma. The proximity of these
different cell types in the CP may provide an opportunity for
recombination of HIV to occur, as well as a site of entry of
HIV into the CNS. Without biological characterization of the
variants found in the CP or elsewhere in the brain, it remains
unclear whether recombinant genomes have been selected or
represent random samplings of phenotypically identical vi¬
ruses. However, the multiple recombination events observed in









FIG. 7. Immunocytochemical detection of p24 antigen in representative sections of cerebral white matter of two study subjects with HIVE. (A) NA173.
Immunopositive mononuclear and giant cells (stained brown with diaminobenzidine) are confined to the perivascular region. (B) NA128. Widely dispersed HIV-
infected microglia in white matter.
8730 MORRIS ET AL. J. Virol.
this study would provide a powerful mechanism for adaptation,
providing, for example, an effective method for the spread of
antiviral agent resistance or cytotoxic T-cell escape mutants
into the CNS. Recombination between these latter determi¬
nants and env could produce new virus populations that retain
their neuroadapted phenotype.
The differing sequence relationships between brain-derived
and lymphoid variants from the four study subjects suggests
that entry of HIV-1 into the CNS can occur at different times.
The current consensus view that entry occurs early during HIV
infection is supported by the observation that HIV RNA se¬
quences can be detected in cerebrospinal fluid throughout the
course of infection and by the detection of low levels of HIV
proviral sequences in brains of asymptomatic individuals (4,15,
41). Early entry is also supported by the extensive sequence
diversity in the pi7^ region of variants recovered from the
brain, such as between lineages A and B observed in NA234 in
this study, which implies several years of divergent evolution
(24). However, the relevance of early entry into the CNS in the
development of late stage HIVE remains unclear, since active
virus replication has not been demonstrated immunocyto-
chemically during early infection (4), and brains show little
evidence of pathology apart from the presence of infiltrating
CD8 lymphocytes in perivascular areas.
Evidence for a contribution of late-entering variants to
HIVE is provided by NA173, who showed a distinctive pathol-
ogy appearance of HIV-expressing infiltrating macrophages
confined to the perivascular regions (Table 1; Fig. 7A). The
hypothesis of recent entry of HIV-infected cells into the brain
parenchyma was supported by the observation of close se¬
quence similarity in the V3 region of brain-derived variants
with those obtained from lymphoid cells. This late-entry pic¬
ture contrasted strongly with the distribution of HIV infection
in NA128, in which HIV was widely dispersed in white (Fig.
7B) and grey matter, while V3 sequences were distinct between
spleen and brain and heterogeneous within brain (Table 2; Fig.
5C). This correlation was, however, not supported by sequence
comparisons in the pi?8** region, where sequence diversity was
greatest in NA173 and least in NA128.
Indeed, to understand the adaptive significance of the se¬
quence differences in different parts of the genome, it will in
the future be necessary to analyze functionally the contribution
of each genomic region to the phenotype of the virus. In
particular, it will be important to determine the phenotypic
significance of recombination between the pi7^ and env re¬
gions, particularly as variants with different combinations of
lineages in the two regions were associated with distinct pa¬
thology appearances. Understanding what contributes to neu¬
rotropism will illuminate the selective pressures (if any) that
produce the recombinant viruses observed in this study. The
lack of genetic linkage in the HIV genome resulting from
recombination greatly enhances its ability to adapt to several
simultaneously acting selection pressures, as indicated by the
rapid emergence in vitro of dual antiviral agent-resistant mu¬
tants (32).
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